



ECDC Advisory Forum

Sixtieth Meeting

Stockholm, 18-19 February 2020

Expert opinion on non-pharmaceutical countermeasures against pandemic influenza

Document number: AF60/03		Date: 10 February 2020	
Summary:	In an effort to support national and regional pandemic preparedness activities, ECDC has reviewed the evidence base for non-pharmaceutical countermeasures (NPC) against pandemic influenza, thus updating the available documentation from 2009. A literature review was procured in 2018 and the draft document reviewed with an international panel of experts in May 2018. This expert opinion was reviewed in the AF58, and all substantive comments have been taken into account in current version. This document will be opened for a public consultation immediately after the AF opinion.		
Action:	The revised Expert Opinion is circulated for information to the AF, prior to public consultation.		
Background:	The purpose of this expert opinion is to summarise to public health decision makers in the EU/EEA Member States, EU institutions and other interested parties, the evidence base on the effectiveness of NPCs and provide an expert opinion on the use of the NPCs that have been proposed for reducing the risk and transmission of human pandemic influenza to date.		

Contents

Summary.....	1
Annex I: Expert opinion on non-pharmaceutical countermeasures against pandemic influenza.....	2

Summary

1. The purpose of this expert opinion is to summarise to public health decision makers in the EU/EEA Member States, EU institutions and other interested parties, the evidence base on the effectiveness of NPCs and provide an expert opinion on the use of the NPCs that have been proposed for reducing the risk and transmission of human pandemic influenza to date.
2. In this document, these measures are categorised into personal protective, environmental, social distancing and travel-related measures. The document also aims to identify gaps in research and inform the planning and design of scientific studies, and of in-depth systematic reviews for specific types of interventions.
3. This Expert Opinion is based upon a review of literature reviews since the 2009 pandemic on the effectiveness of the various NPCs. The document builds on the previous ECDC technical document 'Guide to public health measures to reduce the impact of influenza pandemics in Europe: "The ECDC Menu"', published in 2009, with updated information and lessons learned from the 2009 influenza pandemic.
4. The NPCs ranged from personal protective actions taken by individuals (personal protective, environmental measures) to actions that require extensive preparation by communities, authorities or states (social distancing and travel-related measures). Their use varied in the different countries and settings during the previous pandemics.
5. Overall, there is a limited and sometimes contradictory evidence base on the effectiveness of NPCs against influenza infection especially in community settings. A lot of evidence is indirect, i.e. it comes from studies not directly applicable to pandemic influenza, but on other infectious diseases or respiratory viruses or seasonal influenza. Studies focused on laboratory confirmed influenza are rare.
6. An international panel of experts reviewed the draft document in May 2018 and the AF58 reviewed it in September 2019. Following substantive comments made in the AF meeting, the Expert Opinion has been revised in order to:
 - a. Apply a quality of evidence rating on the identified reviews (AMSTAR2)
 - b. Add table 3 "Potential model for combining NPCs according to the pandemic severity assessment"
 - c. Strengthen language on recommendations as "ECDC expert opinion"; including a revision of Table 2: "Summary of ECDC expert opinion on non-pharmaceutical countermeasures"
 - d. Slightly revise structure of chapter on "Use of facemasks and respirators"
 - e. Describe in Methods the role of the EU/EEA MS pandemic planning colleagues in reviewing the draft Expert opinion

Annex I: Expert opinion on non-pharmaceutical countermeasures against pandemic influenza

Draft for public consultation



1

2

3

4

5 **ECDC** SCIENTIFIC ADVICE

6 **Expert opinion on non-pharmaceutical**
7 **countermeasures against pandemic**
8 **influenza**

9

10

1 *Acknowledgements*

2 This report was drafted by [5.1.2e] and [5.1.2e] (ECDC) based on the ECDC technical document 'Guide to
3 public health measures to reduce the impact of influenza pandemics in Europe: 'The ECDC Menu', published in 2009. [5.1.2e]
4 [5.1.2e] drafted the 'Administrative controls to health care' chapter. The scientific expert panel that participated to the
5 Expert Meeting in May 2018, Stockholm, Sweden and contributed to the report consisted of the following experts that were
6 invited based on their personal expertise and not representing their countries: [5.1.2e] (NL), [5.1.2e] (DE),
7 [5.1.2e] (SE), [5.1.2e] (HK), [5.1.2e] (PL), [5.1.2e] (UK), [5.1.2e] (SE),
8 [5.1.2e] (NO), [5.1.2e] (UK), [5.1.2e] (UK), [5.1.2e] (ES), [5.1.2e]
9 (UK), [5.1.2e] (NL) and [5.1.2e] (US CDC), [5.1.2e] (WHO HQ), [5.1.2e] (European
10 Commission DG SANTE.C3). ECDC experts that participated to the meeting were: [5.1.2e] [5.1.2e], [5.1.2e]
11 [5.1.2e], [5.1.2e] and [5.1.2e]. The report has been reviewed by [5.1.2e] and [5.1.2e] (ECDC).

12

1 Contents

2	<i>Acknowledgements</i>	2
3	Contents.....	3
4	Abbreviations	4
5	Executive summary	6
6	Background	6
7	Objectives	6
8	Methods in short	6
9	Results in short.....	7
10	Conclusions	11
11	1. Background	12
12	Rationale.....	12
13	Objectives of non-pharmaceutical measures	12
14	Pharmaceutical measures.....	13
15	Influenza virus transmission	13
16	The Pandemic Influenza Severity Assessment (PISA) tool	14
17	Surveillance: case reporting, contact tracing and early rapid viral diagnosis	15
18	Contact tracing for transmission on board aircraft	15
19	Administrative controls in healthcare.....	16
20	Specimen/patient transport.....	16
21	Hospital triage and cohorting	16
22	Non-pharmaceutical countermeasures to reduce transmission	17
23	2. Methods	18
24	Limitations.....	20
25	3. Results and conclusions	22
26	Personal protective measures	22
27	Hand hygiene	23
28	Cough etiquette	28
29	Use of facemasks and respirators	30
30	Other personal protective equipment used in health care settings	39
31	Environmental measures.....	42
32	Social distancing measures.....	47
33	Voluntary isolation of cases not requiring hospitalisation.....	48
34	Voluntary quarantine of exposed household members	49
35	Interventions in educational and child care settings.....	51
36	Measures in the workplace and public places	56
37	Measures related to mass gatherings	59
38	Travel-related measures	63
39	International and domestic travel advice	63
40	Entry and exit screening at national borders	64

1	Domestic travel restrictions	65
2	Border closures.....	66
3	4. Prerequisites for NPC implementation.....	70
4	Risk communication	70
5	Education and training.....	70
6	5. Implications for public health research	71
7	References	74
8	Annex. I	84
9	PubMed search strategy	84
10		

11 Abbreviations

12	AR Attack Rate
13	ARI Acute Respiratory Infections
14	CDC U.S. Centers for Disease Control and Prevention
15	CI Confidence Interval
16	ECDC European Centre for Disease Prevention and Control
17	ERLI-net European Reference Laboratory network for Influenza
18	GISRS Global Influenza Surveillance and Response System
19	HC Health Care
20	HCAI Health Care Associated Infections
21	HCS Health Care Setting
22	HCW Health Care Workers
23	ICU Intensive Care Units
24	IHR International Health Regulations
25	ILI Influenza-Like-Illness
26	LCI Laboratory Confirmed Influenza
27	LTCF Long Term Care Facilities
28	MERS-CoV Middle East Respiratory Syndrome Corona Virus
29	NIC National Influenza Centre
30	NHS National Health Service

	Scientific advice - Expert opinion	ECDC	Draft for public consultation 27 August 2019
1	NPC Non-pharmaceutical countermeasure		
2	OD Odds Ratio		
3	PHE Public Health England		
4	PPE Personal Protective Equipment		
5	PPM Personal Protective Measure		
6	RCT Randomised Controlled Trial		
7	RR Risk Ratio		
8	SARI Sever Acute Respiratory Infections		
9	SARS-CoV Severe Acute Respiratory Syndrome Corona Virus		
10	WHO World Health Organization		
11			
12			

1 **Executive summary**

2 **Background**

3 Influenza is a viral respiratory infection spreading efficiently from person to person by direct and indirect contact. Influenza
4 pandemics account for millions of cases of illness, tens of thousands of hospitalisations and deaths and a significant global
5 societal and economic burden. Production and distribution of vaccines and antiviral drugs, complemented with enhanced
6 surveillance, case reporting, early rapid viral diagnosis, and administrative controls, including risk communication, education,
7 training and health care (HC) administration will form the essential response to a pandemic.

8 A reduction in the impact or severity of the pandemic could also be attempted by a variety of non-pharmaceutical
9 countermeasures (NPCs). Several NPCs have been proposed and used as public health responses. The main objective of the
10 use of NPCs is to reduce the impact of the pandemic by reducing viral transmission. The reduction in transmission may
11 delay the epidemic peak, reduce the overall number and peak number of cases, including severe and fatal cases,
12 complementing the available pharmaceutical countermeasures during a pandemic.

13 **Objectives**

14 The purpose of this expert opinion is to summarise to public health decision makers in the EU/EEA Member States, EU
15 institutions and other interested parties, the evidence base on the effectiveness of NPCs that have been proposed for
16 reducing the risk and transmission of human pandemic influenza to date and to review these measures with regards to
17 operational feasibility and acceptability. The NPCs are categorised into personal protective, environmental, social distancing
18 and travel-related measures. The document also aims to identify gaps in research and so inform the planning and design of
19 scientific studies, and of in-depth systematic reviews for specific types of interventions.

20 **Methods in short**

21 This document is a review of literature reviews since the 2009 pandemic on the effectiveness of the various NPCs. The
22 document builds on the previous ECDC technical document 'Guide to public health measures to reduce the impact of
23 influenza pandemics in Europe: 'The ECDC Menu', published in 2009, with updated information and lessons learned from the
24 2009 influenza pandemic.

25 A literature search was restricted to PubMed based on titles and abstracts to retrieve review articles on NPCs related to
26 effectiveness that were published between January 2009 and December 2018. The reference lists of all articles were
27 checked for additional relevant literature, including national and international guidance documents. The search terms that
28 were used to identify review articles can be found in the Annex. Articles were selected based on the following inclusion
29 criteria: 1) English language; 2) Reviews; 3) Publication date; 4) Included evidence on effectiveness. Articles were selected
30 based on their title, abstract and text, in this order. During this process, articles that did not fit the criteria were excluded.
31 The quality of the included reviews was assessed using [AMSTAR 2](#). The information was sorted by intervention type and
32 separated into the relevant chapters.

33 An expert meeting to discuss the evidence base for effectiveness of NPCs and to revise the draft document accordingly was
34 organised by ECDC in May 2018. The discussion panel consisted of scientific content (social science scientists, experts
35 working on non-pharmaceutical interventions, authors of systematic literature reviews and meta-analyses included in this
36 paper) and policy experts (public health professionals, pandemic planners) from Germany, the Netherlands, Norway, Hong
37 Kong, Poland, Spain, Sweden, the United Kingdom, United States, European Commission DG SANTE.C3, the U.S., WHO HQ

1 and ECDC. The independent expert panel members were selected for their specific expertise, and their input was requested
2 on the basis of that expertise rather than on the basis of policy or practice of their countries or employing organisations.
3 The views of the experts were taken into account to the extent possible, however the final Expert opinion is ECDCs
4 understanding of the best available evidence.

5 The draft Expert opinion was also shared with EU Member State pandemic preparedness experts participating in three
6 regional workshops in spring of 2019 and ECDCs advisory forum in September 2019 and a public consultation was launched
7 in November 2019. Feedback from these consultations has been incorporated into the document, to the extent possible.

8 **Results in short**

9 The NPCs range from personal protective actions taken by individuals (personal protective, environmental measures) to
10 actions that require extensive preparation by communities, authorities or states (social distancing and travel-related
11 measures). Their use varied in different countries and settings during the previous pandemics. The number of included
12 reviews for each type of measures and their grading according to the AMSTAR 2 system is shown in Table 1.

13 Overall, there was a limited evidence base on the effectiveness of NPCs against influenza infection especially in community
14 settings and sometimes the conclusions of the reviews (especially regarding hand washing and facemask effectiveness
15 against influenza infection) were variable. The quality of included reviews was variable ranging from high to critically low
16 quality, usually the main flaw being the lack of quality assessment criteria and grading of their included studies. Graded
17 studies that were included in the moderate/high quality reviews were on the other hand often of low quality and sometimes
18 the evidence-base consisted mainly of simulation studies. A lot of evidence is indirect, i.e. it comes from studies not directly
19 applicable to pandemic influenza, but to other infectious diseases or respiratory viruses or seasonal influenza. Studies
20 focused on laboratory confirmed influenza are rare. For environmental measures, most of the evidence is also indirect,
21 originating from studies that focus on the mechanistic mode of action of these measures to reduce the viral load on
22 surfaces, objects and air.

23 Effectiveness of the measures will depend on additional factors, for example proper use, frequency and duration of use,
24 combination of measures and adherence to the measures. Although compliance and adherence to NPCs is and is expected
25 to be variable, public anxiety may increase rates of adherence to NPCs during a pandemic, increasing the effectiveness of
26 the measures. Many reviews have studied the layered approach, using a combination of measures to increase effectiveness;
27 for this reason, it is in some studies difficult to disentangle the effects of specific interventions. In the situation of limited
28 and sometimes conflicting evidence, the expert opinion is based on expert judgement, taking into account theoretical and
29 operational considerations, common practice, feasibility and current guidelines and recommendations of public health
30 organisations.

31 Personal protective measures (PPMs) (hand hygiene, cough etiquette, facemasks and respirators and other measures, i.e.
32 voluntary home isolation when ill) and environmental measures are commonly recommended and undertaken during
33 seasonal influenza epidemics and pandemics. The evidence of PPM effectiveness to mitigate the pandemic is limited or even
34 absent, but they are generally inexpensive, easy to implement and with limited associated risks. Personal protective
35 equipment (i.e. gloves, gowns, eye protection) is mainly used in health care settings (HCSs) and high-risk situations and
36 most evidence of effectiveness originates from such studies. NPCs for use during pandemics depending on the severity
37 level, include voluntary quarantine of exposed household members, wider use of facemasks, school closures and other
38 social distancing and travel-related measures. Proactive school closures may reduce influenza transmission but the timing
39 and duration will determine whether they achieve the mitigation objectives. Travel-related measures, such as travel
40 restrictions and border closures may delay the viral spread for a short period, but only if they achieve almost complete

1 isolation of the country and at very early pandemic phases, which is generally considered unfeasible and can be done only
 2 in specific contexts, such as on small island nations. They are also undesirable due to major societal and economic costs.
 3 Border screening was assessed as unlikely to be successful because current screening methods (e.g. thermal scanners)
 4 have low sensitivity to identify infection and cannot identify asymptomatic or pre-symptomatic infections. The ECDC expert
 5 opinion on options for action based on the evidence of effectiveness for each measure are summarised in Table 2. The
 6 options for implementation of NPCs according to the pandemic severity assessment (using the PISA indicator 'impact') are
 7 summarised in Table 3.

8 **Table 1. Number of included reviews on non-pharmaceutical countermeasures by quality (AMSTAR 2**
 9 **grading)**

Countermeasure	Number of systematic reviews	AMSTAR2 grading of systematic reviews				Number of non systematic reviews
		High	Moderate	Low	Critically low	
Hand hygiene	14*	6	4	1	2	5
Cough etiquette	2	1	1			2
Facemasks and respirators	11	6	3		2	9
Other personal protective equipment	3	2			1	4
Environmental measures	4*		3			14
Voluntary isolation of ill	3	2			1**	1
Voluntary quarantine of exposed	3	2			1**	1
School closures	4				4**	2
Workplace measures	5	2	2		1**	1
Measures in mass gatherings	2		2			3
Travel-related measures (domestic and international travel restrictions, exit/entry screening)	5	2	1		2**	6

10 * One systematic review was not assessed because only a short [version](#) was available in English

11 ** A number of these reviews were graded according to AMSTAR 2 as 'critically low' due to lack of description of risk of bias
 12 for their included studies, which may however not be appropriate for the included studies.

13

14

1 **Table 2. Summary of ECDC expert opinion on non-pharmaceutical countermeasures**

Personal Protective Measures	ECDC expert opinion
Hand hygiene	Although the available evidence from the included literature reviews on effectiveness of hand hygiene in reducing influenza infections is contradicting, the use of hand hygiene has been proven effective against other pathogens. Therefore recommending hand hygiene is considered a rational precaution, with limited costs and no associated risks.
Cough etiquette	Although the available evidence base is very limited, cough etiquette is widely recommended in public health guidelines for all community settings (home, schools, workplaces, HCSs etc.) at all times due to their potential mechanical mode of action.
Use of surgical facemasks	<p>Available evidence supports recommending facemask use for infected persons when in contact with other individuals.</p> <p>Surgical facemask use by HCWs in HCS should be recommended in epidemics or pandemics to reduce transmission and current policies mandating standard and droplet precautions when performing routine care for influenza patients are reasonable.</p> <p>Use of surgical facemasks by people likely to be exposed to infected persons during a pandemic and by infected persons when they have contact with other individuals is supported, although most evidence originates from HCSs. There is lack of evidence on effectiveness of wider use of facemasks in community settings, therefore such recommendations should only be considered in severe pandemic scenarios.</p>
Use of respirators	Respirators should be considered in high risk settings by HCWs especially when aerosol generating procedures are performed.
Other personal protective equipment	Available evidence supports recommending use of PPE in health care settings, when performing aerosol-generating procedures or when the risk of exposure to respiratory secretions is high.
Environmental Measures	
Surface and object cleaning	Available indirect evidence supports recommending the use of environmental measures such as surface cleaning and disinfection at all times during pandemics due to their mechanical action against influenza virus and the potential of these measures to reduce transmission.

Room ventilation

Available limited and mostly indirect evidence supports recommending measures that improve indoor ventilation at all times during pandemics.

Social distancing measures

Voluntary isolation of ill persons

Available evidence supports recommending voluntary isolation of infected individuals at all times during pandemics.

Voluntary quarantine of exposed persons

Available, limited evidence, originating mainly from modelling studies, support recommending voluntary quarantine based on a situational risk assessment.

Interventions in educational and child care settings

Available evidence which is generally of low quality and based on modelling studies, supports recommending *proactive* closures of schools and day care facilities only during severe epidemics and pandemics, as they can be associated with significant societal and economic costs.

Available evidence, does not provide support for *reactive* school and day care closures in order to impact the evolution of a pandemic.

Measures in the workplace and other public places

Available evidence supports recommending measures at workplaces (e.g. teleworking, social distancing), which can be modestly effective and feasible during all phases of a pandemic. Evidence from modelling studies support recommending workplace closures in extraordinarily severe pandemics.

Measures at mass gatherings

Available limited evidence, mainly from modelling studies, supports recommending cancellations of mass gatherings only before the peak of severe pandemics.

Available limited evidence base, mainly indirect in describing the extent of transmission that takes place during mass gatherings, supports recommendations for other measures (e.g. facemask use, web-casting, education campaigns, environmental measures) during moderate or more severe pandemics, depending on the type of the event and a risk assessment.

Travel-related measures

International and domestic travel advice

Although there is lack of evidence to quantify the effectiveness of travel advice to mitigate a pandemic, issuing relative travel advice, consistent with IHR and national law, is recommended during the early stages of epidemics or pandemics at any level of severity.

Entry and exit screening at national borders	The available evidence does not support the notion that entry/exit screening border control measures can delay or mitigate an influenza pandemic due to lack of sensitivity of current systems to detect symptomatic, pre-symptomatic and asymptomatic infections.
Domestic travel restrictions	Available limited evidence does not support recommending domestic travel restrictions, except for very specific, isolated settings in the early stages of extraordinary severe pandemics.
Border closures	Available, limited evidence, mainly from modelling studies, does not support recommending border closures in Europe, as they will have an impact on the timing of the introduction of the pandemic influenza virus into the countries or on the peak of the local epidemic only if almost complete and at early pandemic phases.

1

2 For each measure, the review considers where applicable: objectives, rationale, evidence base of effectiveness and benefits,
3 operational considerations (direct and indirect costs, risks, and potential adverse effects), likely acceptability in Europe and
4 provides an expert opinion on options for action.

5 **Table 3. Potential model for combining NPCs according to the pandemic severity assessment***

Low	Moderate	High	Extraordinary high
Hand hygiene	Hand hygiene	Hand hygiene	Hand hygiene
Cough etiquette	Cough etiquette	Cough etiquette	Cough etiquette
Environmental measures	Environmental measures	Environmental measures	Environmental measures
Voluntary isolation of ill	Voluntary isolation of ill	Voluntary isolation of ill	Voluntary isolation of ill
Travel advice	Travel advice	Travel advice	Travel advice
	Workplace measures	Workplace measures	Workplace measures
	Measures in mass gatherings	Measures in mass gatherings	Measures in mass gatherings
	Facemask use by symptomatic people in the community	Facemasks (in wider community)	Facemasks (in wider community)
		School closures	School closures
			Quarantine of exposed persons
			Workplace closures
			Domestic travel restrictions

6 * taking into consideration the feasibility of each measure (note also that border closures are generally not
7 recommended unless required by national law in extraordinary circumstances during a severe pandemic, and countries
8 implementing this measure should notify WHO as required by the IHR (2005)).

9 Conclusions

10 In the case of an influenza pandemic, NPCs aim to reduce transmission, delay the peak and relieve the peak burden to the
11 HC system. Several NPCs may be used and have been used in the past influenza pandemics, at least since 1918. A layered
12 approach of using a combination of measures simultaneously has been suggested to be the most effective and should be
13 considered in preparedness plans. In the early pandemic phase, such an approach may delay viral transmission and spread
14 more efficiently, giving unaffected areas more time to prepare. As the pandemic progresses, a synergistic effect may
15 increase effectiveness of individual measures. Overall, measures that are implemented early in the pandemic phases and for

1 longer periods have been shown to have a higher impact, although timing and duration need to be carefully considered by
2 measure and according to the pandemic risk assessment due to the high socioeconomic cost and to ensure sustainability.
3 Personal protective and environmental measures are everyday actions with minimal associated risks that are likely to be
4 highly acceptable and undertaken also during seasonal epidemics, whereas social distancing and travel-related measures
5 may be less acceptable and have higher societal, legal, ethical and/or economic consequences. Risk communication and
6 appropriate training are essential for a successful response. Actions will need to be tailored to the pandemic severity, the
7 local situation and to the different population groups and community settings.

8 This document collates the recent scientific evidence in order to assist European Union (EU) and European Economic Area
9 (EEA) Member States to update their pandemic preparedness plans and national recommendations, decide on which
10 measures they may plan to apply and in which circumstances, in the case of an influenza pandemic. Many of the same
11 considerations may also apply to seasonal influenza epidemics. Overall, the evidence base portfolio for NPCs is limited and
12 further research is needed to support pandemic preparedness activities.

13 1. Background

14 Influenza virus infections and seasonal epidemics are responsible for hundreds of thousands of hospitalizations, tens of
15 thousands of deaths and considerable economic burden in Europe [1]. On the other hand, there is a continuous threat of a
16 new emergent influenza virus strain to which humans possess little or no immunity resulting in an influenza pandemic with
17 unpredictable consequences. Such pandemics with varying degrees of severity and impact have occurred repeatedly at
18 unforeseeable intervals: the 1918 "Spanish flu", the 1957 "Asian flu", the 1968 "Hong Kong flu" and the 2009 pandemic
19 being the most recent examples. These pandemics accounted for millions of cases of illness, hospitalizations and death and
20 a significant global societal and economic burden [2-4].

21 Rationale

22 Influenza is a viral respiratory infection spreading efficiently from person to person by direct and indirect contact. Direct
23 spread occurs primarily through person-to-person contact and through aerosols, respiratory droplets produced when
24 infected people cough and sneeze. Indirect spread occurs when respiratory secretions settle on surfaces and objects that
25 are touched by uninfected people, who then infect themselves. A reduction in the impact or severity of influenza pandemics
26 (mitigation or damage limitation) may therefore be accomplished by using a variety of non-pharmaceutical countermeasures
27 (NPCs) that interrupt or decrease transmission, in addition to pharmaceutical measures (vaccine and antiviral drug use, if
28 and when they become available).

29 Objectives of non-pharmaceutical measures

30 The primary objective of the NPCs is to reduce the impact of the pandemic by reducing viral transmission. The epidemic
31 peak may be delayed, and the overall number of cases, peak number of cases, and total number of severe illness cases and
32 deaths may be reduced, complementing pharmaceutical countermeasures.

33 Secondary objectives are to:

- 34 • Gain time for the development, production and distribution of pandemic vaccines and procurement, stockpiling and
35 distribution of antiviral drugs;
- 36 • Reduce the peak burden on HC and other key systems by decreasing the number of cases during the epidemic peak

1 and spreading cases over a longer period.

2 **Pharmaceutical measures**

3 Pharmaceutical countermeasures, most importantly vaccination and antiviral drugs use, are generally effective against
4 influenza viruses [5-10]. ECDC manages a program for monitoring influenza vaccine effectiveness on a seasonal basis, and
5 is able to activate it also for pandemic vaccine purposes [11]. ECDC is also supporting the European Commission with
6 technical advice on a joint procurement programme for several EU Member States. The most important measure against a
7 pandemic virus, as is for seasonal influenza viruses, will be the timely use of a specific pandemic vaccine for the whole
8 population. However, vaccines that match the pandemic strain of influenza virus cannot be developed, produced and be
9 available in sufficient quantities until some months after the pandemic starts. In 2009, the first pandemic vaccines were
10 available around six months after the declaration of the pandemic, while the bulk of the production could only be delivered
11 in subsequent months. Demand for vaccines will exceed global supply in the early phases of the pandemic. It will also
12 require about two weeks following the vaccination until sufficient protective antibodies are produced in the vaccinated
13 individual. Candidate vaccine viruses with pandemic potential are proposed during each WHO Vaccine Composition Meeting
14 in February for the northern hemisphere and September for the southern hemisphere [12], however specific vaccines are at
15 present unlikely to be available for the first wave of a pandemic strain. If the pandemic vaccine is produced and distributed
16 in a timely manner, this should mitigate the impact of the second and subsequent waves. Preparations for vaccine
17 acquisition, prioritisation and deployment are essential steps in national pandemic preparedness planning.

18 Antiviral medicines, specifically neuraminidase inhibitors, and potentially polymerase inhibitors, may play a crucial role in
19 reducing the impact of the pandemic and its clinical implications. They can both protect and treat the individual and reduce
20 virus transmission to others. However, they are mostly effective when administered within 24 to 48 hours after the onset of
21 illness for treatment of patients, or as post-exposure prophylaxis of exposed persons [13,14]. Prophylaxis would be
22 beneficial in public health terms, though in many countries antivirals may be in too limited supply for such use. The
23 effectiveness of the available antiviral drugs against the pandemic virus needs to be ascertained and monitored for every
24 novel virus, since the virus could be inherently resistant to the available drugs, or acquire resistance as a consequence of
25 antiviral drug administration [13,15]. Acquisition of sufficient stockpiles of antibiotics will also be essential for the treatment
26 of increased number of bacterial pneumonia cases that are common after influenza infections and may increase morbidity
27 and mortality during a pandemic.

28 **Influenza virus transmission**

29 The characteristics of influenza virus transmission drive the effectiveness of the various NPIs. The influenza virus may be
30 transmitted among humans via direct contact with infected individuals, via contact with contaminated objects and surfaces
31 or via inhalation of virus-containing aerosols [16,17]. The median basic reproductive number (R_0) is estimated to be 1.28 for
32 seasonal influenza and between 1.46 and 1.80 during the past pandemics [18].

33 There are two modes of respiratory transmission: droplet and airborne transmission. This depends upon the production of
34 aerosols that contain virus particles. Activities such as breathing and speaking produce aerosols, while coughing and
35 sneezing cause forceful expulsion of infectious droplets [19,20]. Recommendations to control influenza virus transmission in
36 various community settings include measures that reduce transmission and spread by aerosol and fomite mechanisms.
37 Aerosolised particles are particles of different sizes; the largest droplets (5-10µm aerodynamic diameter) will transmit an
38 infection only to those in the immediate vicinity, they travel typically 1-2 meters from their source and then settle to objects
39 and surfaces thereby causing indirect transmission. Smaller droplets travel a distance determined by their size. Those
40 droplets are <5µm in diameter and may remain suspended in the air for longer periods, travel longer distances, and reach

1 the lower respiratory tract. Inhalation of droplets places virus particles in the upper respiratory tract, where they may
2 initiate infection [19,21,22].

3 Nasal secretions also contain virus particles. They are responsible for transmission by direct contact or by contaminated
4 objects [16]. Infected persons will frequently touch their nose or conjunctiva, placing virus on their hands. Contact will
5 transfer the virus from one person to another, who will then self-infect by touching the nose or eyes. Studies have shown
6 that the influenza virus remains viable on the hands for 3-5 minutes and may remain on the fingers for at least 30 minutes
7 after contamination [23-25]. When contaminated hands touch other objects, the virus is transferred to them and remain up
8 to 48 hours after attachment to a surface [23,24,26,27]. It is unclear how much transmission of influenza takes place
9 through indirect transmission by hands [28]; most studies on inter-human transmission routes are inconclusive, and most
10 importantly the relative importance of respiratory virus transmission routes is not known [16,17]. In human infections,
11 maximum levels of virus shedding may occur about a day before the peak of symptoms. Asymptomatic infections also occur
12 and spread of the virus is feasible even through asymptomatic hosts or hosts that don't present the typical Influenza-Like-
13 Illness (ILI) symptoms (e.g. fever) [21].

14 Though there are several research studies on this area, there is uncertainty regarding the relative importance of droplet,
15 contact or airborne routes of transmission in influenza infection [17,29,30]. This is important as it would influence the
16 effectiveness of NPCs, depending on the route that they are targeting (e.g. hand hygiene for contact transmission, cough
17 etiquette and facemask use for airborne and droplet transmission). Studies on animal models have shown that temperatures
18 over 30°C have no effect on contact transmission, but prevent aerosol transmission of influenza [31]. Differences in
19 absolute humidity provide an explanation for the observed variability of influenza virus survival, transmission and
20 seasonality in temperate regions [32]. Low relative humidity (20–30%) has been shown to prolong influenza virus survival
21 in the air, increasing aerosol and droplet transmission that are inhibited at high relative humidity ($\geq 80\%$) [17,31]. Colder
22 temperatures ($\leq 4^\circ\text{C}$) tend to prolong the environmental persistence of influenza A, which could potentially increase the
23 relative burden of contact and aerosol transmission [30]. The role of different routes of transmission may shift during
24 influenza pandemics, given their unpredictable seasonality compared to the northern hemisphere influenza season, which
25 tends to start in October and end in May with a peak between December and February [33].

26 The different transmission patterns of the pandemic strain may also alter the effectiveness of PPMs during an influenza
27 pandemic compared to a seasonal epidemic. These uncertainties pose challenges to the public health policy makers and
28 highlight the need to report and review previous experiences and lessons learnt [17].

29 **The Pandemic Influenza Severity Assessment (PISA) tool**

30 The Pandemic Influenza Severity Assessment (PISA) tool was introduced by the WHO to monitor the influenza pandemics
31 [35]. The aims of the influenza severity assessment are to:

- 32 • describe the epidemiological situation and assess the severity of an influenza epidemic or pandemic based on all
33 available information
- 34 • inform national and global risk assessments
- 35 • inform public health preparedness, response and recovery measures as well as resource allocation.

36 The severity of a pandemic is evaluated through three indicators: transmissibility, seriousness of disease and impact. The
37 tool that aims to aid public health authorities to assess the severity of pandemic influenza, can also be used to inform
38 appropriate decisions on NPC use. The final evaluation of severity may inform the choice of which NPCs to use and when to
39 implement the measures. The pandemic impact level ranges from low to moderate, high or extraordinarily high. Some NPCs

1 may be recommended at all times, while others only in severe or extraordinarily severe pandemics.

2 **Surveillance: case reporting, contact tracing and early rapid viral** 3 **diagnosis**

4 Successful containment or control of pandemic influenza will rely on early recognition of sustained human-to-human
5 transmission, which requires a system for outbreak detection, data collection, timely reporting, data analysis and
6 assessment [34,35]. Early detection at the start of a pandemic is crucial to rapidly implement measures to limit the spread
7 of the pandemic at its source. Some situations may warrant case and contact tracing and management by public health
8 authorities in the early stages of the pandemic [36]. The extent of the investigation and recommended measures should be
9 feasible and relevant to the situation [37-39].

10 As part of national pandemic preparedness planning, each country should prepare for enhanced surveillance to detect the
11 emergence of the new disease, characterise the disease (epidemiology, clinical manifestations, severity) and monitor its
12 progress [40]. A surveillance system for monitoring the compliance and effectiveness of public health interventions will need
13 to be implemented. In the case of a novel virus, case reporting and early rapid viral diagnosis will support a range of
14 necessary preparedness activities, including: a) providing information regarding the presence and epidemiology of the virus
15 in the community, b) determining and implementing appropriate interventions, one of which would be the timely targeted
16 implementation of NPIs and c) generating current accurate information for policy makers, public health officials, providers
17 and the public [41].

18 In the light of the most recent experiences with SARS and the 2009 pandemic, enhanced level of national and international
19 surveillance has been proven crucial in order to contain the viral spread. Influenza surveillance at a global level is achieved
20 through an experienced network of laboratories, the Global Influenza Surveillance and Response System (GISRS) and at a
21 European level through the European Reference Laboratory of Influenza network (ERLI-net) supported by WHO and ECDC
22 [42,43].

23 **Contact tracing for transmission on board aircraft**

24 In order to assist national public health authorities in the European Union to assess the risks associated with the
25 transmission of infectious agents on board aircrafts, ECDC initiated in 2007 the RAGIDA project (Risk Assessment Guidance
26 for Infectious Diseases transmitted on Aircraft). RAGIDA consisted of two parts: the production of systematic literature
27 reviews and disease-specific guidance documents [44,45].

28 Considering the lack of published data available on evaluating the risk of transmission of most infectious agents on board
29 aircrafts, and taking into account the key factors that influence the decision making, the RAGIDA guidance provides a viable
30 evidence based tool for public health authorities determining triggers and making decisions on whether to undertake contact
31 tracing in air travellers or crew, in the early stages of a pandemic. These guidance documents may be adapted to the local
32 situation, national and international regulations or preparedness plans [45,46].

33 Overall, for influenza viruses, the evidence in the published literature was not adequate to assess the risk for transmission
34 on-board aircraft and the effectiveness of contact tracing measures remains unclear; it has been suggested that air
35 transportation appears important in accelerating and amplifying influenza propagation [47]. Transmission occurs aboard
36 aeroplanes, at the destination and possibly at airports [47]. Control measures to prevent influenza transmission on cruise
37 ships are needed to reduce morbidity and mortality [47]. The feasibility and cost benefit of contact tracing needs to be
38 carefully assessed.

1 Contact tracing should not be undertaken by default, but rather in exceptional situations, if indicated by the outcome of the
2 situational risk assessment. In order to reduce transmission, contact tracing should be performed at early pandemic stages.
3 This situational risk assessment should take into account how the index case was classified (probable or confirmed), the
4 time of travel in relation to onset of symptoms, the epidemiological situation in the country of destination and in the country
5 of departure, and the purpose of the contact tracing. For more information on options for action, it is advisable to refer to
6 the relevant document [45].

7 **Administrative controls in healthcare**

8 Administrative controls are measures taken to ensure that the entire HC system is working effectively. The HC facility
9 management team needs to ensure that resources are available for implementation of necessary measures. These
10 resources include the establishment of sustainable infrastructures and activities, clear policies and guidelines on early
11 recognition of infections, access to rapid laboratory testing, appropriate hospital triage and placement of patients and
12 organisation of services [48]. They include risk communication policies, designation of responsibilities, education of
13 employees about the hazards to which they are exposed and training on the proper use and disposal of Personal Protective
14 Equipment (PPE) as well as provision of means by which to avoid infection, while establishing appropriate programmes for
15 staff vaccination and antiviral drug prophylaxis [49].

16 **Specimen/patient transport**

17 All human specimens of respiratory secretions and excretions should be considered as potentially infectious [50].
18 Precautions should be taken during patient transport within healthcare facilities, as respiratory secretions from influenza-
19 infected patients are the main source of infectious material in HCSs [51]. The movement and transport of patients to and
20 from the isolation areas should be limited and if possible through dedicated corridors and elevators. The receiving facility
21 should be informed prior to the patient's arrival of the patient diagnosis and of the precautions that are indicated. The use
22 of mobile diagnostic devices should be encouraged when available. In case transport outside the isolation room is required,
23 the patient should wear appropriate PPE and perform hand hygiene after contact with respiratory secretions.

24 **Hospital triage and cohorting**

25 Hospital triage and cohorting of patients has the objective of isolating potentially infectious patients and using appropriate
26 protective measures and treatment rapidly thereby mitigating the impact of the pandemic on the rest of the HC services
27 [49]. Hospital triage procedures are the process of prioritising patients on first contact based on their need for immediate
28 medical care and treatment (e.g. high risk groups) as compared to the chance of benefiting from such care. These
29 procedures may allow triage of potentially infectious patients before the entry into the facilities (for example use of a flu
30 Emergency Department (ED) and a non-flu ED where space allows), and appropriate protective measures and treatment to
31 be applied rapidly, reducing the impact of the infection on the rest of the HC services. It is used in emergency rooms,
32 disasters, and wars, when limited medical resources are allocated to maximize the number of survivors. Cohorting patients
33 into wards or areas in the facility with clear designation of 'flu dirty' and 'flu clean' areas also offers the potential to reduce
34 nosocomial spread if applied successfully. Dedicated waiting and isolation rooms need to be determined.

35 No empirical studies have quantified the effectiveness of hospital triage protocols for containing pandemic influenza.
36 Hospitals may use available guidelines for HCSs to be able to categorise patients in case of a pandemic. Early recognition of
37 patients with suspected influenza will allow for appropriate patient management and reduced risk of transmission within the
38 HC facilities. All staff will need to be able to recognise the symptoms and signs of the disease that fit with the current 'case
39 definition' of the pandemic in patients and respond appropriately [60]. High risk groups during a pandemic may vary from
40 those during seasonal influenza seasons, due to the uncertain viral characteristics and pre-existing immunity against the

1 pandemic virus. Guidelines must be developed with public health, scientists, and legislative authorities to help clinicians
2 define, adopt, and communicate to the public those practice standards that will be followed in case of a pandemic [61].

3 Triage procedures may require changes to emergency room facilities, additional temporary facilities and protective
4 measures for first-line responders and might require reallocation of staff. During a pandemic, health authorities will provide
5 a more specific case definition or testing algorithm to detect cases. Definitions used by health authorities to identify cases of
6 pandemic influenza may change at different phases of a pandemic, as knowledge of the disease increases. General
7 practices need to maintain good communication pathways with state and territory health authorities to ensure timely
8 notification of any changes to case definitions or clinical management [52].

9 **Non-pharmaceutical countermeasures to reduce transmission**

10 Several NPCs have been proposed and used as public health responses during the past pandemics. In this document, these
11 measures are categorised in:

- 12 • Personal protective measures;
- 13 • Environmental measures;
- 14 • Social distancing measures;
- 15 • Travel-related measures.

16 A range of measures have been previously recommended by WHO in several guidance documents, including a guide specific
17 for the prevention and control of influenza in long-term care facilities [53-59]. ECDC in 2009 published a technical report
18 that is a guide to public health measures to reduce the impact of influenza pandemics in Europe [44,60,61]. The U.S.
19 Centers for Disease Control and Prevention (CDC) has recently updated the 2007 guide Community Mitigation Guidelines to
20 Prevent Pandemic Influenza [60]. Several other guidance documents that include NPC use are available from national public
21 health institutes and agencies, such as the Public Health England (PHE) [62-64], Public Health Canada (PHAC) [37], Robert
22 Koch Institute [65], Ministry of Health Singapore [66], New Zealand [67], Australia [68], as well as professional
23 organisations, such as The Royal Australian College of General Practitioners (RACGP) [69] and other government-funded
24 bodies, such as the UK National Health Service (NHS) [63].

25 All of the reviewed guidelines agree that NPC implementation is crucial at all phases prior, during and after the pandemic.
26 There are important issues to consider when planning and implementing such public health measures. One of the key issues
27 is to identify and define the triggers that will be used for the implementation of NPCs at each pandemic stage. The
28 measures should ideally be used in combination, in a layered approach, as the effectiveness of each individual measure may
29 be limited when implemented on its own [9,70]. In the early pandemic phases, a layered approach may contain the virus or
30 delay its spread, allowing unaffected areas to activate preventive measures. During a pandemic, a synergistic effect may
31 increase effectiveness of individual measures, whilst reducing the societal and economic impact of individual measures [70].
32 Despite the anticipated effectiveness of each measure, NPCs are often evaluated in terms of their perceived necessity,
33 acceptability, and feasibility. To enhance uptake, it will be necessary to address key barriers, such as beliefs about
34 transmission of the virus, rejection of personal risk of infection and concern about the potential stigma associated with some
35 of the interventions [71-74]. Intercountry variability and differences between populations within a single country suggest
36 that one-size-fits-all plans may be less effective [73]. Planned public health actions should therefore be tailored to the
37 pandemic impact, severity and local situation.

1 The EU decision no 1082/2013/EU on serious cross-border threats to health regulates the risk assessment, communication
2 and coordination of responses due to situations such as influenza pandemics, and ensures risk management measures in EU
3 Member States are taken in consultation with each other and in liaison with the European Commission.

4 2. Methods

5 The purpose of this document is to summarise to public health decision makers in European Member States, EU institutions
6 and other interested parties, the evidence base on the effectiveness of NPCs for reducing the risk and transmission of
7 human pandemic influenza, to aid the connection between science and policy. It is a comprehensive review of literature
8 reviews since the 2009 pandemic on the NPC effectiveness. Risks and secondary consequences associated with their use,
9 their likely acceptability, the probable public health expectations and the knowledge gaps are also discussed.

10 We searched PubMed for reviews on the effectiveness of NPCs from January 2009 until December 2018 (last search on 18
11 December 2018), using the combination of search terms that are listed in the Annex. The following search terms were used
12 to identify review articles: 'influenza', 'pandemic', 'respiratory infection', 'respiratory tract infection', 'respiratory virus', 'non-
13 pharmaceutical measures', 'public health measures', 'non-pharmaceutical interventions', 'personal protective measures',
14 'personal protective equipment', 'environmental', 'cleaning', 'surface', 'humidification', 'ventilation', 'disinfectants',
15 'disinfection', 'copper', 'alloy', 'sunlight', 'hand hygiene', 'mask', 'respirator', 'hand disinfection', 'social distancing', 'voluntary
16 isolation', 'workplace', 'quarantine', 'mass gatherings', 'Hajj', 'school closure', 'entry screening', 'exit screening', 'border
17 closure', 'travel advice', 'travel measures'. Duplicate search results were removed. Following the initial search results, the
18 titles and abstracts (in this order) were reviewed to exclude those outside the scope. If the paper described the NPC and its
19 effectiveness against influenza and other respiratory virus transmission, the full-length text was read and relevant data were
20 extracted. Articles were selected based on the following inclusion criteria: 1) English language; 2) Reviews; 3) Publication
21 date; 4) Included evidence on effectiveness. During this process, articles that did not fit the criteria were eliminated. The
22 final list of papers was reviewed. The included systematic reviews were assessed using [AMSTAR 2](#) [75]. The grading system
23 scored the reviews as follows:

- 24 • High - Zero or one non-critical weakness: The systematic review provides an accurate and comprehensive
25 summary of the results of the available studies that address the question of interest.
- 26 • Moderate - More than one non-critical weakness: The systematic review has more than one weakness, but no
27 critical flaws. It may provide an accurate summary of the results of the available studies that were included in the
28 review.
- 29 • Low - One critical flaw with or without non-critical weaknesses: The review has a critical flaw and may not provide
30 an accurate and comprehensive summary of the available studies that address the question of interest.
- 31 • Critically low - More than one critical flaw with or without non-critical weaknesses: The review has more than one
32 critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available
33 studies.

34 The information was sorted by intervention type and separated into the relevant chapters. Systematic and non systematic
35 reviews have been designated accordingly in the tables. The ECDC expert opinion on options for action based on the
36 evidence of effectiveness for each measure were summarised. The options for implementation of NPCs according to the
37 pandemic severity assessment were summarised in a table using the PISA indicator 'impact', and taking under consideration
38 the feasibility.

1 The document is building on the ECDC technical document 'Guide to public health measures to reduce the impact of
2 influenza pandemics in Europe: 'The ECDC Menu', published in 2009, with updated information including the most recent
3 data, guidance documents and lesson's learned from the 2009 influenza pandemic [60].

4 Between 2009 and 2018, a substantial amount of studies, reviews and guidelines have been published [9,64,67,71,76-90].
5 We examined infection control policies and guidelines from WHO, US CDC and other aforementioned health organisations
6 for recommendations on the use of NPCs. We also included previous ECDC guidelines. Such guidance documents, e.g. the
7 WHO's 2005 Pandemic Plan [53], more recent WHO documents [58,59,91,92] and WHO's 2009 guidance on NPCs [93], the
8 CDC Interim Pre-pandemic planning guidance 2007 [94] and the Community Mitigation guidelines to prevent pandemic
9 influenza published in 2017 [24,77] provide clear recommendations for national and subnational authorities. In this review,
10 and it's previous version [60], no explicit recommendations are formulated, although an expert opinion on options for action
11 based on the evidence is provided. The content is intended to collate the available scientific evidence in order to assist
12 European Member States to update their pandemic preparedness plans, decide on which measures they may plan to apply
13 and in which circumstances, in the case of an influenza pandemic. Many of the same considerations may apply to seasonal
14 influenza epidemics and especially to more severe epidemics.

15 ECDC convened a group of experts in 16-17 May 2018 in Solna, Sweden with the participating panel consisting of public
16 health policy and scientific experts from Germany, the Netherlands, Norway, Hong Kong, Poland, Spain, Sweden, the United
17 Kingdom, United States, European Commission DG SANTE.C3, U.S. CDC, WHO HQ and ECDC [95]. The independent expert
18 panel members were selected and invited based on their specific expertise, and their input was requested on the basis of
19 that expertise rather than on the basis of policy or practice of their countries or employing organisations. The specific
20 expertise included in the panel were public health professionals, pandemic planners, social science scientists, experts
21 working on non-pharmaceutical interventions, and included some who were authors of systematic literature reviews and
22 meta-analyses included in this paper. The main objectives of this meeting were to present and discuss the evidence base
23 derived from the literature review for the following subjects and review the related draft guidance: PPMs in HC and long-
24 term facilities, PPMs in community and workplaces, environmental measures, social distancing measures, travel measures
25 and restrictions on international travel. Moreover, the following topics were discussed: pandemic preparedness, non-
26 pharmaceutical approaches in non-EU Countries, WHO related guidelines. The opinions of the experts were noted and taken
27 into account in producing the final ECDC expert opinion. The experts also suggested the inclusion of a number of relevant
28 studies which were not captured in the initial literature review, such as epidemiological modelling studies and health
29 economic analysis.

30 The draft Expert opinion was also shared with EU Member State pandemic preparedness experts participating in three
31 regional workshops in spring of 2019 and ECDC Advisory Forum in September 2019 and a public consultation was launched
32 in November 2019. Feedback from these consultations has been incorporated into the document, to the extent possible.

33 WHO published in October 2019 a guidance on "Non-pharmaceutical public health measures for mitigating the risk and
34 impact of epidemic and pandemic influenza", based on a systematic literature review [96]. ECDC experts reviewed the WHO
35 guidance and assessed that key recommendations contained within the WHO guidance are consistent and aligned with the
36 ECDC expert opinion.

37 The following NPCs have been included, categorised as follows:

38 **Personal protective measures**

- 39 • Hand hygiene
- 40 • Respiratory hygiene
 - 41 • Cough etiquette

- 1 • Facemask use
 2 - by staff in healthcare settings
 3 - situations with high exposure risk
 4 - outside home
 5 - by people outside of healthcare and patients with respiratory symptoms
 6 • Other personal protective equipment.

7
 8
 9 **Environmental measures**

- 10 • Surface and object cleaning
 11 • Room air ventilation

12 **Social distancing measures**

- 13 • Voluntary isolation of ill persons not requiring hospitalisation
 14 • Voluntary quarantine of exposed persons
 15 • Interventions in educational and child care settings
 16 • Reactive school closures
 17 • Proactive school closures
 18 • Measures in the workplace and other public places
 19 • Measures at mass gatherings

20 **Travel-related measures**

- 21 • International and domestic travel advice
 22 • Entry and exit screening at national borders
 23 • Domestic travel restrictions
 24 • Border closures

25
 26 For each measure, the review considers where applicable: the objective, rationale, evidence base of effectiveness and
 27 benefits, operational considerations (direct and indirect costs, risks, and potential adverse effects), acceptability in Europe
 28 and provides the ECDC expert opinion on options for action.

29 **Limitations**

30 Evidence of effectiveness is lacking or is limited for some of the measures and systematic literature reviews are lacking for
 31 some of the measures; for those measures, options for action are provided based on the experts' opinion, existing
 32 reviews/studies and WHO and other international guidelines. Some evidence is indirect, focusing on the mechanistic mode
 33 of action of the measures against influenza viruses and not directly on their effectiveness to mitigate the epidemic. The
 34 expert opinion includes only PubMed papers and only in the English language. The paper extraction, selection and quality
 35 assessment was performed by one reviewer only. The potential impact of each measure was not quantified or compared to
 36 the other measures. AMSTAR 2 was used to assess the quality of systematic reviews, but this tool does not assess the
 37 quality of studies included in these reviews; some of the reviews have identified and/or included poor quality studies. The
 38 included reviews often include the same studies. The AMSTAR 2 tool is also not equally applicable for grading all of the
 39 included reviews and some of the otherwise high quality reviews may be graded as 'critically low' due only to the absence of
 40 an assessment of the risk of bias of included studies. This review has taken into account all of the reviews that have
 41 assessed effectiveness of NPCs against LCI and/or ARI and/or ILI and/or respiratory infections irrespective of which one;
 42 the focus of each included review has been described in the summary table at the respective chapter. Cost-effectiveness
 43 and feasibility studies have not been included in this review.

1 **3. Results and conclusions**

2 The NPCs range from personal protective actions taken by individuals (personal protective, environmental measures) to
3 actions that require extensive preparation by communities, authorities or states (social distancing and travel-related
4 measures). Their use has varied for each measure and from one country to another during the previous pandemics [41,97-
5 100]. Evidence was stronger for some of the measures (e.g. hand hygiene) and weak (e.g. border closures) or limited (e.g.
6 cough etiquette) for others. PPMs (hand hygiene, cough etiquette), a few social distancing measures (voluntary home
7 isolation when ill) and environmental measures are commonly recommended and undertaken during influenza epidemics.
8 They are generally inexpensive and easy to implement, though their effectiveness during other respiratory virus or seasonal
9 influenza epidemics may differ from an influenza pandemic, due to the uncertain characteristics of the pandemic and the
10 pandemic strain. Facemasks and other PPMs (gloves, gowns, eye protection) are mainly used in HCSs and most evidence of
11 effectiveness originates from such studies. Although compliance and adherence to the measures is variable, public anxiety
12 may actually increase rates of adherence to the public health interventions. NPCs for use during pandemics, depending on
13 the severity level, include voluntary quarantine of exposed household members, wider use of facemasks in the community
14 and other social distancing measures (e.g. school closures and measures in mass gatherings). The evidence-base does not
15 support entry/exit screening, and travel restrictions are overall considered unfeasible and undesirable.

16 The PubMed search for literature reviews on the NPCs after 2009, using the search terms that are listed in the Annex
17 generated 2 253 results. The following study designs were included in the considered reviews and are specified in the
18 respective table for each measure were applicable (See Tables 4-13): randomised controlled trials (RCTs) and observational
19 studies, including cohort, case-control, cross-over, before-after, time series and other modelling studies. Following duplicate
20 paper removal and review of the titles, abstracts and full texts (in this order) of the initial search results to exclude those
21 outside the scope, the final number of review papers included in this review is presented in Table 1. The expert opinion for
22 the options for action of each measure is presented in Table 2. The options for implementation of NPCs according to the
23 pandemic severity assessment are summarised in Table 3. A summary of included reviews per measure is provided in the
24 table following the respective measure (Tables 4-13).

25 Overall, there is a limited evidence base on the effectiveness of NPCs against influenza infection especially in community
26 settings and sometimes the conclusions of reviews (especially regarding hand washing and facemask effectiveness against
27 influenza infection) were contradictory. The quality of included reviews is variable ranging from high to critically low quality,
28 usually the main flaw being the lack of quality assessment criteria and grading of their included studies. Furthermore,
29 studies that were included in the moderate/high quality reviews were often assessed by the individual reviews as having
30 increased risk of bias and for some measures the evidence-base consisted mainly of modelling studies (e.g. for border
31 closures, domestic travel restrictions, voluntary isolation when ill, voluntary quarantine) that are considered as evidence of
32 weak strength.

33 **Personal protective measures**

34 PPMs refer to, hand and respiratory hygiene, cough etiquette, and respirator or facemask use; these are commonly
35 recommended and undertaken during influenza outbreaks and they are generally inexpensive and easy to implement
36 [41,101-103]. Their effectiveness during respiratory virus or seasonal influenza epidemics may differ from an influenza
37 pandemic, due to the uncertain characteristics of the pandemic strain and its preferred mode of transmission, while public
38 anxiety may actually increase rates of adherence [104-108]. Despite persisting knowledge gaps in relative effectiveness
39 between the different PPMs and across population groups, results suggest that campaigns to increase the frequency of

1 PPMs use in situations with a high risk of exposure are likely to contribute to preventing pandemic influenza infection
2 [73,76].

3 **Hand hygiene**

4 Hand hygiene refers to hand washing with soap and water or cleaning with alcoholic solutions, gels or tissues.

5 **Objective:** Proper hand hygiene aims to reduce viral transmission from person to person by direct or indirect contact in
6 any community setting. It will also prevent other communicable diseases that may add burden during a pandemic if they
7 occur simultaneously.

8 **Rationale:** Influenza transmission can be direct or indirect through hand-mediated transfer and could be reduced by
9 washing hands often with soap and water or alcohol-based hand cleansers.

10 **Evidence of effectiveness:** Twenty reviews have been included and the evidence is summarised in Table 4. Of those
11 reviews, 14 were systematic (six 'high', four 'moderate', one 'low' and two 'critically low' AMSTAR 2 score).

12 Ignaz Semmelweiss documented the dramatic effectiveness of handwashing and disinfection in decreasing mortality from
13 puerperal fever in 1847, before the germ theory had emerged. More recent studies have shown that the influenza virus
14 remains viable on the hands for 3-5 minutes [23,25]. Several studies and reviews have evaluated hand washing
15 effectiveness against respiratory infections both before [41,104,105,109-114] and after the 2009 pandemic [9,76,82,87-
16 89,103,115-131]. Overall, the evidence supports the use of this common measure to reduce the risk of infectious diseases
17 in various settings: HCSs, households, educational settings, workplaces. In meta-analyses, the highest quality cluster-
18 randomised control trials (RCTs) suggested respiratory virus spread can be reduced by hygienic measures, such as
19 handwashing [132-134] and this is especially evident in younger children that are less capable of hygienic behaviour
20 themselves, have longer-lived infections and increased social contact, acting as portals of infection into the household
21 [132,133,135].

22 In an attempt to quantify the effectiveness of PPMs specifically in preventing influenza transmission, several systematic
23 reviews and meta-analyses were conducted, some of which concluded that regular hand hygiene provided a significant
24 protective effect against infection [76,89,132,133,135], however many studies on the effectiveness of this measure were
25 not focused on LCI. A recent systematic literature review conducted by WHO suggested that hand hygiene has a limited
26 effect in reducing LCIs when combined with facemask use (9%), while hand hygiene alone did not have any effect in six out
27 of seven RCTs [136]. The included studies were heterogeneous and in many cases had a high risk of bias.

28 The frequency of hand washing is an important factor that may influence the effectiveness of the intervention. It is unclear
29 what constitutes an appropriate "threshold" for adequate, protective hand hygiene; it is likely that this may vary depending
30 on individual factors such as exposure, individual susceptibility and risk of severe outcomes [76]. Increased frequency of
31 hand washing and motivation by influenza exposure, was found to be significantly protective in several studies, but the
32 quality of those individual studies has not been evaluated by this review [76,82,116,117,119,120,137]. Hand washing may
33 also confer indirect protection, through minimising the influenza virus surface contamination in households [24,89,121,138].

34 Both soap and water and alcohol based solutions may be used against respiratory viruses. The mechanism of action for
35 alcohol is to denature proteins on the respiratory virus surface and disrupt the lipid envelope, which is required for entry
36 into host cells. Some studies suggest that use of an alcohol-based hand sanitizer is more effective in preventing direct
37 spread of most respiratory infections compared to antimicrobial soap or no hand washing, but antimicrobial hand washing
38 products have not been shown to offer an advantage over soap and water [41,138,139]. An evidence based review on the

1 use of soap and water versus alcohol solutions concluded both were effective [122]. Regarding hand washing techniques,
2 there is evidence that the WHO-recommended technique reduced microbial load on HCWs hands, although the most
3 effective hand hygiene technique was not identified [140].

4 **Operational considerations:** There will be moderate direct costs. The major limiting factor would be the availability of
5 facilities for hand washing and of hand sanitisers (tissues, gels, solutions). In many settings, it will be difficult to increase
6 the amount of resources to build special facilities for hand washing only for a pandemic response. Such facilities and
7 practices would be advisable for other hygienic reasons, without considering the pandemic, in many communal settings,
8 such as schools, day-care centres, restaurants, cafeterias and churches or religious institutions. Some irritation from alcohol-
9 based solutions or very frequent hand washing has been reported. There is no consensus on the duration, frequency or
10 type of hand washing.

11 **Likely acceptability:** Hand hygiene is broadly acceptable and easy to implement, while giving people a practical measure
12 to enact in the case of a pandemic [73]. Based on a systematic review of public perceptions of NPCs for reducing
13 transmission of respiratory infections, hand hygiene was viewed as a familiar and socially responsible action to take [71].
14 Multimodal strategies to enhance hand hygiene compliance were shown to achieve slight to moderate improvements [141].
15 Compliance with good hand hygiene practices may be higher than that for facemasks, which have been less acceptable in
16 the past [73,107]. The international experience shows that the level of hand washing can be increased, if the easiness of
17 hand washing is increased. Addressing determinants such as knowledge, awareness, action control, social influence,
18 attitude, self-efficacy and intention will enhance effectiveness of hand hygiene improvement activities [142].

19 **ECDC expert opinion:** Although the available evidence from the included literature reviews on effectiveness of hand
20 hygiene in reducing influenza infections is contradictory, the use of hand hygiene has been proven effective against other
21 pathogens. Therefore recommending hand hygiene is considered a rational precaution, with limited costs and no significant
22 associated risks. Hand hygiene should be recommended in all community settings (home, schools, workplaces etc.) at all
23 times as frequently as possible, especially following possible exposure to infectious agents. Effectiveness is likely to increase
24 when used in combination with other measures (e.g. facemasks). Compliance may also increase during a pandemic,
25 increasing effectiveness. It is an essential hygiene measure in HC and long-term care settings, which manage vulnerable
26 individuals. Educational programmes for proper and frequent hand washing will be needed during ordinary seasonal
27 influenza seasons and during pandemics. Sanitising gels may be used if hand-washing with soap and water is not possible;
28 sanitising gel solutions based on 60-85% alcohol content should be preferred [24].

29

1 **Table 4. Summary of reviews and meta-analyses on hand hygiene effectiveness**

Hand hygiene - Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Hansen et al., 2018 [125]	Moderate	Workplace settings (3 cluster RCTs, 2 prospective interventional, 2 pre-post design)	Infectious diseases	Moderate evidence to support hand hygiene programs.
McGuinness et al., 2018 [135]	High	Childcare, school, domestic settings (14 cluster RCTs)	ARI	Evidence suggests that hand-hygiene interventions can reduce ARI morbidity, but effectiveness varies according to setting, intervention target and compliance.
Zivich et al., 2018 [129]	Low	Workplace settings (8 experimental, 2 observational, 1 simulation)	Infectious diseases	Minimal hand-hygiene interventions effective at reducing the incidence of employee illness.
Kumar et al., 2017 [143]	Not systematic	Various settings (Children)	Influenza	Cough etiquette, use of facemasks and hand hygiene are the most important measures to reduce the risk of infection transmission from person to person.
Mbakaya et al., 2017 [130]	Moderate	Various settings - children (8 RCTs)	Respiratory and other infections	Multi-level hand-washing interventions can reduce the incidence of diarrhoea, respiratory infections, and school absenteeism.
Saunders-Hasting et al., 2017 [76]	High	Community (2 RCTs, 8 case-control studies, 4 cohort studies, 2 cross-sectional surveys)	Pandemic influenza 2009 infections	Hand hygiene provided a significant protective effect.
Kingston et al., 2016 [141]	Critically low	HCSs (16 RCTs)	HC associated infections	Adopting a multimodal approach to hand hygiene achieved slight to moderate improvements in hand hygiene compliance.

Scientific advice - Expert opinion		ECDC	Draft for public consultation 27 August 2019	
Willmott et al., 2016 [124]	High	Educational settings (18 cluster RCTs)	Respiratory and gastrointestinal pathogens	Evidence of the effect of hand hygiene interventions on infection incidence in educational settings is mostly equivocal but they may decrease respiratory infection among children.
Hocine et al., 2015 [128]	Critically low	Nursing homes (22 outbreak reports, 13 observational, 8 before-after, 13 RCTs)	Various infections	Infection control strategies were more effective when a hand hygiene measure was implemented (70% vs 30% with no implementation). 25% of randomised trials concluded that hand hygiene-related interventions led to a reduction of infection risk.
Lidal et al., 2015 [144]	N/A*	Day-care centres (18 primary studies)	Respiratory and other infections	Attention to hand hygiene reduces respiratory infections by 17-43%, absenteeism rates by 4-20%. Complex interventions that combine hand disinfection, handwashing, and hygiene education reduce absenteeism due to infections with 30- 50% in school children (age 5 to 12 years).
Smith et al., 2015 [89]	Moderate	Community –adults (2 RCTs, 5 cluster RCTs)	Influenza infections	Hand hygiene and dental hygiene has a positive effect on reducing the risk of infection. Poor quality data.
Benkouiten et al., 2014 [145]	Not systematic	Community	Respiratory tract infections	Contradictory results on effectiveness of hand hygiene in preventing respiratory infections among Haji and variable compliance.
Wong et al., 2014 [86]	High	Community (10 RCTs)	LCI and ILI	Hand hygiene combined with medical facemask had a significant effect (RR 0.73 (0.53 to 0.99) compared to hand hygiene only, which did not have a significant effect (RR 0.90 (0.67-1.20).

Scientific advice - Expert opinion		ECDC	Draft for public consultation 27 August 2019	
Haworth et al., 2013 [146]	Not systematic	Community (mass gatherings)	Respiratory tract infections	Supportive of hand hygiene in Haji due to protection against respiratory viruses, not specific influenza.
Warren-Gash et al., 2013 [127]	Moderate	Community (3 RCTs, 1 case-control for LCI and 9 RCTs, 3 non randomised for ARI/ILI)	Influenza (LCI, ARI/ILI)	Hand washing can reduce transmission of influenza and acute respiratory tract infections, but effectiveness varies depending on setting, context and compliance.
Lee et al., 2012 [126]	Not systematic	Various community settings-Children	Influenza	Hand washing is an important adjunct but improving compliance, standardizing regimens and quantifying its impact remain challenging.
Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Respiratory viruses	The highest quality cluster-RCTs suggest respiratory virus spread can be prevented by hygienic measures, such as handwashing, especially in younger children. The effectiveness of adding virucidals or antiseptics to normal handwashing to decrease respiratory disease transmission remains uncertain.
Carlson et al., 2010 [123]	Not systematic	HCSs	Influenza	Data on physical interventions to prevent influenza transmission support the use of hand hygiene, gowns, gloves, face shields and respiratory protection.
Aiello et al., 2010 [101]	Not systematic	Various settings	Influenza	Hand hygiene and alcohol-based sanitisers and combined approaches with facemask use are effective in reducing ILI rates.
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort, 5 retrospective cohort, 13 before-after)	Respiratory viruses	Frequent handwashing effective against respiratory infections (OR 0.54, 0.44 – 0.67) especially in young children that are less capable of hygienic behaviour themselves and in household members of index cases. Additional benefit from

reduced transmission from children to other household members is broadly supported in results of other study designs, where the potential for confounding is greater. Combination of measures were effective in preventing influenza in households (OR 0.09, CI 0.02 to 0.35) . The incremental effect of adding virucidals or antiseptics to handwashing remains uncertain.

1 *Not assessed because only short [version](#) was available in English

2

3 Cough etiquette

4 Cough etiquette, as a respiratory hygiene measure, refers to covering mouth and nose when coughing and sneezing for
5 example with the use of tissue paper or cloth.

6 **Objective:** Cough etiquette aims to reduce the person-to-person transmission through droplets.

7 **Rationale:** Influenza transmission can be reduced by covering nose and mouth when coughing or sneezing. As a virus,
8 influenza particles are extremely small, measuring 0.08–0.12 µm in diameter [147], and can easily be carried in small
9 droplets expelled during coughs and sneezes.

10 **Evidence of effectiveness:** Four reviews have been included and are presented in Table 5. Of those reviews, two were
11 systematic (one 'high' and one 'moderate' AMSTAR 2 score). There is lack of evidence for the effectiveness of cough
12 etiquette.

13 Recent reviews found no data on the effectiveness of cough etiquette and effectiveness of the measure was therefore
14 considered questionable [76,136]. A recent study that evaluated the effectiveness of cough etiquette in blocking aerosol
15 particles, found that it did not block the release or dispersion of aerosol droplets, particularly those smaller than one micron
16 in size [85]. Although evidence of effectiveness is unavailable, the use of a cough etiquette is traditionally supported in
17 guidelines and recommendations [41,143,148-153].

18 **Operational considerations:** Improper disposal of tissues may increase the risk of virus transmission and spread. There
19 will be small direct costs. Proper disposal bins should be installed. The only major costs are the purchase of tissues and the
20 disposal of significant amounts of contaminated paper to appropriate disposal containers.

21 **Likely acceptability:** Respiratory hygiene would be expected and probably well accepted in a pandemic. Based on a
22 systematic review of public perceptions of NPCs for reducing transmission of respiratory infections, respiratory hygiene
23 measures were viewed as familiar and socially responsible actions to take [71]. They will empower people and give them a
24 practical measure to enact.

25 **ECDC expert opinion:** Although the available evidence base is very limited, cough etiquette use is widely recommended in

1 public health guidelines for all community settings (home, schools, workplaces, HCSs etc.) at all times due to their plausible
 2 mode of action. If recommended as a measure, supplies of materials (e.g. tissues, no-touch bins, covered sputum pots) will
 3 need to be ensured. Proper disposal of the tissues is important, immediately after the use, followed by hand hygiene
 4 measures. Educational programmes can be implemented during ordinary seasonal influenza seasons and pandemics.

5

6

7

8 **Table 5. Summary of reviews and meta-analyses on respiratory hygiene and cough etiquette**

Cough etiquette - Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Kumar et al., 2017 [143]	Not systematic	Various settings (children)	Influenza	Cough etiquette, use of facemasks and hand hygiene are considered by the authors the most important measures to reduce risk of infection transmission from person to person.
Saunders-Hasting et al., 2017 [76]	High	Community (2 RCTs, 8 case-control studies, 4 cohort studies, 2 cross-sectional surveys)	Pandemic influenza 2009 infections	Found no data on the effectiveness of cough etiquette.
Smith et al., 2015 [89]	Moderate	Community –adults (2 RCTs, 5 cluster RCTs)	Influenza infections	Some evidence of effectiveness of oral hygiene (tooth brushing and use of oral solutions).
Benkouiten et al., 2014 [145]	Not systematic	Community (mass gatherings, 17 studies)	Respiratory tract infections	Use of disposable handkerchiefs had no significant beneficial effect on the prevalence of either respiratory symptoms among pilgrims during the Hajj or viral pathogens from their nasal samples.

9

1 **Use of facemasks and respirators**

2 This measure refers to using surgical/medical masks or respirators.

3 **Types of facemasks**

4 Types of facemasks range from the simplest, even home-made masks, to cloth and surgical/medical masks. Surgical masks
5 can protect users from large respiratory droplets (89). They vary in thickness and permeability and are not certified to
6 protect users from airborne infection. After the 2009 pandemic, several studies have focused on assessing the effectiveness
7 of the different types of facemasks. Cloth/gauze masks may induce moisture retention and poor filtration and it is unclear
8 whether they confer clinical protection [154].

9 **Types of respirators**

10 Respirators are specifically designed to protect users from small airborne particles, including aerosols [90,155]. Complex
11 respirators need 'fit testing' and are produced in many different sizes to fit all. They usually have three available sizes
12 (small, medium or large) to cover the anatomical differences of the individuals. Some types of respirators are not
13 appropriate for children and people with facial hair. European standard (EN 149:2001+A1:2009) defines classes for
14 respirators entirely or substantially constructed of filtering material (FFP1-3) [156], while the US National Institute for
15 Occupational Safety and Health (NIOSH) classifies respirators according to their ability to filter airborne particles
16 (N95,N99,N100). FFP2 respirators are equivalent to N95 respirators, filtering >94% of particles smaller than 0.6 µm, and
17 FFP3 respirators are equivalent to N99 respirators, filtering >99% of particles [156]. There are studies that compare the
18 effectiveness of the different types of masks [78,90,155,157].

19 Use of facemasks or respirators:

- 20 • by staff in healthcare settings;

21

22 Use of facemasks:

- 23 • in other high-exposure situations;
- 24 • outside home by healthy people;
- 25 • by people outside of healthcare and patients with respiratory symptoms.

26

27 ***Facemask or respirator use by staff in healthcare settings***

28

29 At least since the 17th century use of a beak-like mask when treating plague cases, physicians have used various types of
30 masks with the objective of preventing transmission of illness. At the end of 19th century, following the realisation of the
31 potential role of human exhalation as a cause of surgical wound sepsis, Huebner recommended the use of a mask made out
32 of two layers of gauze to be used during operations. Here we refer to facemask-wearing by people who are at higher risk
33 through possible or probable exposure to infectious patients in HCSs. Mask-wearing can be recommended for patients and
34 for health care workers (HCWs). The emergence of novel respiratory pathogens, such as SARS-Coronavirus (SARS-CoV) and
35 pandemic A(H1N1) influenza in 2009 highlighted the vulnerability of HCWs to respiratory infections. Similar considerations
36 will apply for situations when people are caring for ill persons in domestic settings.

37 **Objective:** To reduce transmission in HCSs and to provide protection from infection to HCWs to enable them to continue
38 with their activities.

1 **Rationale:** Facemasks and respirators will act as a physical barrier to protect individuals from droplets and/or aerosols,
2 reducing the exposure to the virus and the individual risk of infection.

3 **Evidence of effectiveness:** Twenty-one reviews have been included and the evidence is summarised in Table 6. Of those
4 reviews, 11 were systematic (six 'high', three 'moderate' and two 'critically low' AMSTAR 2 score).

5 Recent systematic reviews and meta-analyses to quantify the effectiveness of PPMs in preventing pandemic influenza and
6 other respiratory virus transmission overall demonstrated mixed results regarding facemask use. Some studies suggested
7 facemask use is significantly protective, especially in HCSs, while others suggested limited or no effectiveness
8 [76,86,90,101,104,123,132,133,145,158-160].

9 Overall, there is some evidence for a protective effect of facemasks and respirators against clinical and laboratory-confirmed
10 respiratory infection among HCWs [78]. Evaluating the different types of facemasks, some studies have shown that
11 compared to surgical masks, respirators may provide greater protection against clinical or bacterial respiratory infection and
12 against self reported ILI, but the studies may have been underpowered to detect a superior protective effect of respirators
13 against influenza [78,90,161]. Evidence of superiority was limited and other studies supported that surgical masks were not
14 inferior to respirators [123,133]. Generally, the findings for the comparative effectiveness of surgical masks and respirators
15 are often inconsistent within and across studies leading to some variability in current guidance documents [78,154,161-
16 165]. No protective effect against SARS was reported for cotton, or paper masks [78].

17 It is unclear what constitutes a sufficient "threshold" for proactive facemask or respirator use to ensure its effectiveness;
18 similar to hand hygiene, this may vary depending on several factors such as susceptibility of the host, level of exposure and
19 risk of severe outcomes [76]. The frequency of use is an important factor that will influence the intervention effectiveness
20 [76,155]. It is unclear what each study considers as regular, irregular, continuous facemask use in a quantitative manner,
21 so this varied substantially in the included studies [76]; for example continuous facemask use in children was shown to
22 confer a significant protective effect relative to non-users in one cross-sectional study, while another reported a non-
23 significant risk increase associated with frequent use of surgical masks and respirators relative to infrequent use, but was
24 based on a small sample size [166]. Wearing a surgical mask or respirator from HCWs continuously throughout the work
25 shift was shown to confer significant protection against self-reported clinical respiratory illness and ILI [78]. Wearing a
26 facemask when ill and in close contact with other individuals has been shown to reduce airborne transmission [167].

27 A combined layered approach may increase the effectiveness of the measures [70,104,155]. Results suggest that
28 campaigns to increase the use of facemasks and the frequency of hand washing in situations with a high risk of exposure
29 will likely contribute to preventing pandemic influenza infection [76]. A targeted intervention strategy could be a combined
30 approach, where frequent hand washing is combined with targeted facemask use, especially among high-risk populations
31 (HCWs, school-aged children, the elderly) [104,168].

32 Education of the users in proper use and disposal of the facemasks is essential and the evidence is that, though people can
33 be supplied with masks and respirators, they will often use them improperly, thus reducing their effectiveness, especially in
34 the case of the more demanding respirators [161,169,170]. Facemasks need to be worn closely fitting and be replaced with
35 new clean and dry masks as soon as they become soiled or moist/humid. The effectiveness of masks and respirators is
36 likely linked to early, consistent and correct usage [155,168].

37 Conclusively, there is evidence to support facemask use in hospital settings as part of infection control measures to reduce
38 the risk of clinical respiratory infection and ILI amongst HCWs during a pandemic. Overall, respirators may convey greater
39 protection compared to facemasks when aerosol-generating procedures are performed [152,154,171-174], although

1 superiority was not shown in all of the studies and universal use throughout the work shift was reported to be likely less
2 acceptable due to greater discomfort [78,89,132,155].

3 **Operational considerations:** Some studies have suggested that there could be adverse effects, as mask-wearing may
4 increase indirect transmission; they may allow symptomatic patients to feel confident that they can continue with their
5 everyday routine, causing a higher risk to further transmit the virus, especially if the mask is not worn properly [170].
6 Another argument is that the constant touching and adjusting of masks with the hands may actually increase influenza
7 transmission. Improper mask disposal may also increase the risk of transmission. Combination with hand hygiene measures
8 after mask disposal may increase effectiveness. Issues of supply and storage of facemasks may rise. Moderate costs will be
9 incurred due to facemask supply, disposal and training, with respirators having increased cost compared with surgical masks
10 [175].

11 **Likely acceptability:** This measure will likely be highly acceptable among HCWs, as there is a tradition of mask wearing in
12 HCSs in the EU. It is quite likely that HCW associations would request or insist that their members have higher level of
13 protection in all circumstances. On the other hand, operational studies in the EU have shown that people wearing
14 respirators find it considerably harder to carry out practical tasks [176,177]. Perceived susceptibility to infection is likely to
15 increase intervention uptake [74].

16 **ECDC expert opinion:** Surgical facemask use by HCW should be recommended in epidemics or pandemics to reduce
17 transmission, in line with current policies mandating standard and droplet precautions when performing routine care for
18 influenza patients. Respirators should be considered in high risk settings by HCWs especially when aerosol generating
19 procedures are performed. Combined measures are also supported, as they seem to increase the effectiveness of the
20 individual measures. Training and monitoring proper use of facemasks will be needed during ordinary seasonal influenza
21 seasons and pandemics.

22 *Facemask use in other high-exposure situations*

23
24 This refers to mask wearing by people who are at higher risk through possible or probable exposure to infectious persons.
25 The following groups may be considered:

- 26 • care-providers for ill people with presumed pandemic influenza (please refer to previous section);
- 27 • people in public places;
- 28 • people in occupations with face-to-face contact with the public.

29 **Objective:** To reduce transmission in higher risk settings and allow persons in key activities to continue to work, while
30 being protected from infection.

31 **Rationale:** Please look at the previous 'Facemask use in HCSs' chapter.

32 **Evidence of effectiveness:** Twenty-one reviews have been included and the evidence is summarised in Table 6. Of those
33 reviews, 11 were systematic (six 'high', three 'moderate' and two 'critically low' AMSTAR 2 score).

34 The evidence for effectiveness of mask use in other high-exposure situations is limited. A meta-analysis showed that
35 facemask use was beneficial against certain respiratory infections at mass gatherings. However, its effectiveness against
36 influenza remained unproven [159]. Several reviews from data obtained at the yearly Hajj mass gatherings have shown that
37 combined facemask use with hand hygiene and vaccination might offer protection from infection, though there is a limited
38 evidence-base and compliance was considered low [146]. Data about the effectiveness of facemask use in such settings are

1 limited, and results are contradictory, highlighting the need for future large-scale studies [145,146,159,178]. See previous
2 'facemask use in HCSs' chapter on evidence of effectiveness.

3 **Operational considerations:** Moderate costs will be incurred due to supply and training. Please also see previous
4 'facemask' chapter on operational considerations.

5 **Likely acceptability:** This is unknown, as there is no tradition of wearing facemasks outside HCS or other occupational
6 settings in Europe. During and following the 2009 pandemic labour representatives (e.g. trade unions) have requested or
7 insisted that their members have protection in certain circumstances. A meta-analysis, not restricted to Europe, showed that
8 about half of the attendees of selected mass gatherings used facemasks [159], while others suggest that compliance was
9 low [146]. Please also see previous 'facemask use in HCSs' chapter on likely acceptability.

10 **ECDC expert opinion:** Use of surgical facemasks by people likely to be exposed to infected persons during a pandemic
11 and by infected persons when they have contact with other individuals is supported, although most evidence originates
12 from HCSs. Facemask use by healthy individuals may be considered when caring for ill persons, especially when the carers
13 belong to high-risk groups or if there are other high-risk circumstances (e.g. due to occupation). A risk-based approach
14 should be considered, identifying people at special risk (e.g. workers with high frequency of face-to-face contact with
15 unselected public) or higher risk settings (e.g. public transport). Wider use of facemasks may need to be considered in
16 severe situations. Proper use and disposal of masks need to be ensured by training users prior to distribution of masks.

17 *Facemask use outside the home by healthy people*

18

19 This refers to healthy people in the community widely wearing masks outside the home to protect against acquisition of
20 infection.

21 **Objective:** To reduce influenza transmission in public places, workplaces and schools.

22 **Rationale:** Please look at previous 'Facemask use' chapters. Although facemask-wearing in public is a common social
23 action in some societies in Asia, this is not the case in Europe.

24 **Evidence of effectiveness:** A recent systematic review and meta-analysis was conducted by WHO to quantify the efficacy
25 of community based use of facemasks in the reduction of LCI [136]. In the pooled analysis, there was a non-significant
26 relative risk reduction of 22% (RR = 0.78, 95% CI: 0.51–1.20, I2 = 30%, p = 0.25) in the face mask group and 8% in the
27 face mask group regardless of the addition of practice of hand hygiene (RR = 0.92, 95% CI: 0.75–1.12, I2 = 30%, p =
28 0.40) [136]. Please see previous 'Facemask use' chapters for evidence of effectiveness.

29 **Operational considerations:** The costs would be substantial. Even though the unit cost is low, considering two or more
30 masks per citizen per day for their outside activities, over the three to five month period of a pandemic the supply costs are
31 high [175]. There would also need to be considerable planning to ensure adequate supplies. There is a need for more
32 comprehensive economic evaluations to compare the relative costs and benefits of these interventions in situations and
33 settings where alternative options are potentially applicable [175]. Please also see previous 'Facemask use' chapters on
34 operational considerations.

35 **Likely acceptability:** This is unknown, as there is little tradition of routine facemask wearing in the community in Europe.
36 Compliance with the facemask use will also affect its effectiveness; preliminary results related to influenza infections showed
37 poor compliance with the measure [101,107,179]. Patients may wear facemasks to protect themselves from further
38 infection, but often not to protect their surroundings [73,107]. A review of the evidence from the 2009 pandemic showed

1 that masks were not used unless there was a perception of high risk, which is in line with evidence from the SARS epidemic
2 [73,74]. Perceived susceptibility and perceived benefits of mask-wearing appeared to be the most significant factors
3 determining compliance [74]. Perceived barriers included experience or perception of personal discomfort and sense of
4 embarrassment [74].

5 **ECDC expert opinion:** There is lack of evidence on effectiveness of wider use of facemasks in community settings,
6 therefore such recommendations should only be considered in severe pandemic scenarios. With extensive implementation of
7 the use of facemasks, the current production capacity of surgical facemasks would be rapidly exceeded, therefore
8 stockpiling facemasks would be needed to ensure the implementation in a pandemic situation. There are implications for
9 training and communication, because proper use and disposal of masks would need to be ensured. Combining facemask use
10 with hand hygiene is likely to increase the effectiveness of the interventions. For high/exposure situations please refer to
11 the 'Facemask use in other high-exposure situations' chapter.

12 *Facemask use by people and patients with respiratory symptoms*

13

14 This refers to mask wearing by people (presumably infected) and confirmed patients with respiratory symptoms.

15 **Objective:** To reduce transmission from people known or presumed to be infected and infectious.

16 **Rationale:** Please look at previous 'Facemask use' chapters.

17 **Evidence of effectiveness:** There is some evidence to support the facemask or respirator wearing during illness to
18 protect others, and public health emphasis on facemask-wearing during illness may help to reduce influenza virus
19 transmission. There are fewer data to support the use of facemasks or respirators to prevent transmission in households
20 [88,136]. Please see previous 'facemask use' chapters on evidence of effectiveness.

21 **Operational considerations:** Some authorities have suggested adverse effects could result if mask wearing was
22 perceived as an alternative to early self-isolation of ill people. Moderate costs will be incurred due to the supplies required
23 per person [175]; these would be considerable, as the masks would presumably be contaminated very quickly and require
24 frequent changing. Please also see previous 'Facemask use' chapters on operational considerations.

25 **Likely acceptability:** This may be better accepted than mask wearing by the general population outside home, and is
26 understandable to the patients and their households and is already a common practice in some healthcare settings [57]. It
27 may also make early self-isolation in home settings more acceptable. People with severe illness find it hard to wear masks,
28 but it is more acceptable by people with mild illness. If masks are recommended exclusively for ill people, some social
29 stigma may be attached to it.

30 **ECDC expert opinion:** Available evidence supports recommending facemask use for infected persons when in contact with
31 other individuals. In HCSs the recommended practice for mask wearing should be followed. Depending on the severity of
32 the pandemic, public health authorities should consider recommending facemask use by symptomatic people in the
33 community. This may be the best use of resources when there are limited amounts of facemasks available.

34

1 **Table 6. Summary of recent reviews and meta-analyses on facemask use effectiveness**

Facemasks and respirators – evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Chao et al., 2017 [171]	Moderate	HCSs (1 study)	Droplet-borne infections	Lack of evidence for the superiority of N95 respirators compared to facemasks against droplet transmission.
Offeddu et al., 2017 [78]	High	HCSs (6 RCTs, 23 observational studies)	Respiratory illness (ILI, bacterial, SARS, other viral infections)	RCTs showed a protective effect of facemasks and respirators against acquisition of clinical respiratory illness (RR 0.59, 95% CI 0.46-0.77) and ILI (RR 0.34, 95% CI 0.14-0.82). Compared to masks, N95 respirators conferred superior protection against CRI (RR 0.47, 95% CI 0.36-0.62) and laboratory-confirmed bacterial (RR = 0.46; 95% CI: 0.34-0.62), but not viral infections or ILI. Observational studies provided evidence of a protective effect of masks (OR 0.13, 95% CI 0.03-0.62) and respirators (OR 0.12, 95% CI 0.06-0.26) against SARS.
Saunders-Hasting et al., 2017 [76]	High	Community (2 RCTs, 8 case-control studies, 4 cohort studies, 2 cross-sectional surveys)	Pandemic influenza 2009 infections	Facemask use provided a statistically non-significant protective effect against acquisition of influenza infection.
Smith et al., 2016 [90]	High	HCSs (3 RCTs, 1 cohort, 2 case-control, 23 surrogate exposure)	Lab-confirmed respiratory infection, ILI, workplace	No significant difference between N95 respirators and surgical masks in associated risk of (a) laboratory-confirmed respiratory infection (RCTs: odds ratio [OR] 0.89, 95% confidence interval [CI] 0.64-1.24; cohort study: OR 0.43, 95% CI 0.03-6.41; case-control studies: OR 0.91, 95% CI 0.25-3.36); (b) influenza-like illness (RCTs: OR 0.51, 95% CI 0.19-1.41); or (c) reported workplace absenteeism (RCT: OR 0.92, 95% CI 0.57-1.50). In the surrogate exposure

				studies, N95 respirators were associated with less filter penetration, less face-seal leakage and less total inward leakage under laboratory experimental conditions, compared with surgical masks, N95 respirators showed a protective advantage over masks in laboratory settings.
Barasheed et al., 2016 [159]	Moderate	Mass gatherings (12 cross sectional, 10 cohort, 2 case studies, 1 RCT)	Respiratory infections	Pooled estimate showed significant protectiveness against respiratory infections, not specific to influenza (RR 0.89, 95% CI: 0.84-0.94).
Bunyan et al., 2013 [155,161]	Not systematic	HCSs	Respiratory infections	Authors conclude that respiratory and facial protection should be used to reduce transmission via the droplet and/or airborne routes or when airborne particles have been created during aerosol-generating procedures (AGPs). There is no strong evidence on superiority of respirators and the list of AGPs needs to be determined. For AGPs, respirators may be beneficial.
Wei et al., 2016 [167]	Not systematic	Various settings	Respiratory infections	Short-range airborne route is potentially very important and may be controlled by mask use and mechanical or natural ventilation.
MacIntyre et al., 2015 [154]	Not systematic	Community and HCSs	Influenza and other respiratory infections	Of the nine trials of facemasks identified in community settings, in all but one, facemasks were used for respiratory protection of well people. These studies found that facemasks and facemasks plus hand hygiene may prevent infection in community settings, subject to early use and compliance. Two trials in healthcare workers demonstrated greater effectiveness of respirators compared to facemasks. There is lack of evidence of effectiveness of cloth masks.
Smith et al., 2015 [89]	Moderate	Community – adults (2 RCTs, 5 cluster RCTs)	Influenza infections	Evidence supporting facemask use in clinical settings, non-superiority of N95 respirators.

Scientific advice - Expert opinion		ECDC		Draft for public consultation 27 August 2019
Wong et al., 2014 [86]	High	Community (10 RCTs)	LCI and ILI	Hand hygiene combined with facemask use had a significant effect (RR 0.73, 95% CI 0.53 to 0.99).
Benkouiten et al., 2014 [145]	Not systematic	Community (mass gatherings)	Respiratory tract infections	Contradictory results on effectiveness of masks in Haji and low compliance.
Rainwater-Lovett et al., 2014 [180]	Critically low	Long term care facilities (LTCFs) (37 observational studies)	ILI, influenza	Moderate protective effect of PPE but not statistically significant (OR 0.63, 95% CI 0.33 - 1.19) for influenza A/B outbreaks.
Haworth et al., 2013 [146]	Not systematic	Community (mass gatherings)	Respiratory tract infections	Observational studies failed to demonstrate any clear benefit of using facemasks among Hajj pilgrims, but no large trial had yet been conducted so lack of sufficient evidence.
Al-Tawfiq et al., 2013 [178]	Not systematic	Mass gatherings	Influenza and other respiratory infections	Mask use may reduce exposure to (inhalation of) droplet nuclei.
Roberge et al., 2011 [177]	Not systematic	Community	Infectious diseases	Surgical masks and respirators have shown efficacy in attenuating the dispersal of infectious agents by adults and children. Limited data on the imposed physiological and psychological burden, tolerance, and proper use by children.
Bin-Reza et al., 2012 [168]	Critically low	Community and HC (8 RCTs, 9 observational studies)	Influenza and other respiratory infections	In 6/8 RCTs no difference between control and intervention. 8/9 observational studies masks/respirators independently associated with reduced risk of SARS. None of the studies established a conclusive relationship between mask/respirator use and protection against influenza infection. Some evidence suggests that mask use is best undertaken as part of a package of personal protection especially hand hygiene. The effectiveness of masks and respirators is likely linked to early, consistent and correct usage.

Scientific advice - Expert opinion		ECDC	Draft for public consultation 27 August 2019	
Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Respiratory viruses	Surgical masks or N95 respirators were effective prevention measures (OR 0.32, CI 0.25 to 0.40), wearing N95 masks (OR 0.09, CI 0.03 to 0.30). N95 respirators and surgical masks equally effective.
Aiello et al., 2010 [101]	Not systematic	Various settings	Influenza	The review concluded that both facemask use and combined approaches with hand hygiene were effective in preventing influenza virus infection.
Cowling et al., 2010 [160]	Critically low	Various settings (6 studies in HC)	Influenza	There is some evidence to support wearing of masks or respirators during illness to protect others, and public health emphasis on mask wearing during illness may help to reduce influenza virus transmission. There are fewer data to support the use of masks or respirators to prevent becoming infected.
Carlson et al., 2010 [123]	Not systematic	HCSs	Influenza	Evidence from one trial that surgical masks are non-inferior to N95 respirators in preventing infection, but data are limited. Significant protective effects when combined with hand hygiene.
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort, 5 retrospective cohort, 13 before-after)	Respiratory viruses	Highly effective in preventing the spread of SARS: wearing masks (OR 0.32, 95% CI 0.25-0.40), wearing N95 masks OR (0.09, 95% CI 0.03-0.30) and handwashing, masks, gloves, and gowns combined (OR 0.09, 95% CI 0.02-0.35). The combination was also effective in interrupting the spread of influenza within households. Limited evidence that respirators superior to simple surgical masks.

1

2 **Other personal protective equipment used in health care settings**

3 Other personal protective equipment (PPE) refers to gloves, gowns and eye protection (goggles or shields) used in special
4 settings for protection against infection. A range of PPE that provides facial and respiratory protection is available
5 [113,125,126].

6 **Objectives:** Other PPE aim to reduce the possibility of exposure to respiratory pathogens and the risk of transmission
7 especially to health-care workers and people in high-risk situations and in close contact with infected individuals.

8 **Rationale:** PPE create a barrier between the infectious agent and the skin and mucous membranes of the healthcare
9 worker reducing contact, droplet, and aerosol transmission depending upon the PPE selected. Eye protection (goggles or
10 shields) may be used to act as a physical barrier to protect conjunctivae. In most clinical scenarios where other PPE are
11 required, they will comprise either a surgical mask or a respirator, with or without eye protection [49,155]. The use of PPE
12 such as gowns, gloves and protective eye covers are suggested mainly for use in HCSs or caring for patients at home or at
13 long-term care facilities [56,57,89,123].

14 When there is contact with blood and other body fluids, including respiratory secretions, gloves made of latex, vinyl, nitrile
15 or other synthetic materials are considered appropriate. Gloves should be removed and discarded after patient care and
16 should not be washed or reused. Hand hygiene should follow glove removal.

17 **Evidence of effectiveness:** Seven reviews have been included and the evidence is summarised in Table 7. Of those
18 reviews, three were systematic (two 'high and one 'critically low' AMSTAR 2 score).

19 Routine care of seasonal influenza infected patients should not necessitate the use of goggles or face shields.
20 Bronchoscopy, respiratory and airway suctioning, and other medical procedures that cause aerosol formation likely facilitate
21 virus dispersal by increasing the risk of splashing/spraying to the eyes. Therefore, face and eye protection may be needed
22 in these occasions [155,181]. The reviews suggest that HCWs should wear an isolation gown when there is a risk that
23 soiling with blood or other body fluids (e.g. respiratory secretions) may occur. There is lack of reviews focusing on the
24 effectiveness of PPE against pandemic influenza infection.

25 Overall, data on physical interventions to prevent transmission of communicable diseases support the use of gowns, gloves,
26 face shields and respiratory protection accompanied by hand hygiene in HCSs [123,182]. A meta-analysis suggested that
27 physical measures are highly effective in preventing the spread of SARS: wearing masks, wearing gloves, wearing gowns
28 and handwashing more than 10 times daily [132,134]. A combination of masks, gloves, gowns and handwashing, was also
29 effective in interrupting the spread of influenza within households [132,134]. A literature review on the influenza outbreak
30 control practices and the effectiveness of interventions in long-term care facilities, showed that PPEs may have modest
31 protective effects [180]. Another review suggested that all means combined (handwashing, masks, gloves and gowns)
32 achieved very high effectiveness [133].

33 **Operational considerations:** Additional costs due to the purchase of such equipment will be incurred in HCSs. Training in
34 proper use and disposal of the PPE will be needed as improper use of PPE may result in increased risk of infection. Proper
35 disinfection/sterilisation of reusable eyewear/gowns is essential after use. Gloves should not be used as a substitute for
36 hand hygiene.

37 Most routine pandemic influenza patient encounters will not necessitate the use of gowns, but it is recommended during
38 procedures such as intubation or when in close contact with a paediatric patient. Isolation gowns can be disposable and

- 1 made of synthetic material or reusable and made of washable cloth. Gowns should be the appropriate size to fully cover the
2 areas requiring protection. After patient care is performed, the gown should be removed and placed in a laundry room or
3 waste container. Hand hygiene should follow gown removal. While some studies show no benefit of the routine use of
4 isolation gowns, others demonstrate that its use is associated with reduced infection rates [81]. Various parameters, such
5 as fabrics used, gown design and interfaces, as well as critical parameters that affect microorganism and liquid transmission
6 through fabrics need to be considered [81].
- 7 **Likely acceptability:** Such measures will be likely highly acceptable in HCSs, as they are already common practice.
- 8 **ECDC expert opinion:** Available evidence supports recommending use of PPE in health care settings, when performing
9 aerosol-generating procedures or when risk of exposure to respiratory secretions is high. The selection and use of PPEs
10 must be accompanied by appropriate education and training. PPE should always be used in combination with proper hand
11 hygiene measures and proper equipment disinfection or disposal.
- 12

1 **Table 7. Summary of recent reviews and meta-analyses on other personal protective equipment (gloves,**
 2 **gowns, facial/eye protection) effectiveness**

PPE (glove, gown, facial/eye protection)- Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Bunyan et al., 2013 [155,161]	Not systematic	HCSs	Respiratory infections	Authors conclude that respiratory and facial protection should be used to reduce transmission via the droplet and/or airborne routes or when airborne particles have been created during aerosol-generating procedures (AGPs). There is no strong evidence on superiority of respirators and the list of AGPs needs to be determined. For AGPs respirators may be beneficial.
Kilinc et al., 2015 [81]	Not systematic	HCSs	Infectious diseases	While some studies show no benefit of the routine use of isolation gowns, others demonstrate that their use is associated with a reduced infection rate.
Rainwater-Lovett et al., 2014 [180]	Critically low	LTCFs (37 observational studies)	ILI	Moderate protective effect of PPE but not statistically significant (OR 0.63 (0.33 - 1.19) for influenza A/B outbreaks.
Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Respiratory viruses	Barriers were shown to be effective in combination (handwashing, masks, gloves, gowns) (OR 0.09, CI 0.02 – 0.25) – result from two studies.
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort, 5 retrospective cohort,	Respiratory viruses	Highly effective in preventing the spread of severe acute respiratory syndrome: wearing masks (OR 0.32, 95% CI 0.25-0.40), wearing N95 masks (OR 0.09, 95% CI 0.03-0.30), wearing gloves (OR 0.43,

		13 before-after)		95% CI 0.29-0.65), wearing gowns (OR 0.23, 95% CI 0.14-0.37), and handwashing, masks, gloves, and gowns combined (OR 0.09, 95% CI 0.02-0.35). The combination was also effective in interrupting the spread of influenza within households. Effective also in paediatric ward or combined with isolation.
Carlson et al., 2010 [123]	Not systematic	HCSs	Influenza	Data support the use of hand hygiene, gowns, gloves, face shields and respiratory protection.
Weber et al., 2010 [182]	Not systematic	HCSs	Influenza	Proper use of personal protective equipment such as masks, N95 respirators, eye protection, and gowns when caring for patients with potentially communicable diseases is proposed by the authors for effective infection control program.

1 Environmental measures

2 Environmental countermeasures include routine cleaning of frequently used surfaces and objects and minimized sharing of
 3 routinely touched objects. Room air ventilation, the use of UV light sources and antimicrobial surfaces (such as copper-alloy
 4 surfaces) are also considered as environmental measures.

5 **Objective:** To enhance protection, reduce the risk of infection and the spread and impact of the pandemic.

6 **Rationale:** Hand mediated transfer of influenza virus from contaminated surfaces/objects to the mouth or nose is a known
 7 route of virus transmission and spread [121,183]. Disinfection of surfaces and objects may therefore reduce the risk of
 8 transmission through hand mediated transfer of influenza viruses. Room air ventilation (natural or mechanical) moves
 9 outdoor air into a building or a room, and distributes the air within the building or room [184]. The general purpose of
 10 ventilation in buildings is to provide healthy air for breathing by both diluting the pollutants originating in the building and
 11 removing the pollutants from it [184]. It may therefore assist in the refreshment of air from aerosolised influenza particles
 12 that cause infection through inhalation or contaminate surfaces and objects.

13 **Evidence of effectiveness:** Eighteen reviews have been included and the evidence is summarised in Table 8. Of those
 14 reviews, four were systematic (three were assessed and had 'moderate' AMSTAR 2 score). Overall, there is indirect evidence
 15 for the effectiveness of environmental measures that mostly originate from studies suggesting that they can mechanically
 16 reduce the viral load from surfaces/objects/air.

1 Studies have shown that disinfection of surfaces and objects reduces the risk of infection and the spread of influenza and
2 other respiratory viruses [89,185-188]. There is indirect evidence that elimination of viruses from surfaces can have a
3 significant impact on contact transmission. Influenza viruses can remain viable on hard, nonporous materials (for example
4 stainless steel) for two weeks and on porous materials (for example microfiber and cotton) for one week, during which time
5 they can spread from those surfaces to human hands [189]. If porous materials dry within 15 minutes, influenza virus
6 becomes undetectable and can remain viable to transfer to hands up to 12 hours. Influenza viruses have been detected on
7 handles, telephones, TV controllers, and kitchen surfaces [186]. Reduced sharing of such objects is presumed to be
8 beneficial. Influenza viruses survive on hands for only 3-5 minutes, but touching contaminated surfaces and then the eyes,
9 mouth, or nose can result in self-inoculation [185].

10 Although direct evidence of effectiveness against influenza infection is limited, the routine surface cleaning measures are
11 considered to reduce the spread of viruses, like SARS and influenza and HC associated infections [183,190-193]. WHO has
12 conducted a systematic literature review and identified three studies (two RCTs and one cross-sectional study) with
13 evidence on object and surface cleaning effectiveness [136]. There was evidence that this could reduce detections of virus
14 in the environment, but there was no evidence of effectiveness against LCIs [136]. Influenza viruses are sensitive to
15 disinfection and can be removed from surfaces by routine cleaning using detergent-based cleaners (e.g. regular soap) or
16 bleach. Other common disinfectants and heat have been also found effective at inactivating influenza viruses [194].
17 Phenolic compounds and glutaraldehyde were found to be effective against viruses [190]. Other means for inactivation of
18 influenza viruses include methylene oxide (used in HCSs), quaternary ammonium compounds (used in poultry farms),
19 triethylene glycol, glucoprotamin-containing disinfectants (used in HCSs), although these methods may not be appropriate
20 for most households and other community settings. Hydrogen peroxide vapour (10 parts per million hydrogen peroxide)
21 that is used in HCSs is found to have virucidal properties also for viruses dried on surfaces [193,195,196].
22 Vapour concentrations of 2 parts per million triethylene glycol can provide effective surface disinfection [197].
23 Formaldehyde and alcohol were also considered effective against pathogens and they are compatible with aircraft
24 components [198]. On the other hand, surface-dried viruses were found to resist glucoprotamin-based disinfection [199]. In
25 addition, it has been shown that the exposure of surfaces to disinfectants alone might be insufficient for virus inactivation
26 and mechanical action should be applied to bring attached viruses into contact with virucidal compounds [199]. Self-
27 disinfecting surfaces are under active investigation and could prove useful, especially in HCSs [200]. They can be created by
28 coating surfaces with heavy metals (e.g. silver or copper), germicides (e.g. triclosan), or using other methods (e.g. light-
29 activated antimicrobials) [200]. Copper alloy surfaces have been considered effective in reducing the microbial load,
30 although their effectiveness specifically against influenza viruses has not been studied [201-206].

31 To help prevent airborne infections, adequate ventilation in HC facilities in all patient-care areas is considered necessary
32 [184,207,208]. It has been suggested from national guidance documents that room ventilation and improving airflow in the
33 living space by opening windows three-four times daily for 10 minutes each time, would be sufficient. There is mechanistic
34 possibility for increased ventilation to reduce mainly aerosol transmission, and to a lesser extent droplet and indirect contact
35 transmission and maintain the appropriate humidity levels in the air [136,209]. The ventilation rate, airflow pattern and flow
36 direction impacts the effectiveness [207]. Increasing ventilation rate may effectively reduce the risk of long-range airborne
37 transmission, while it may be of little usefulness in preventing the droplet-borne transmission [207]. Fresh air natural
38 ventilation and sunlight has been shown to reduce the risk of infection [210,211]. However, evidence on the effectiveness
39 of different ventilation measures are limited [144]. WHO recently conducted a systematic literature review to which only
40 three simulation studies were identified [136]. It is concluded that there is mechanistic plausibility that increased ventilation
41 may reduce influenza virus transmission, especially aerosol-mediated transmission [136].

1 Continuous very low dose-rate far-ultra-violet C (UVC) light in indoor public locations is a promising, safe and inexpensive
2 tool to reduce the spread of airborne-mediated microbial diseases [193,212]. Violet-blue light, particularly 405 nm light, has
3 significant antimicrobial properties against a wide range of bacterial and fungal pathogens and, although efficacy is lower
4 than UV light, it is considered safer for continuous use in occupied environments [200,213,214]. As influenza virus prefers
5 low humidity levels, humidification is another measure that has been proposed [215]. WHO recently conducted a systematic
6 literature review to which no evidence were identified that increasing or decreasing humidity is an effective intervention
7 [136]. The use of novel disinfectants and no-touch decontamination technologies to improve disinfection of surfaces in
8 healthcare is supported by some studies [214,216]. There is, however lack of epidemiological evidence to support the use
9 of the above measures (such as UV light and humidification) and decisions to implement them should be made with caution
10 due to safety concerns.

11 **Operational considerations:** There are implications of incorrect use of the disinfectants, with consequences related to
12 the safety of individuals (e.g. triggering asthma attacks) and appropriate disinfection. Most disinfectants (e.g., bleach)
13 require a pre-cleaning step before applying the disinfectant. Regardless of the product, it is important to follow the
14 manufacturer instructions to ensure safety and effective usage. Depending on the extent of implementation of the measure,
15 there will be increased direct costs, due to material and staff costs that will need to be provided for disinfection. Exposure to
16 UV light may increase the risk of skin cancer and eye conditions. Alternative methods, e.g. use of copper-alloy surfaces,
17 increase building costs and their effectiveness specifically against influenza viruses is yet to be studied.

18 **Likely acceptability:** The likely acceptability of environmental measures in Europe will be high. Everyday actions will
19 engage and empower the public.

20 **ECDC expert opinion:** Available indirect and limited (for some measures) evidence supports recommending the use of
21 environmental measures such as surface cleaning and disinfection, and sufficient ventilation, during epidemics and
22 pandemics due to the transmission modes of influenza viruses and the potential of these measures to reduce transmission.
23 Routine cleaning of frequently used surfaces and objects, minimal sharing of routinely touched objects and air ventilation
24 are especially important in settings where people gather regularly.

25 There is lack of direct evidence on effectiveness against LCI and effectiveness on mitigating the pandemic. Evidence to
26 support use of low-dose far UV-light and air humidification as a disinfection measure against influenza is not sufficient.

27

1 **Table 8. Summary of recent reviews and meta-analyses on effectiveness of environmental measures**

Environmental measures- Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Qian et al., 2018 [207]	Not systematic	HCSs	Respiratory viruses	Properly used ventilation systems can reduce the risk of airborne infection significantly.
Rajakaruna et al., 2017 [208]	Not systematic	HCSs	SARS, Ebola, MERS	Use of quarantine and ventilation functions supported.
Boyce et al., 2016 [214]	Not systematic	HCSs	Various pathogens	Newer disinfectants and no-touch decontamination technologies will improve disinfection of surfaces.
Cook et al., 2016 [203]	Not systematic	N/A	Noroviruses	Copper alloy surfaces may inactivate norovirus by damaging viral capsids. Effective disinfection was achieved by chlorine, calcium or sodium hypochlorite, chlorine dioxide, high hydrostatic pressure, high temperatures, pH values >8.0, freeze-drying, and UV radiation.
Klaus et al., 2016 [198]	Not systematic	Aircraft	Various hogens	Formaldehyde, hydrogen peroxide, and alcohol allow the varying techniques of standard disinfection of surfaces.
Muller et al., 2016 [204]	Moderate	HCSs (11 studies on microbial contamination using copper alloy surfaces)	Various pathogens	Copper alloy surfaces have antimicrobial properties and are effective against health care associated infections (HCAI). Limited information on viruses.
Otter et al., 2016 [183]	Not systematic	HCSs	SARS, MERS CoV, Influenza	Importance of indirect contact transmission (involving contamination of inanimate surfaces) in HCSs is uncertain compared with other transmission routes, principally direct contact transmission (independent of

				surface contamination), droplet, and airborne routes.
Thomas et al., 2016 [196]	Not systematic	HCSs	Influenza	The literature on cleaning surfaces shows influenza can be effectively removed with correct chemicals and techniques. Clean rooms with hydrogen peroxide vapour is effective against influenza and clean the areas that cleaners do not reach.
Wei et al., 2016 [167]	Not systematic	Various settings	Respiratory infections	Short-range airborne route is potentially very important and may be controlled by mechanical or natural ventilation.
Lidal et al., 2015 [144]	N/A*	Day-care centres	Respiratory and other infections	The effectiveness of initiatives concerning physical conditions (occupation density, time spent indoors/outdoors, space, ventilation, etc.) is uncertain, due to limited high quality evidence.
Smith et al., 2015 [89]	Moderate	Community – adults (2 RCTs, 5 cluster RCTs)	Influenza infections	Limited information on effectiveness of surface disinfection effectiveness.
McLean et al., 2014 [213]	Not systematic	-	Bacteria, fungi	Violet-blue light, particularly 405 nm light, has significant antimicrobial properties against a wide range of bacterial and fungal pathogens and, although germicidal efficacy is lower than UV light, this limitation is offset by its facility for safe, continuous use in occupied environments.
Serra et al., 2014 [191]	Moderate	Day-care centres (8 guidelines)	Respiratory infections	Appropriate cleaning of the environment have been uniformly recommended by different guidelines as non-specific prevention measures against respiratory infections. The evidence on the usefulness of

these measures in this setting is limited.

Hobday et al., 2013 [210]	Not systematic	Community	Influenza	There is recent evidence and historical data to support the effects of natural ventilation but no evidence for sunlight.
Rutala et al., 2013 [193]	Not systematic	HCSs	HCAI	Room decontamination units (such as UVC and hydrogen peroxide systems) aid in reducing environmental contamination after terminal room cleaning and disinfection.
Weber et al., 2013 [200]	Not systematic	HCSs	Various pathogens	Improved cleaning and disinfection of room surfaces decreases the risk of HCAI. Self-disinfecting surfaces can be created by impregnating or coating surfaces with heavy metals (e.g. silver or copper), germicides (e.g. triclosan), or miscellaneous methods (e.g. light-activated antimicrobials).
O'Gorman et al., 2012 [201]	Not systematic	HCSs	HCAI	Promising but lack of consensus on: minimum percentage copper alloys required for effectiveness, impact of organic soiling on the biocidal effect of copper, and best approach to routine cleaning of such surfaces.
Grass et al., 2011 [205]	Not systematic	Various settings	Microbes	Effectiveness of metallic copper surfaces.

1 *Not assessed because only short [version](#) was available in English

2 Social distancing measures

3 Social distancing measures refer to measures, such as school closures, voluntary quarantine of exposed persons, voluntary
4 home isolation of patients and other measures in workplaces, schools or mass gatherings.

5 **Objective:** Social (/interpersonal) distancing policies aim to minimize illness and transmission of infection within the various
6 community settings such as home, workplace, pre-school, school, university, childcare centre, long-term care facility, HCSs
7 etc.

1 **Rationale:** Increasing the physical distance between individuals by various means will reduce the spread and transmission
2 of influenza.

3 **Evidence of effectiveness:** Various measures exist within this category. Some are considered to be effective, while others
4 lack direct evidence of effectiveness. They are often expensive, unpopular and difficult to implement, although social
5 distancing measures have been a recent focus of investigation and some of these measures were implemented during SARS
6 outbreak and the 2009 A(H1N1) influenza pandemic [79,100,217-221]. Results from simulation exercises suggested a
7 critical role of social distancing in the potential control of a future pandemic and indicated that such interventions are
8 capable of arresting influenza epidemic development, if they are used in combination with other measures, activated
9 without delay and maintained for a relatively long period [70,222]. For the implementation of social distancing measures,
10 consideration of asymptomatic infections and individuals that are infected but do not have fever is important, as fever is not
11 always present in influenza infections; there are studies that show that only half of the influenza cases are presented with
12 fever [21,223]. Individual social distancing measures are considered separately in the following chapters.

13 **Operational considerations:** Depending on the measure, social distancing measures may have societal, ethical, legal and
14 economic implications.

15 **Likely acceptability:** Based on a systematic review of the public perceptions of NPCs for reducing transmission of
16 respiratory infection, there was hesitation about adopting interpersonal distancing behaviours due to their perceived
17 adverse impact and potential of social stigma [71]. Common perceived barriers included beliefs about personal
18 susceptibility, transmission of infection and concerns about self-diagnosis in emerging respiratory infections [71]. Limited
19 information is available to develop policies and procedures on some of the social distancing measures. Additional research is
20 needed to assess the feasibility and effectiveness of practices to promote social distancing [224].

21 **ECDC expert opinion:** Available evidence supports a layered approach of social distancing measures, depending on the
22 severity level and the impact of the pandemic. Such measures may potentially have a high societal impact, so they would be
23 mostly applicable in more severe pandemics. In the following chapters, the social distancing measures are considered
24 separately.

25 **Voluntary isolation of cases not requiring hospitalisation**

26 This measure refers to ill persons likely infected by influenza but with no need for hospital care, requested to voluntarily
27 remain in a single, dedicated room through the duration of symptoms (usually 5-7 days or depending on the estimated
28 infectious period of the pandemic virus).

29 **Objective:** To reduce transmission by reducing contact between uninfected and infected persons.

30 **Rationale:** Typically, influenza virus can be transmitted from an ill person to another person via direct or indirect contact,
31 between one day before the onset of symptoms and 5-7 days after the onset of symptoms. This may vary in the pandemic
32 situation, according to the characteristics of the pandemic strain. Isolation of infected individuals should reduce the
33 likelihood of transmission and spread of the virus.

34 **Evidence of effectiveness:** Four reviews have been included and the evidence is summarised in Table 9. Of those
35 reviews, three were systematic (two 'high' and one 'critically low' AMSTAR 2 score).

36 The amount of influenza virus shed by symptomatic individuals is greater than in the asymptomatic phase, but viral
37 shedding typically begins shortly after infection and before the onset of symptoms [225]. This limits the efficacy of isolation,
38 with maximum effectiveness if individuals are completely isolated almost immediately after contact with an infected person

1 [41]. Generally, the measure is considered effective, although the quality of evidence is low and partly originating from
2 modelling studies. There is also an increased risk of intra-household transmission from index cases to contacts that may be
3 reduced with the use of antiviral prophylaxis of household members (if available) [70,100,133]. A small proportion of
4 infected cases will have a very high likelihood of transmission, either due to shedding patterns or contact patterns. The
5 possibility of such "super spreaders" needs also to be considered [226]. In the case of young children and
6 immunocompromised patients, viral shedding and its duration will likely be increased.

7 WHO recently conducted a systematic literature review, to which four epidemiological studies and 11 simulation studies
8 (and therefore evidence of low strength) were included. They suggested that isolation of sick individuals could reduce
9 transmission in epidemics and pandemics [136,227-229]. There is also mechanistic plausibility for this measure to be
10 effective in reducing transmission [136].

11 **Operational considerations:** There may be moderate secondary effects, as other healthy individuals in the same house
12 may be exposed to the risk of infection. Unless carefully managed, the isolated person may not receive adequate care and
13 support, especially if elderly or living alone. There would be issues of people not being available for work, including
14 caregivers. There can be moderate financial and practical disincentives, job or income insecurity or the need to care for
15 others.

16 **Likely acceptability:** Acceptability is considered high as this is an extension of advice given during seasonal influenza.
17 However, acceptability will vary by circumstance. Based on a systematic review of the public perceptions of NPCs for
18 reducing transmission of respiratory infection, there were concerns about adopting isolation due to the perceived adverse
19 impact and social stigma [71]. In five studies, between 50% and 96% of respondents reported intending to stay home from
20 work with symptoms of A(H1N1)pdm09, whereas in six studies, the proportion ranged from <1% to 26% [73].

21 **ECDC expert opinion:** Available evidence supports recommending voluntary isolation of infected individuals at all times
22 during epidemics and pandemics. Prompt recognition of illness will be important in order to ensure rapid isolation and
23 antiviral prophylaxis of household members should be considered for the duration of isolation. Support for financial, social,
24 physical, and other needs of the patients and caregivers needs to be carefully planned. Training and supplies will be
25 essential for infection control for household members providing care for the ill person. A combination with personal
26 protective and environmental measures will increase the intervention effectiveness.

27 **Voluntary quarantine of exposed household members**

28 Quarantine, or the sequestration of potentially infectious individuals, was first used in the mid – 14th century in Southern
29 European cities such as Reggio in Italy and Ragusa in Croatia as a countermeasure to slow the introduction of plague into
30 these cities.

31 Voluntary quarantine of household contacts of a person with suspected influenza refers to remaining at home for a defined
32 period (e.g. for the incubation period) after the last exposure. If symptoms of illness occur, they would then self-isolate and
33 seek medical advice.

34 **Objective:** To reduce transmission by decreasing the spread of the influenza virus from household settings.

35 **Rationale:** The people at highest risk of acquiring influenza are the household contacts of a case. Since infectivity early in
36 the infection is high, voluntary quarantine of household contacts before they become ill may help prevent further
37 transmission of the virus to the community.

38 **Evidence of effectiveness:** Four reviews have been included and the evidence is summarised presented in Table 9. Of

- 1 those reviews, three were systematic (two 'high' and one 'critically low' AMSTAR 2 score).
- 2 Implementing transmission barriers, like quarantine, are considered effective at containing respiratory virus epidemics
3 [70,132,133]. Most of the evidence originate from modelling studies that suggest that cumulative attack rates would be
4 reduced by such measures although some argue that the reduction would be less than might be thought intuitively
5 [227,228]. Household quarantine alone reduced overall AR by 10% and peak AR by 20%, whereas a combination of school
6 and workplace closure, antiviral treatment and prophylaxis, and household quarantine reduced overall AR by more than
7 60% and peak AR by more than 80% [228]. Based on the A(H1N1) 2009 experience, a review concluded that strategies like
8 quarantine may have been beneficial in reducing transmission at the individual level at home, although secondary attack
9 rates during the pandemic were similar to those with seasonal influenza [230]. WHO recently conducted a systematic
10 literature review, to which six epidemiological and 10 simulation studies were included; overall, quarantine was effective in
11 reducing burden of disease, transmissibility and in delaying the peak of the epidemic [136]. Some studies suggested a
12 significant improvement in effectiveness of quarantine when combined with other measures, such as isolation, antiviral drug
13 prophylactic use or school closure [136]. Severity is an important determining factor in the definition of a pandemic when
14 considering to undertake such social distancing measures [231]. Please also see the chapter on evidence of effectiveness
15 for 'Voluntary isolation of cases not requiring hospitalisation'.
- 16 **Operational considerations:** There will be substantial cost, mainly due to a significant number of people being off work.
17 Social, legal and ethical issues may rise due to the restriction in the freedom of movement of individuals. The likelihood of a
18 household contact who is concurrently quarantined with an isolated individual, becoming infected has been estimated to
19 increase with each day of quarantine The likelihood of a household contact who is quarantined with an isolated patient
20 becoming a second case has been estimated to increase with each day of quarantine [136,232].
- 21 **Likely acceptability:** The acceptability may be low and compliance may be difficult with a measure for which no personal
22 benefit is perceived and the community benefit is unclear [233]. There might be lack of compliance or abuse (real or
23 perceived) by some people undermined confidence in the measure and particular problems with special groups in the
24 population [233]. Experience from previous pandemics and the SARS epidemic is variable but often negative in communities
25 with cultural similarities to Europe [105,234]. If such disruptive measures are implemented, national laws and regulations
26 will need to be considered.
- 27 **ECDC expert opinion:** Available, limited, evidence, originating mainly from modelling studies that are considered evidence
28 of weak strength, support recommending voluntary quarantine based on a situational risk assessment. Voluntary quarantine
29 may delay the start of the local epidemic during early stages of pandemics, and as such it is an option that may be
30 considered during pandemics of high severity, although the dis-benefits and issues of compliance would need to be carefully
31 weighed against the benefits. Antiviral prophylaxis will further decrease the risk of infection among exposed persons, at
32 least in household settings. Rapid identification of cases in the household will enhance the effectiveness of quarantine. If
33 such a measure is implemented, support to households that are affected as a whole should be planned. Training/education
34 on infection control in the home would be necessary.
- 35 **Table 9. Summary of recent reviews and meta-analyses on the effectiveness of isolation of cases and**
36 **voluntary quarantine of exposed persons**

Isolation of cases/voluntary quarantine of exposed persons- Evidence of effectiveness

Study	AMSTAR 2	Setting (included	Infection	Conclusions
-------	----------	-------------------	-----------	-------------

	score	studies)	type	
Rashid et al., 2015 [100]	Not systematic	Various settings	Pandemic influenza	Voluntary home isolation and quarantine are effective and acceptable measures but there is an increased risk of intra-household transmission from index cases to contacts.
Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Respiratory viruses	Case-control studies suggested implementing transmission barriers, isolation and hygienic measures are effective at containing respiratory virus epidemics. Cohorting in paediatric wards, early identification of cases and isolation of close contacts were effective.
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort, 5 retrospective cohort, 13 before-after)	Respiratory viruses	Limited evidence showing social distancing is effective, especially if related to risk of exposure. Early identification of cases followed by isolation was effective.
Lee et al., 2009 [70]	Critically low*	Community (19 modelling studies)	Pandemic influenza	Isolation of cases and quarantine of close contacts are considered by the authors as important interventions during containment phase. Combined approaches (also with pharmaceutical interventions will increase effectiveness).

1 *According to AMSTAR 2 graded as critically low due to lack of description of risk of bias for their included studies, which
2 may however not be appropriate for the included studies.

3 **Interventions in educational and child care settings**

4 School closure policies as an example of social distancing measures have been considered as a policy to mitigate influenza
5 epidemics and pandemics spread [235]. Respiratory infections spread easily in day care and school settings, and children
6 are considered to be the main drivers of influenza transmission in the community. During previous pandemics, schools have
7 closed reactively due to widespread transmission and increased absenteeism of children and employees, instead of a more
8 proactive controlled manner before extensive viral spread [235]. Schools and day care institutions should have an
9 operational plan for closure and reopening triggers in a crisis, and parents and carers would need to be involved in order to
10 make the necessary arrangements. Other measures, such as student distancing, division of classes in smaller groups,
11 division of school activities in morning/afternoon groups, open-air classes/activities, shortened day/week duration, e-

1 learning opportunities and cessation of transportation with school buses may be alternative solutions, when the situation
2 does not justify school closures [77].

3 Several difficulties arise in implementing this policy: the need to define and measure the triggers and level of severity and
4 transmissibility in children to justify closures; the secondary effects that will probably be major and the transmission of the
5 virus outside school [41]. In many settings, schools additionally perform special social functions providing social care, HC
6 and meals [236].

7 Other, less disruptive, non pharmaceutical measures may also be applied in educational settings to mitigate the impact of
8 the pandemic. Those are: hand and respiratory hygiene, voluntary isolation at home, isolation of staff and students when
9 they become ill during school hours, reducing crowding at schools and school buses, proper environmental cleaning and
10 ventilation, dissemination of public health messages, ensuring essential services and supplies [229].

11 *Proactive school and day care closures*

12
13 Proactive closures refer to the early and planned closure of schools and day care facilities prior to the start of local
14 transmission of the virus.

15 **Objective:** To prevent the amplification and spread of influenza transmission in schools and the community.

16 **Rationale:** School children and children attending day care facilities are considered to be the main drivers of influenza
17 transmission and contact transmission occurs extensively at educational settings. School closures will reduce the extensive
18 influenza virus transmission and spread that occurs in schools and its further spread to the community.

19 **Evidence of effectiveness:** Six reviews on the effectiveness of school closures have been included and the evidence is
20 summarised in Table 10. Of those reviews, four were systematic (all had 'critically low' AMSTAR 2 score, although the
21 AMSTAR 2 tool may not be an appropriate tool to score three of these reviews that included only observational or modelling
22 studies).

23 Reviews suggest that school closures can be a useful and effective control measure during an influenza pandemic,
24 particularly for reducing peak demand on health services [9,100,136,220,221]. Some observational analyses have shown a
25 decrease in virus transmission during seasonal influenza outbreaks or pandemics that coincided with school holidays
26 [105,111,237,238]. The positive effects were however smaller than predicted by some modelling studies, perhaps because
27 children also mix outside schools [179,236,239-242]. During the 2009 A(H1N1) pandemic, school closures were shown to
28 have caused a contact rate reduction and lower number of influenza cases in school-aged children [9,236,243]. Modelling
29 studies generally support school closures and confinement in the home, as an effective measure for reducing overall attack
30 rates within communities, especially when coupled with antiviral prophylaxis [70,242].

31 From the experience from the 2009 A(H1N1) pandemic shared during a WHO consultation, countries suggested that school
32 closures were effective in mitigating the spread of influenza and reducing within school transmission, especially in the early
33 phases of an outbreak, although they were not necessarily effective (or the effect could not be readily measured) for
34 reducing overall community transmission [235].

35 A recent meta-analysis also investigated the impact of school closure and the optimal duration of closure [244]. It
36 concluded that implementing school closure before or after the epidemic reaches its peak, reduced the overall influenza
37 epidemic, by a mean reduction of 29.65%. A more pronounced effect was observed if the measure was implemented earlier
38 during the pandemic and the longer the duration of closure the more the epidemic peak would be delayed [244]. These

1 findings suggest that policy makers could consider school closure policies as a response strategy to influenza pandemics,
2 depending on the feasibility and the cost [84,244,245].

3 The advantage of proactive closures is that they can be performed before any transmission has taken place in schools. The
4 disadvantage is the difficulty of identifying the optimal triggers to activate and de-activate the measure, so that the
5 intervention is not implemented too early, in which case it will be costly and difficult to sustain. School closures appear to
6 have the potential to reduce influenza transmission, but the heterogeneity in the data available means that the optimum
7 strategy (e.g. the ideal timing and duration of closure) remains unclear [219]. Please also see 'Reactive school closure'
8 chapter for evidence of effectiveness.

9 **Operational considerations:** There can be financial and practical disincentives [235] and major secondary effects from
10 job or income insecurity or the need to care for others. Consideration of a public policy to permit a paid leave of absence
11 from work for parents during school closures may be beneficial to mitigate some of the secondary effects. A significant
12 proportion of healthcare workers that have school-aged children might also need to refrain from their duties in order to care
13 for their children [236]. School closures have the potential to cause adverse consequences, which may likely
14 disproportionately affect students, families and the communities [246,247]. There would be disruption of education, as well
15 as other services provided by the schools (e.g. school meals, doctor visits). Legal issues would need to be closely monitored
16 [235]. The disruption caused by school closures would be significant, especially for west European societies that have little
17 tradition of school closures outside holiday seasons. A greater understanding of age-dependent behaviours, during school
18 closures as a consequence of a pandemic, is required [248]. Moderate costs will be incurred due to the planning and
19 logistics of school closures. There is a need for studies of the cost-effectiveness of this measure [248]. Existing studies
20 suggest that school closures may not be cost effective for mild pandemics, although they might be for more severe
21 situations [249].

22 **Likely acceptability:** EU countries have implemented school-related measures during seasonal epidemics and the 2009
23 A(H1N1) pandemic. The fact that some countries already have experience of gradual or regional closures for seasonal or
24 pandemic influenza outbreaks demonstrates that logistic and feasibility challenges of school closure strategies can be to
25 some extent managed [84,221,250].

26 **ECDC expert opinion:** Available evidence supports recommending proactive closures of schools and day care facilities only
27 during severe epidemics and pandemics, as they can be associated with significant societal and economic costs. The extent
28 of proactive school closures should be decided taking into account the balance of the assessed severity level of the
29 pandemic compared to the adverse effects of such closures on the community. The optimal timing and duration of the
30 implementation of the measure would need to be carefully considered on a case-by-case basis. Whole-of-society plans to
31 mitigate secondary effects should be considered. Policy makers should also consider intermediate options, such as partial
32 school closures. Planning to mitigate transmission within schools, while children continue attending, is always advisable.

33 *Reactive school and day care closures*

34
35 Reactive closures of schools have been implemented when widespread virus transmission was observed in the school. A
36 distinction can be made between school closures and class dismissal (when a school remains open but the students are
37 dismissed). The latter might be preferable in some instances, as it makes re-opening and support of vulnerable children and
38 families easier [236,251].

39 **Objective:** To reduce the anticipated amplification and spread of influenza transmission in schools, as well as reduce the
40 indirect impact on the community.

- 1 **Rationale:** Please see 'Proactive school closure' chapter above.
- 2 **Evidence of effectiveness:** Six reviews on the effectiveness of school closures have been included and the evidence is
3 summarised in Table 10. Of those reviews, four were systematic (all had 'critically low' AMSTAR 2 score, although the
4 AMSTAR 2 tool may not be an appropriate tool for three of these reviews that included only observational or modelling
5 studies).
- 6 The effectiveness of reactive school closure in reducing influenza transmission varied in the included studies, but was
7 generally limited. A review of modelling studies suggested that reactive school and workplace closures alone did not impact
8 on overall attack rate, but reduced peak attack rate by about 40%, while combination approaches (antiviral treatment and
9 prophylaxis, school closure and pre-pandemic vaccination with 20% coverage) reduced overall AR by more than 60% and
10 peak AR by more than 75% [70,228]. During the 2009 A(H1N1) pandemic, closures mostly occurred in schools that
11 reported significant illness and were likely motivated by excessive absenteeism, rather than done proactively [252].
- 12 Few studies have analysed more specific policies; one model-based analysis categorised four types of school closures:
13 reactive gradual closure, starting from class-by-class, then grades and finally the whole school [84]. Four closure strategies
14 were considered: nationwide, countywide, reactive school-by-school, reactive gradual and their potential impact was
15 assessed. Policies were considered based on triggers that are feasible to monitor, such as school absenteeism and national
16 ILI surveillance system. This study found that, under specific constraints on the average number of weeks lost per student,
17 reactive school-by-school, gradual, and county-wide closure gave comparable outcomes in terms of optimal infection attack
18 rate reduction, peak incidence reduction or peak delay. Optimal implementations generally required short closures of one
19 week each; this duration was considered long enough to break the transmission chain without leading to unnecessarily long
20 periods of class interruption. Gradual and county closures were less sensitive to variations in school absenteeism and thus
21 were slightly more feasible in practice [84]. Please see 'Proactive school closure' chapter.
- 22 **Operational considerations:** Please see 'Proactive school closure' chapter above.
- 23 **Likely acceptability:** Please see 'Proactive school closure' chapter above.
- 24 **ECDC expert opinion:** Available evidence, which is generally of low quality and based on modelling studies, do not
25 provide support for reactive school and day care closures on order to impact the evolution of a pandemic. Reactive school
26 closures may however be necessary to prepare for, due to high absenteeism and operational issues. As for proactive school
27 closures, the timing and duration of the closures will need to be carefully considered on a case-by-case basis. Planning to
28 mitigate transmission within schools while children continue attending, is always advisable. Whole-of-society plans to
29 mitigate secondary effects should be considered.
- 30

1 **Table 10. Summary of recent reviews and meta-analyses on school closure effectiveness**

School closures- Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Bin Nafisah et al., 2018 [244]	Critically low	Educational settings (31 studies)	Influenza	Implementing school closure before or after the epidemic reaches its peak, reduced the overall peak of the influenza epidemic, by a mean reduction of 29.65%. Early implementation and long duration increased the effectiveness.
Uscher Pines et al., 2018 [224]	Not systematic	Educational settings	Influenza	Limited information available on effectiveness and to develop policies and procedures on social distancing. Most frequently identified school practices were cancelling or postponing after-school activities, cancelling classes or activities with a high rate of mixing/contact that occur within the school day, and reducing mixing during transport.
Rashid et al., 2015 [100]	Not systematic	Educational and other community settings	Pandemic influenza	School closure, whether proactive or reactive, appears to be moderately effective and acceptable in reducing the transmission of influenza and in delaying the peak of an epidemic but is associated with very high secondary costs.
Jackson et al., 2014 [220]	Critically low*	Educational settings (45 modelling studies)	Influenza	Most modelling analyses indicated that school closures would lead to reductions in the peak incidence and cumulative attack rate. Predictions of the reduction in the peak incidence were in most studies between 20–60%.
Jackson et al., 2013 [219]	Critically low*	Educational settings (79 epidemiological	Influenza	Effective to reduce influenza transmission, but due to

		studies)		heterogeneity in the available data optimum strategy remains unclear (e.g. ideal length and timing of closure).
Lee et al., 2009 [70]	Critically low*	Educational settings (19 modelling studies)	Influenza	Effective if done early, decisively, and for prolonged periods.

1 * According to AMSTAR 2 graded as critically low due to lack of description of risk of bias for their included studies, which
2 may however not be appropriate for the included studies.

3 Measures in the workplace and public places

4 These measures refer to a variety of means to reduce risk of infection in the workplace, on the way to and from work and in
5 public places. These measures include: flexible working schedules/shifts for employees, the opportunity of distance
6 working/teleworking, encouraging social distancing measures within the workspace, increased use of emails,
7 teleconferences to reduce close contact, reduced contact between employees and customers, reduced contact between
8 employees, adoption of flexible leave policies and promotion of use of other personal protective countermeasures in
9 combination [70].

10 **Objective:** To reduce workplace and community transmission, delaying the spread and slowing the peak of the pandemic.

11 **Rationale:** Influenza can easily transmit from person-to-person in work and other public places where people gather in
12 contained spaces for long periods. Viral transmission will be reduced by decreasing the frequency and length of social
13 interactions and the physical contact between individuals.

14 **Evidence of effectiveness:** Six reviews have been included and the evidence is summarised in Table 11. Of those
15 reviews, five were systematic (two 'high', two 'moderate' and one 'critically low' AMSTAR 2 score, although the AMSTAR 2
16 tool may not be an appropriate tool to score one of these reviews that included only modelling studies).

17 Influenza attack rates in working-age adults (aged 18-64 years) have been reported to be as high as 15.5% over an
18 influenza season [24]. Measures at work, such as home working, are considered modestly effective and could reduce the
19 overall and peak number of influenza cases, as well as delaying the peak occurrence [100,253]. Combination with other
20 interventions can improve the effectiveness [136].

21 Overall the evidence on effectiveness of workplace closures is limited and of low strength, mostly originating from
22 simulation studies [136]. Modelling studies suggest that workplace closures resulted in a small reduction in cumulative
23 attack rates or peak attack rates, although there is a decrease when assessing the effect of combining interventions
24 [72,228,254,255]; most modelling studies assessed workplace closure in combination with school closures or other
25 measures. A recent review of modelling studies suggests that workplace closures in combination with other measures may
26 be effective, although will have marked implications [70]. Workplace closures in combination with home working were found
27 to be modestly effective and were acceptable, but likely to be economically disruptive [100]. Overall, large-scale workplace
28 closures could delay the epidemic peak for more than 1 week, and small-scale closures may have a modest impact on
29 attack rate or peak number [136]. A decision for workplace closures is difficult because of the lack of objective information
30 on the level of influenza transmission that takes place in the workplace, on transport going to and from work and in other
31 public places. Modelling studies suggest proportions of transmission in such settings, however there are few empirical data

1 to support these suggestions [105,111]. A recent review of epidemiological and modelling studies showed that social
2 distancing in workplaces was associated with a reduction in influenza-like illness and seroconversion to A(H1N1)pdm09
3 [253]. However, the overall risk of bias in the epidemiological studies was high. The modelling studies estimated that
4 workplace social distancing measures alone produced a median reduction of 23% in the cumulative influenza AR in the
5 general population [253]. It also delayed and reduced the peak influenza attack rate [253]. The reduction in the cumulative
6 attack rate was more pronounced when workplace social distancing was combined with other non-pharmaceutical or
7 pharmaceutical interventions. However, the effectiveness was estimated to decline with higher basic reproduction number
8 values, delayed triggering of workplace social distancing, or lower compliance [253].

9 Multiple factors, such as guilt associated with missing work, inability to complete tasks, security and access to paid leave
10 days, affect employees' decision to stay home when experiencing ILI symptoms [256]. Their willingness to stay home when
11 ill may thus be associated with access to paid leave days. Other measures that would enable them to fulfil their tasks would
12 be more acceptable and effective.

13 **Operational considerations:** There will be variable to moderate secondary effects that will depend on the extent of the
14 measures. There will be significant secondary societal and economic effects from workplace closures in the highly
15 interdependent societies of Europe.

16 **Likely acceptability:** Some organisations are used to closing, or at least scaling activities down, during holiday seasons
17 but not for extended periods. Employees will accept workplace closures if there is no anxiety regarding job security and
18 income replacement. It would be convenient for parents if they need to care for their children during school closures. There
19 will be moderate costs that will depend on the extent of the measures. Costs of full workplace closures for any period of
20 time will be significant. Other workplace measures will be more acceptable.

21 **ECDC expert opinion:** Available evidence supports recommending measures at workplaces (e.g. teleworking, social
22 distancing), which can be modestly effective and feasible during all phases of a pandemic. The selection of measures will
23 depend on the company and the type of work and may have significant economic and social consequences. Other personal
24 protective and environmental measures should be applied in combination with workplace measures. Limited evidence from
25 modelling studies support recommending workplace closures in pandemics of higher severity. Business continuity plans
26 should include pandemic scenarios.

27

1 **Table 11. Summary of recent reviews and meta-analyses on effectiveness of measures at workplaces and**
 2 **public places**

Workplace/Public place measures- Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Ahmed et al., 2018 [253]	Moderate	Workplaces (12 modelling studies, 3 epidemiological)	Pandemic Influenza	Epidemiological and modelling studies indicated that workplace social distancing reduced the overall number of influenza cases. It also reduced and delayed the influenza peak. Combination with other measures increased effectiveness. Effectiveness was estimated to decline with higher basic reproduction number values, delayed triggering of workplace social distancing, or lower compliance.
Hansen et al., 2018 [125]	Moderate	Workplace settings (3 cluster RCTs, 2 prospective interventional, 2 pre-post design)	Infectious eases	Workplace strategies to prevent and control infectious illness transmission may reduce costs and productivity losses experienced by businesses related to infectious illness absenteeism.
Rashid et al., 2015 [100]	Not systematic	Various setting	Pandemic influenza	Work closure and home working are also modestly effective and are acceptable, but likely to be economically disruptive.
Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Respiratory viruses	Insufficient evidence to support social distancing (spatial separation of at least one metre between those infected and those non-infected).
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort,	Respiratory viruses	Limited evidence for social distancing being effective, especially if related to risk of exposure.

		5 retrospective cohort, 13 before-after)		
Lee et al., 2009 [70]	Critically low*	Community (19 modelling studies)	Influenza	Workplace closures in combination with other measures may be effective, although will have marked implications.

1 * According to AMSTAR 2 graded as critically low due to lack of description of risk of bias for their included studies, which
2 may however not be appropriate for the included studies.

3 Measures related to mass gatherings

4 This refers to interpersonal distancing measures implemented during mass gatherings to avoid crowding, as well as
5 organisational measures, such as postponing or cancelling an event. It also refers to other NPCs, such as hand and
6 respiratory hygiene that will need to be applied.

7 **Objective:** This measure will aim to reduce transmission and dissemination of influenza through large gatherings.

8 **Rationale:** Mass gatherings increase the close contact of people for long periods of time in contained spaces, increase
9 influenza virus transmission and spread, assist in the introduction of the virus to the community hosting the event, and
10 increase influenza virus spread in the gathering and to healthy household members after attending the event. Restricting,
11 modifying, postponing, or cancelling large gatherings may slow virus spread [257-262]. Combined use of other NPCs will
12 aim to reduce the person to person viral transmission.

13 **Evidence of effectiveness:** Six reviews on the effectiveness of measures in mass gatherings have been included and the
14 evidence is summarised in Table 12. Of those reviews, two were systematic (2 'moderate' AMSTAR 2 score).

15 Large meetings, conferences, religious pilgrimages, sports events and other national and international events play an
16 important role in spreading infectious diseases [257,261-267]. In the case of gastrointestinal and respiratory illnesses, the
17 explosive spread following small or large gatherings is commonly reported [145,264,265]. The most common outbreaks at
18 these mass gatherings involve respiratory infections and vaccine preventable diseases, mainly influenza and measles
19 [83,145,159].

20 Restricting mass gatherings, in combination with other social distancing measures, may help reduce transmission, but
21 conclusive evidence on the individual effect of mass gathering restriction alone could not be identified [136,145]. Models
22 suggest that cancellation of non-essential public gatherings might help to decrease rates of transmission and overall
23 morbidity, but the effectiveness of the intervention has not been quantified [41,257]. Evidence suggests that event duration
24 and extent may be the key factors that determine the risk of influenza transmission, along with whether the venue is
25 indoors or outdoors [268]. A modelling study has shown that monitoring, postponing, or cancelling large public gatherings
26 may be warranted close to the epidemic peak, but not earlier or later during the epidemic [269]. From the experience of the
27 2009 pandemic shared during a WHO consultation on 24 June 2009, reporting countries stated they had not instituted
28 restrictions on mass gatherings and were taking a case-by-case approach for any upcoming events in their countries [235].

29 Regarding the other NPCs that could be implemented during such events to mitigate the impact of the pandemic, it is often
30 difficult to assess the effect of a single NPC independently from other NPCs or factors in infection control, such as
31 environmental hygiene, crowding and education [145]. There is lack of evidence regarding adherence to NPCs and

1 vaccination. One review suggested that a modest proportion of attendees was shown to adhere to facemask use [159],
2 while others suggested that adherence was low [145,146]. Facemask use seems to be beneficial against certain respiratory
3 infections at mass gatherings, although evidence is lacking regarding the effectiveness against influenza [145,146,159,178].

4 **Operational considerations:** There will be secondary societal and economic effects on organisers, attendees and
5 employees and considerable costs; any decision to cancel all events over a period would be controversial and costly, so
6 therefore will need to be considered with a risk-based approach. The issue of financial liability and meeting insurance would
7 need to be considered.

8 **Likely acceptability:** The public likely expects cancellation, postponements and re-arrangements of mass gatherings
9 based on the perceived pandemic severity. The use of other NPCs during mass gatherings will also be likely acceptable
10 [270].

11 **ECDC expert opinion:** Available limited evidence, mainly from modelling studies, supports recommending cancellations of
12 mass gatherings only before the peak of severe pandemics.

13 Available limited evidence, mainly indirect in describing the extent of transmission that takes place during mass gatherings,
14 supports recommendations for other measures (e.g. facemask use, web-casting, education campaigns, environmental
15 measures) during moderate or more severe pandemics, depending on the type of the event and a risk assessment. The risk
16 assessment should consider the severity assessment of the pandemic, the local pandemic situation, the timing, duration,
17 type of venue (indoor/outdoor) and size of the event and the area from and to which the attendees are commuting
18 (affected or non-affected). Instead of cancellation, the postponement or re-scheduling of the event can be considered.
19 Other personal protective and environmental measures should be considered in combination.

20

1 **Table 12. Summary of recent reviews and meta-analyses on mass gathering measure effectiveness**

Mass gatherings- Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Hoang et al., 2018 [264]	Not systematic	Mass gatherings	Various pathogens	The most commonly acquired respiratory viruses were human rhinovirus, followed by human coronaviruses and influenza A virus. Vaccination, use of facemasks, disposable handkerchiefs and hand hygiene may be recommended, but the effectiveness of these measures has been poorly investigated in the context of MGs.
Barasheed et al., 2016 [159]	Moderate	Mass gatherings (12 cross sectional, 10 cohort, 2 case studies, 1 RCT)	Respiratory infections	Pooled estimate showed significant protectiveness of facemasks against respiratory infections, not specific to influenza (RR=0.89, 95% CI: 0.84-0.94), modest proportion of attendees used facemasks.
Benkouiten et al., 2014 [145]	Not systematic	Mass gatherings	Respiratory tract infections	Contradictory results for effectiveness of hand washing, cough etiquette and facemasks. Low compliance with travel advice to postpone participation.
Al Tawfiq et al., 2013 [178]	Not systematic	Mass gatherings	Respiratory tract infections	The practice of social distancing, hand hygiene, and contact avoidance was associated with reduced risk of respiratory illness.
Haworth et al., 2013 [146]	Not systematic	Mass gatherings	Respiratory tract infections	Observational studies failed to demonstrate any clear benefit of using facemasks or hand washing among Hajj pilgrims.

Scientific advice - Expert opinion

ECDC

Draft for public consultation 27 August 2019

Ishola et al.,
2011 [268]

Moderate

Mass gatherings (9
observational, 7
outbreak reports, 3
historical outbreak
analyses, 4 event
surveillance reports,
1 quasi-experimental
study)

Influenza

Some evidence suggests that restricting mass gatherings together with other social distancing measures may help to reduce transmission. However, the evidence is not strong enough to advocate legislation or proscription. Evidence suggests that event duration and crowdedness may be the key factors that determine the risk of influenza transmission, and possibly the type of venue (indoor/outdoor).

1

2

1 **Travel-related measures**

2 Travel-related measures include provision of travel advice and recommendations, screening of travellers and travel
3 restrictions. Evidence for the effectiveness of some of those measures is limited and their implementation would depend on
4 the risk assessment and resultant risk/ benefit analysis of the actions being considered [35].

5 Nine reviews on the effectiveness of travel-related measures have been included and the evidence is summarised in Table
6 13. Of those reviews, five were systematic (two 'high' and one 'moderate' and two 'critically low' AMSTAR 2 score, although
7 the AMSTAR 2 tool may not be an appropriate tool to score one of these reviews that included only modelling studies).

8 **International and domestic travel advice**

9 Travel advice (or travel recommendations) can refer to official government advice, which has legal and economic
10 implications on measures that travellers should consider to minimise risk of infection. Travel and trade restrictions are
11 regulated under International Health Regulations (IHR) part III.

12 **Objective:** Through advising against travel during the pandemic, to reduce the number of people who are infected during
13 a trip to areas/ countries where transmission is higher, and reduce the risk of importation from countries with high
14 transmission. A secondary objective is to reduce transmission among people who are travelling (in airports queues, on
15 planes, etc.). Travel recommendations may also be given on the use of preventative measures during traveling to minimise
16 the risk of developing influenza and complications.

17 **Rationale:** Travelling facilitates the spread of influenza from infected to uninfected areas. Close contact of people increases
18 transmission and spread of the virus during the actual travels. Reduced travelling and using other measures while travelling
19 may therefore delay the spread of the pandemic.

20 **Evidence of effectiveness:** There is lack of evidence of effectiveness of travel advice on reducing influenza transmission.

21 In the case of a pandemic, the net number of influenza infections that are likely to be prevented is small compared to the
22 total number of infections and modelling studies suggest in order to have a small delaying effect, adherence to international
23 advice should be 100% [271]. While border control is considered impractical and ineffective (see next chapters), travel
24 advice, even at border entry points is considered to be likely more effective to the international control of communicable
25 diseases [272,273]. Advice may promote the use of preventative measures for travellers especially those at high-risk for
26 developing complications among crew members and passengers, as well as those participating in mass gatherings [273].
27 Providing advice and information on isolation, health monitoring and hygiene measures has been suggested to be more
28 effective than travel restrictions [46]. There is, however no evidence to quantify the effectiveness of travel advice during an
29 influenza pandemic.

30 **Operational considerations:** The costs related to issuing the advice will be limited, but indirect, secondary societal and
31 economic effects will be significant, as the advice may have considerable impact on the travel industry and commerce.
32 Complex issues of liability may arise and be costly to resolve, irrespective if costs are borne by individuals, companies,
33 insurance or the public.

34 **Likely acceptability:** Travel advice will likely be anticipated by the public. There are considerable concerns that European
35 residents abroad will attempt to return to their home countries despite the advice.

36 **ECDC expert opinion:** Although there is lack of evidence to quantify the effectiveness of travel advice to mitigate a
37 pandemic, issuing relative travel advice, particularly regarding personal protective measures, consistent with IHR and

1 national law, is recommended during the early stages of epidemics or pandemics at any level of severity. Information
2 campaigns and health information at the ports of entry/exit and travel recommendations for travellers concerning use of
3 other NPCs are also supported.

4 **Entry and exit screening at national borders**

5 This measure refers to the use of devices and other means for entry and exit screening at national borders.

6 **Objective:** To reduce the number of infectious people entering or leaving a country, focusing on those coming from
7 countries that are first experiencing the pandemic wave [272,274].

8 **Rationale:** With the use of measures such as active screening, non-contact infrared thermometers (NCITs) or encouraging
9 reporting of infection, the number of infectious people entering/leaving a country with infection may be reduced, in this way
10 reducing viral spread.

11 **Evidence of effectiveness:** The reviews on travel-related measures that have been included in this document are
12 presented in Table 13.

13 Experience from the SARS outbreak and influenza 2009 pandemic showed that both entry and exit screening were
14 ineffective in preventing spread [136,272,275]. There is no evidence to compare the effectiveness of entry versus exit
15 screening, although exit screening would be more logical and was recommended in the past. Application of what we know
16 about the natural history of influenza suggests that attempts to screen infected persons will be equally unsuccessful
17 because many infectious people may be pre-symptomatic or asymptomatic or may even hide their symptoms before the
18 screening point [276]. That is also the conclusion of modelling studies [271].

19 Reviews suggested that there is insufficient evidence that support screening at entry/exit points [46,132-134]. Studies from
20 the 2009 pandemic found that the positive predictive value of detecting a laboratory-confirmed pandemic influenza using
21 NCITs ranged from 0.9% to 76.0%, and was likely to be too low to effectively detect and contain pandemic infection [276].
22 Molecular diagnostics or point of care antigen detection tests could be considered, but will be expensive, resource intensive
23 if used in a large population and there is no evidence of effectiveness to mitigate a pandemic [277]. Border screening using
24 self-reported symptoms and temperature testing also showed limitations for preventing pandemic influenza from entering a
25 country. Using "any symptom" or cough would lead to many uninfected people being investigated, yet some infected people
26 would remain undetected. If more specific criteria such as fever were used, most infected people would enter the country
27 despite screening [21,22,278]. The high prevalence of other respiratory virus infections also had important implications for
28 the prediction of influenza in airline travellers [279]. The general consensus appears to be that even rigorous and extensive
29 border control measures will likely delay the spread of pandemic influenza by only a few days [9,280]. It is suggested that
30 travel advice and outbreak related communication for travellers at border entry points, together with effective
31 communication with clinicians and more effective disease control measures in the community, may be a more effective
32 approach to the international control of communicable diseases [272].

33 **Operational considerations:** Widespread and sustained screening of travellers would ultimately be impractical and
34 inefficient as long as detecting asymptomatic shedding is not feasible. On the other hand, difficulties with the rapid
35 diagnosis of influenza patients increase the risk of detaining and restricting travel of a large number of symptomatic persons
36 who will not be infected by influenza.

37 There would be moderate secondary societal and economic effects, especially with regards to dealing with people who are
38 considered possibly infectious on entry, their investigation, diagnosis and care [281]. Direct costs for equipment and
39 employees would be considerable. Healthcare staff would be occupied at the entry and exit points, although their expertise

1 would be more essential in other settings [281]. Screening, if undertaken, should be conducted with caution and informed
2 consent according to the IHR should be obtained from the travellers in case of specimen collection.

3 **Likely acceptability:** Following from the previous experience, there is likely to be an expectation among the public, the
4 media and decision-makers that there will be entry screening. This requires preparation, e.g. with simulation exercises, to
5 explain to decision-makers why this is not desirable and anticipated to be ineffective.

6 **ECDC expert opinion:** The available evidence does not support the notion that entry/exit screening border control
7 measures can delay or mitigate an influenza pandemic due to lack of sensitivity of current systems to detect symptomatic,
8 pre-symptomatic and asymptomatic infections.

9 **Domestic travel restrictions**

10 This measure refers to travel restrictions (e.g. airport and train station closures) implemented within a country or region.

11 **Objective:** Domestic travel restrictions aim to prevent or limit the geographic extent of virus transmission. Through
12 restricting travel during the pandemic, to reduce the number of people who are infected during a trip to areas where
13 transmission is higher. Another objective is to reduce transmission among people who are travelling (in airports queues, on
14 planes, etc.).

15 **Rationale:** Travelling facilitates the spread of influenza from infected to uninfected areas. Close contact of people increases
16 transmission and spread of the virus during the actual travel. Reduced travelling may therefore delay the spread of the
17 pandemic.

18 **Evidence of effectiveness:** The reviews on travel-related measures that have been included in this document are
19 presented in Table 13.

20 Overall, the evidence for the effectiveness of internal travel restrictions mainly originate from simulation studies and are
21 therefore of lower strength [136]. This measure may have a minor delaying effect depending on the timing and extent of its
22 implementation. Some observations concluded that this measure was successful in a few settings during previous
23 pandemics. However, these were rare instances and in rather isolated settings in which there was very limited travel
24 anyway [99,100]. Internal mobility restriction could be effective only if prohibitively high (50% of travel) restrictions are
25 applied [100]. Models suggest that restrictions on long-distance travel might help to decrease rates of transmission and
26 overall morbidity, but the effectiveness of the interventions has not been quantified [41,257]. A systematic review has
27 concluded that internal travel restrictions could delay the spread of influenza epidemics by one week [80,281]. In this
28 review, travel restrictions reduced the incidence of new cases by less than 3%, while impact was reduced when restrictions
29 were implemented more than six weeks after the notification of epidemics or when the level of transmissibility was high
30 [80]. Overall, travel restrictions would have minimal impact in urban centres with dense populations and travel networks.
31 There was no evidence that travel restrictions would contain influenza within a defined geographical area [72,80], although
32 combined approaches (antiviral treatment and prophylaxis, household quarantine, school and workplace closure, combined
33 with effective border control) have been shown to be increase effectiveness [228]. During the 2009 pandemic WHO did not
34 recommend travel restrictions, as it would have very little effect on stopping the virus from spreading, but would be highly
35 disruptive to the global community [55,282].

36 **Operational considerations:** There would be important secondary effects. In most European settings, this measure
37 would result in large social and economic effects as many functions, like food distribution and fuel supply, may be impacted.
38 There will be major costs to the transport system. Costs through loss of revenue would be considerable though internal
39 travel is likely to decline anyway. Other direct costs on travel-dependent industry and trade would need to be considered.

1 **Likely acceptability:** Acceptability is unknown in Europe although a reduction in non-essential travel is likely to be
2 accomplished relatively easily. Voluntary measures and guidelines would likely be more acceptable and thus more effective.
3 Efforts to forcibly limit public assembly or movement could have legal and ethical implications, especially when there is
4 limited scientific evidence supporting such restrictions. There are also important practical and logistical limitations to
5 mandatory long-term community restrictions, in addition to the problem of likely public opposition to such measures [41].

6 **ECDC expert opinion:** Available evidence does not support recommending domestic travel restrictions, except for very
7 specific, isolated, settings. Broad domestic travel restrictions are unlikely to have a major impact on transmission in modern,
8 mainly urban, populations. They have significant economical, legal and ethical implications and should only be considered in
9 early phases of pandemics with extraordinary high consequences.

10 **Border closures**

11 This measure refers to the closure of international borders due to an influenza pandemic, which is regulated under the IHR.

12 **Objective:** To reduce the risk of importation from countries with high transmission, through travel restrictions to or from
13 an affected area. Through restricting travel during the pandemic, to reduce the number of people who are infected during a
14 trip to areas/countries where transmission is higher and to reduce transmission among people who are travelling (in airports
15 queues, on planes, etc.).

16 **Rationale:** Please see 'International and domestic travel restrictions' chapter.

17 **Evidence of effectiveness:** The reviews on travel-related measures that have been included in this document are
18 presented in Table 13.

19 Systematic reviews mainly based on modelling studies (and therefore provide evidence of lower strength) have concluded
20 that international border restrictions could delay the spread and peak of influenza epidemics by two months, ranging from a
21 few days to four months depending on the extent of its implementation [70,80,136]. There will be limited effectiveness
22 from border closures, unless almost complete and rapidly implemented in the early pandemic phases [46]. Travel
23 restrictions reduced the incidence of new cases by less than 3%, while the positive impact was even more reduced when
24 restrictions were implemented more than six weeks after the notification of epidemics or when the level of transmissibility
25 was already high [80].

26 Overall, travel restrictions are considered to have minimal impact and no evidence was found that such travel restrictions
27 would contain influenza within a defined geographical area [80]. The experience is that, unless there is almost complete
28 stop of travel to a country, the attempts of border closure will be unsuccessful in preventing entry [271]. Such aggressive
29 measures to attempt to stop or slow an emerging pandemic in its early stages were previously considered possible based on
30 modelling studies; experience from the 2009 pandemic has resulted in a general agreement that such attempts are
31 undesirable due to massive secondary effects [37].

32 **Operational considerations:** There would be massive secondary effects within Europe due to the high extent of essential
33 day-to-day travel across borders. For most settings in Europe, the direct and indirect costs of trying to close borders would
34 be very high. Border closures should be carefully considered even in small island nations, because they may affect the
35 supply of essential items to the population.

36 **Likely acceptability:** The general public and decision-makers may perceive the need to close borders during a pandemic.

37 **ECDC expert opinion:** Evidence mainly originating from modelling studies shows that border closures may delay the

1 introduction of influenza into a country only in specific contexts, such as on small, isolated, island nations, if they are almost
2 complete and rapidly implemented in the early pandemic phases. Available evidence therefore does not support
3 recommending border closures in Europe. Border closures will create large secondary effects and significant societal and
4 economic disruption. Due to public health risks, they are regulated internationally under the IHR. Within the EU, freedom of
5 movement may be limited for public health reasons within the limits of the EU Treaties and in accordance with Directive
6 2004/38/EC (art. 29).

7

1 **Table 13. Summary of recent reviews and meta-analyses on travel-related measure effectiveness**

Travel-related measures – Evidence of effectiveness				
Study	AMSTAR 2 score	Setting (included studies)	Infection type	Conclusions
Huizer et al., 2015 [46]	Not systematic	Community	Infectious diseases	Travel advice, isolation of ill travellers, health monitoring of affected travellers and hygiene measures are applicable measures which can be effective to prevent disease spread. Contact tracing, although frequently practiced, is less applicable, and experiences are less positive. Exit and entry screening, quarantine and travel restrictions are unlikely to be effective, and require extensive resources.
Rashid et al., 2015 [100]	Not systematic	Various settings	Pandemic influenza	Internal mobility restriction is effective only if prohibitively high (50% of travel) restrictions are applied.
Selvey et al., 2015 [272]	Not systematic	Airports	Infectious diseases (including influenza and SARS)	Entry/exit screening was not effective. Travel advice at border entry points and more effective disease control measures in the community are more effective.
Mateus et al., 2014 [80]	Moderate	Community (19 modelling, 1 time-series analysis, 2 literature reviews and 1 systematic review)	Influenza	Internal travel restrictions and international border restrictions delayed the spread by one week and two months, respectively. International travel restrictions delayed the spread and peak by few days-four months and reduced the incidence of new cases by less than 3%. Impact reduced when restrictions were implemented late (>six weeks after notification of epidemic) or when the level of transmissibility was high. Travel restrictions had minimal impact in urban centres with dense populations and travel networks. No evidence that

travel restrictions would contain influenza within a defined geographical area.

Jefferson et al., 2011 [133]	High	Community and hospital settings (56 RCTs, cluster RCTs, observational studies, case-control)	Influenza	Insufficient evidence to support screening at entry/exit points.
Cowling et al., 2010 [280]	Not systematic	Community	Influenza	Entry/exit screening may lead to short-term delays in local transmission: 7-12 day delays compared to nations that did not implement it, with lower bounds of 95% CI consistent with no additional delays and upper bounds extending to 20-30 day additional delays.
Jefferson et al., 2009 [132,134]	High	Various settings (4 RCTs, 14 cluster RCTs, 7 case-control, 16 prospective cohort, 5 retrospective cohort, 13 before-after)	Respiratory viruses	Insufficient evidence to support screening at entry/exit points.
Bitar et al., 2009 [276]	Critically low	Airport	Pandemic influenza	Limited efficacy of NCIT to detect symptomatic passengers at the early stages of a pandemic influenza. External factors can also impair the screening strategy.
Lee et al., 2009 [70]	Critically low*	Community (19 modelling studies)	Pandemic influenza	Most modelling studies found that travel restrictions alone did not impact overall AR. Reducing air travel restrictions has been modelled to be effective in delaying pandemic spread if nearly 100% reduction can be achieved, which is difficult or impossible to achieve. Combination approaches are more effective.

1 * According to AMSTAR 2 graded as critically low due to lack of description of risk of bias for their included studies, which
2 may however not be appropriate for the included studies.

1 **4. Prerequisites for NPC implementation**

2 **Risk communication**

3 Risk communication, including community engagement and social mobilisation, is a core capacity for emergency response
4 that all countries should establish to respond to an influenza pandemic [34,283-285]. Communication is a key element of all
5 preparedness and response plans, and can directly influence the success of the response against epidemics and pandemics
6 at any severity level. Communication needs to be tailored to the audience, accurate, timely and honest. Messages need to
7 be clear and unambiguous – otherwise this can generate uncertainty and more questions. Recent experiences with MERS-
8 CoV, avian influenza, Ebola virus disease, Zika virus disease, and yellow fever have shown that communicating risk in health
9 emergencies is essential and can have a serious impact on the epidemic response. A structured schedule of briefings can
10 help manage requests for information. Well-trained, confident and trustworthy spokespeople are essential to delivery of
11 messages. Building relationships with media organizations – press, radio, internet and TV – in advance of an incident can
12 help with relationships during a response. Risk communication strategies should clarify locations and situations where
13 exposure to the virus is likely, emphasizing the value of engaging in protective behaviours during and immediately following
14 exposure to these environments. Social media also need to be increasingly considered, and the role of pseudo-experts, as
15 well as hoax or wilfully false messages.

16 **Education and training**

17 A well-trained and educated workforce is essential to a successful response. This will instil self-confidence in the staff
18 themselves, and can reduce the need for rapid training in a response. There is a challenge with when to do training and
19 maintaining competencies and capabilities, however regular refresher training can be a useful approach. Additionally,
20 training and education could be given to members of the public – for example around self-care, accessing healthcare and
21 community cohesion. A variety of mechanisms can be used to provide training, including face to face or on-line, group
22 lectures or one to one. Training should be tailored to the subject being taught and the recipients. Written guidance
23 documents will aid the response and the necessary knowledge acquisition. It is crucial upon employers to educate
24 employees about the hazards to which they are exposed and to provide the necessary means to avoid them. This is
25 particularly important in healthcare settings.

26 ECDC and WHO provide on-line **5.1.2e** and on-line material to enhance knowledge about different aspects of
27 pandemic preparedness and response [286-288].

28

1 **5. Implications for public health research**

2 The evidence base on public health measures to mitigate the impact of pandemic influenza is limited. Research on
3 innovative approaches to environmental control, social distancing, travel related measures and PPMs should be encouraged
4 and funded; an option would be to establish collaborations and sleeping contracts, with pre-approved protocols, in advance
5 of a future pandemic that can be activated when needed. WHO has published in 2017 an update on the public health
6 research agenda for influenza [289,290]. Moreover, evaluation of effectiveness and appropriate monitoring after the
7 implementation of the measures will provide valuable evidence for the next pandemics.

8 Understanding the effectiveness and optimal implementation of public health measures is important for public health
9 decision makers in planning interventions and targeting limited resources. Many studies have focused on the evaluation of
10 the effectiveness of both personal and community-level public health measures since 2009. However, the relative
11 effectiveness of one public health measure compared to another and across the different population groups is still unclear.
12 There is a limited number of observational studies and large well designed RCTs to assess the actual impact of public health
13 measures in the different settings [289,290]. Research could focus on the effectiveness, adherence, acceptability and new
14 ways of reducing the risk of infection during a pandemic.

15 The lack of quantitative data on effectiveness supports the role of mathematical modelling in understanding pandemic virus
16 transmission and evaluating NPCs under conditions of uncertainty. It would be useful to extend modelling concepts through
17 the application of alternative approaches, including cost effectiveness and feasibility studies [291].

18 The variability in pandemic situations, including the degree of infectiousness, timing, population demographics and
19 susceptibility, and availability of pharmaceutical and NPCs, inhibit the ability to draw general conclusions for the
20 effectiveness of the measures reported from a small number of studies, to other settings and future pandemics [78].

21 **Influenza transmission**

22 Enhancing knowledge in the area of influenza transmission and shedding is crucial for informing recommendations on the
23 use of individual protective measures during future influenza pandemics. Future studies are needed to evaluate the relative
24 impact of different modes of influenza transmission, and how this may shift between seasonal and pandemic settings.
25 Studies should investigate the relative importance of droplet, contact and airborne transmission in seasonal and pandemic
26 influenza in relation to the effectiveness of various interventions to reduce transmission; furthermore, studies should
27 investigate the details of aerosol transmission including the infectious dose, survival of the virus in aerosols and aerosol
28 generating procedures in clinical settings [290]. Virus survival on the different types of surfaces should also be determined.
29 Limited reviews have quantified the effectiveness of PPE against different pathogens, although their effectiveness may differ
30 against viral and bacterial agents or pathogens with potentially different transmission modes. The role (prevalence and
31 impact) of heterogeneity in influenza infectiousness and transmission, i.e. of asymptomatic infections and super spreaders,
32 in the transmission chain should be clarified [21,290]. Mathematical models for virus transmission in the various community
33 settings would be helpful [292].

34 **Influenza diagnosis**

35 Adequate diagnostic algorithms for case detection and case definitions for surveillance are essential. Research could focus
36 on the development of sensitive and specific influenza rapid tests for community-based studies and early rapid diagnosis of
37 influenza viruses. The clinical implications of influenza viral load are still undetermined.

1 **Hand hygiene**

2 Research could focus on the effect of increased frequency and quality of hand washing on influenza virus transmission,
3 aiming to identify the optimal threshold for advising guidelines. A comparison of various hand hygiene methods would be
4 useful.

5 **Respiratory hygiene and other PPEs**

6 Data about the effectiveness of facemask use in the different settings are limited, and results are contradictory, highlighting
7 the need for future studies. The efficacy of the different types of masks for reducing transmission and spread of influenza in
8 the general community needs to be determined. Large, well-designed studies would also enable investigation of the role of
9 facemask and respirator use specifically against laboratory confirmed influenza infections and clarify the circumstances
10 under which individual PPE use is most warranted. The inclusion of relevant controls would be important [78]. There is lack
11 of evidence on effectiveness of cough etiquette.

12 **Environmental measures**

13 Research could aid in understanding surface contamination issues and identifying situations in which surface cleaning
14 should be emphasized. Research should focus on identifying the best practice guidelines (dosage, duration, frequency) and
15 evaluate the different products. There are limited RCTs on the effect of surface and object cleaning on influenza prevention
16 in the different settings. Novel techniques (e.g. far-UV-C light) for safe and effective surface and air disinfection for use in
17 the different settings should be studied. Research should also focus on the efficacy of ventilation in reducing influenza
18 transmission. The role of humidification still needs to be assessed.

19 **Social distancing measures**

20 Though there is evidence for the use of social distancing measures, research could focus on gathering data on social mixing
21 patterns in schools and the various community settings. Studies should focus on the timing and duration of school closures
22 and other social distancing and environmental measures in schools [290]. An important aspect is to provide evidence base
23 for assessing societal and economic secondary effects of the measures for individuals, families and communities. Depending
24 on the age of school children, there will be different consequences from school-closures that need to be determined. Most
25 of the current evidence on effectiveness of voluntary isolation and voluntary quarantine practises originates from modelling
26 studies; more robust experimental data should be produced. The role of asymptomatic infections and super-spreaders need
27 to be clarified in relation to these measures.

28 **Border control**

29 Sensitive and specific novel screening tools for identifying infected travelers at international borders should be investigated.
30 There are limited data on the possible differences in effectiveness of exit compared to entry screening.

31 **Social behaviour, ethical and legal aspects**

32 The public knowledge, perception and behavioral aspects related to the use of NPCs across the different populations need
33 to be assessed, as is the role of cultural and demographic factors on NPC common practices, in relation to NPC
34 effectiveness. Prospective studies could aid in the verification of behaviour and would enhance understanding of
35 intervention effectiveness. Studies should focus on the role of social science research in establishing social, ethical and legal

- 1 standards in the application of public health policy, and address the public perception of influenza and its impact on
- 2 societies, particularly in under-resourced populations [289,290]. Research could focus on determining effective risk
- 3 communication strategies for enhancing compliance and adherence to NPCs and the extent of barriers to NPC
- 4 implementation [293].

5

6

1 References

- 2 1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet*. 2017 Dec 14.
- 3 2. Guan Y, Vijaykrishna D, Bahl J, Zhu H, Wang J, Smith GJ. The emergence of pandemic influenza viruses. *Protein Cell*. 2010 Jan;1(1):9-13.
- 4 3. Henderson DA, Courtney B, Inglesby TV, Toner E, Nuzzo JB. Public health and medical responses to the 1957-58 influenza pandemic. *Bio Secur Bioterror*. 2009 Sep;7(3):265-73.
- 5 4. Simonsen L, Spreuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. *PLoS Med*. 2013 Nov;10(11):e1001558.
- 6 5. Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. *Vaccine*. 2013 Oct 25;31(45):5168-77.
- 7 6. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev*. 2018 Feb 1;2:Cd001269.
- 8 7. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. *PLoS One*. 2011;6(9):e24384.
- 9 8. Yin JK, Chow MY, Khandaker G, King C, Richmond P, Heron L, et al. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. *Vaccine*. 2012 May 2;30(21):3209-22.
- 10 9. Saunders-Hastings PR, Krewski D. Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission. *Pathogens*. 2016 Dec 6;5(4).
- 11 10. Lansbury LE, Smith S, Beyer W, Karamehic E, Pasic-Juhar E, Sikira H, et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. *Vaccine*. 2017 Apr 11;35(16):1996-2006.
- 12 11. European Centre for Disease Prevention and Control(ECDC). Influenza vaccine effectiveness [cited 2019]. Available from: <https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccine-effectiveness>.
- 13 12. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines [cited 2019]. Available from: <http://www.who.int/influenza/vaccines/virus/recommendations/en/>.
- 14 13. European Centre for Disease Prevention and Control(ECDC). Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza 2017. Available from: <https://ecdc.europa.eu/sites/portal/files/documents/Scientific-advice-neuraminidase-inhibitors-2017.pdf>.
- 15 14. Halloran ME, Hayden FG, Yang Y, ^{5.1.2e} IM, Jr., Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. *Am J Epidemiol*. 2007 Jan 15;165(2):212-21.
- 16 15. European Centre for Disease Prevention and Control(ECDC). Public health use of influenza antivirals during influenza pandemics 2009. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0907_GUI_Public_Health_use_of_Influenza_Antivirals_during_Influenza_Pandemic.pdf.
- 17 16. Kutter JS, Spronken M, Fraaij PL, Fouchier R, Herfst S. Transmission routes of respiratory viruses among humans. *Current Opinion in Virology*. 2018;28.
- 18 17. Killingley B, Nguyen-Van-Tam J. Routes of influenza transmission. *Influenza Other Respir Viruses*. 2013 Sep;7 Suppl 2:42-51.
- 19 18. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. *BMC Infect Dis*. 2014 Sep 4;14:480.
- 20 19. Cowling BJ, Ip DK, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al. Aerosol transmission is an important mode of influenza A virus spread. *Nat Commun*. 2013;4:1935.
- 21 20. Bischoff WE, Swett K, Leng I, Peters TR. Exposure to influenza virus aerosols during routine patient care. *J Infect Dis*. 2013 Apr;207(7):1037-46.
- 22 21. Ip DK, Lau LL, Leung NH, Fang VJ, Chan KH, Chu DK, et al. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community. *Clin Infect Dis*. 2017 Mar 15;64(6):736-42.
- 23 22. Ip DKM, Lau LLH, Chan KH, Fang VJ, Leung GM, Peiris MJS, et al. The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. *Clin Infect Dis*. 2016 Feb 15;62(4):431-7.
- 24 23. Thomas Y, Boquete-Suter P, Koch D, Pittet D, Kaiser L. Survival of influenza virus on human fingers. *Clin Microbiol Infect*. 2014 Jan;20(1):O58-64.
- 25 24. Centers for Disease Control and Prevention (CDC). Community Mitigation Guidelines to Prevent Pandemic Influenza – United States, 2017 2017. Available from: <https://www.cdc.gov/media/dpk/cdc-24-7/preventing-pandemic-influenza/community-mitigation-guidelines-for-preventing-pandemic-flu.html>.
- 26 25. Dorigatti I, Cauchemez S, Ferguson NM. Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England. *Proc Natl Acad Sci U S A*. 2013 Aug 13;110(33):13422-7.
- 27 26. Kuo PC, Huang JH, Liu MD. Avian influenza risk perception and preventive behavior among traditional market workers and shoppers in Taiwan: practical implications for prevention. *PLoS One*. 2011;6(9):e24157.

- 1 27. Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH, Jr. Survival of influenza viruses on
2 environmental surfaces. *J Infect Dis.* 1982 Jul;146(1):47-51.
- 3 28. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. *Lancet Infect*
4 *Dis.* 2007 Apr;7(4):257-65.
- 5 29. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. *Clin*
6 *Infect Dis.* 2003 Oct 15;37(8):1094-101.
- 7 30. Poulson RL, Tompkins SM, Berghaus RD, Brown JD, Stallknecht DE. Environmental Stability of Swine and Human
8 Pandemic Influenza Viruses in Water under Variable Conditions of Temperature, Salinity, and pH. *Appl Environ Microbiol.*
9 2016 Jul 1;82(13):3721-6.
- 10 31. Lowen A, Palese P. Transmission of influenza virus in temperate zones is predominantly by aerosol, in the tropics by
11 contact: a hypothesis. *PLoS Curr.* 2009 Aug 17;1:Rm1002.
- 12 32. Shaman J, Kohn M. Absolute humidity modulates influenza survival, transmission, and seasonality. *Proc Natl Acad Sci*
13 *U S A.* 2009 Mar 3;106(9):3243-8.
- 14 33. World Health Organization(WHO). Global Influenza Programme [cited 2019]. Available from:
15 <http://www.who.int/influenza/en/>.
- 16 34. Cordova-Villalobos JA, Macias AE, Hernandez-Avila M, Dominguez-Cherit G, Lopez-Gatell H, Alpuche-Aranda C, et al.
17 The 2009 pandemic in Mexico: Experience and lessons regarding national preparedness policies for seasonal and epidemic
18 influenza. *Gac Med Mex.* 2017 Jan-Feb;153(1):102-10.
- 19 35. Nguyen-Van-Tam JS, Sellwood C. Intervention strategies for emerging respiratory virus infections: policy and public
20 health considerations. *Curr Opin Virol.* 2013 Apr;3(2):192-8.
- 21 36. Mizumoto K, ^{5.1.2e}, Yamamoto T. Effectiveness of antiviral prophylaxis coupled with contact tracing in reducing
22 the transmission of the influenza A (H1N1-2009): a systematic review. *Theor Biol Med Model.* 2013 Jan 16;10:4.
- 23 37. Pan-Canadian Public Health Sector. Canadian pandemic influenza preparedness: Planning Guidance for the Health
24 Sector 2015. Available from: <http://www.phac-aspc.gc.ca/cpip-pclcpi/assets/pdf/report-rapport-2015-eng.pdf>.
- 25 38. Enanoria WT, Crawley AW, Tseng W, Furnish J, Balido J, Aragon TJ. The epidemiology and surveillance response to
26 pandemic influenza A (H1N1) among local health departments in the San Francisco Bay Area. *BMC Public Health.* 2013 Mar
27 27;13:276.
- 28 39. Holloway R, Rasmussen SA, Zaza S, Cox NJ, Jernigan DB. Updated preparedness and response framework for
29 influenza pandemics. *MMWR Recomm Rep.* 2014 Sep 26;63(Rr-06):1-18.
- 30 40. World Health Organization (WHO). Global Surveillance during an Influenza Pandemic 2009. Available from:
31 http://www.who.int/csr/disease/swineflu/global_pandemic_influenza_surveillance_apr09.pdf.
- 32 41. Aledort JE, Lurie N, Wasserman J, Bozzette SA. Non-pharmaceutical public health interventions for pandemic
33 influenza: an evaluation of the evidence base. *BMC Public Health.* 2007 Aug 15;7:208.
- 34 42. World Health Organization(WHO). Fact sheet: Global Influenza Surveillance and Response System (GISRS) 2018
35 [cited 2019]. Available from:
36 https://www.who.int/influenza/gisrs_laboratory/updates/GISRS_one_pager_2018_EN.pdf?ua=1.
- 37 43. European Centre for Disease Prevention and Control(ECDC). European Reference Laboratory Network for Human
38 Influenza (ERLI-Net) 2017 [cited 2019]. Available from: <https://www.ecdc.europa.eu/en/about-us/networks/disease-and-laboratory-networks/erlinet-about>.
- 39 44. European Centre for Disease Prevention and Control(ECDC). Risk assessment guidelines for diseases transmitted on
40 aircraft(RAGIDA) 2010. Available from:
41 https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/1012_GUI_RAGIDA_2.pdf.
- 42 45. Control(ECDC) ECDFPa. Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA) -
43 Influenza. 2014.
- 44 46. Huizer YL, Swaan CM, Leitmeyer KC, ^{5.1.2e}. Usefulness and applicability of infectious disease control measures in
45 air travel: a review. *Travel Med Infect Dis.* 2015 Jan-Feb;13(1):19-30.
- 46 47. Browne A, Ahmad SS, Beck CR, Nguyen-Van-Tam JS. The roles of transportation and transportation hubs in the
47 propagation of influenza and coronaviruses: a systematic review. *J Travel Med.* 2016 Jan;23(1).
- 48 48. Weber DJ, Rutala WA, Fischer WA, Kanamori H, Sickbert-Bennett EE. Emerging infectious diseases: Focus on
49 infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory
50 Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and
51 A(H7N9). *Am J Infect Control.* 2016 May 2;44(5 Suppl):e91-e100.
- 52 49. World Health Organization (WHO). Infection prevention and control of epidemic- and pandemic-prone acute
53 respiratory infections in health care 2014. Available from:
54 <https://ecdc.europa.eu/EnterpriseVault/Search/htmlview.aspx?VaultId=1A6178B738C995E42A4F12A94C54AE3771110000ecdcvtclu&SaveSetId=201808224954187~201805181542280000~Z~A102A926DB0E9339A9FBDB1204A7EDD1&AttachmentId=1>.
- 55 50. World Health Organization(WHO). Recommended composition of influenza virus vaccines for use in the 2019-2020
56 northern hemisphere influenza season. 2019.
- 57 51. World Health Organisation(WHO). Hospital preparedness checklist for pandemic influenza. 2009.
- 58 52. Ministry of Health Singapore. MOH pandemic readiness and response plan for influenza and other acute respiratory
59 diseases. 2014.
- 60 53. World Health Organization (WHO). WHO global influenza preparedness plan 2005. Available from:
61 http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf.
- 62
63
64

- 1 54. World Health Organization (WHO). WHO Global Influenza Preparedness Plan. 2005 Annex One Recommendations for
 2 non-pharmaceutical public health measures (p42-46) 2005. Available from:
 3 http://www.who.int/indae34t/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf.
- 4 55. World Health Organization (WHO). Pandemic influenza preparedness and response. WHO guidance document April
 5 2009 2009. Available from: <http://www.who.int/csr/disease/influenza/pipguidance2009/en/index.html>.
- 6 56. World Health Organization (WHO). Prevention and control of outbreaks of seasonal influenza in long-term care
 7 facilities: a review of the evidence and best-practice guidance 2017. Available from:
 8 http://www.euro.who.int/data/assets/pdf_file/0015/330225/LTCF-best-practice-guidance.pdf.
- 9 57. Lansbury LE, Brown CS, Nguyen-Van-Tam JS. Influenza in long-term care facilities. *Influenza Other Respir Viruses*.
 10 2017 Sep;11(5):356-66.
- 11 58. World Health Organization (WHO). WHO guidance for surveillance during an influenza pandemic 2017. Available
 12 from:
 13 http://www.who.int/influenza/preparedness/pandemic/WHO_Guidance_for_surveillance_during_an_influenza_pandemic_08_2017.pdf?ua=1.
- 14 59. World Health Organization (WHO). A checklist for pandemic influenza risk and impact management: building capacity
 15 for pandemic response 2018. Available from: [http://apps.who.int/iris/bitstream/handle/10665/259884/9789241513623-
 16 eng.pdf;jsessionid=56168CA9105F59E1462CAE04AA1922EC?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/259884/9789241513623-eng.pdf;jsessionid=56168CA9105F59E1462CAE04AA1922EC?sequence=1).
- 17 60. European Centre for Disease Prevention and Control(ECDC). Guide to public health measures to reduce the impact of
 18 influenza pandemics in Europe: 'The ECDC Menu' 2009. Available from:
 19 https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0906_TER_Public_Health_Measures_for_Influenza_Pandemics.pdf.
- 20 61. European Centre for Disease Prevention and Control(ECDC). Personal protective measures (non-pharmaceutical) for
 21 reducing the risk of acquiring or transmitting human influenza [cited 2019]. Available from:
 22 <https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/personal-protective-measures>.
- 23 62. Public Health England. Pandemic Influenza Response Plan. 2014.
- 24 63. National Health Service UK. Health and Social Care Influenza Pandemic Preparedness and Response 2012. Available
 25 from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213696/dh_133656.pdf.
- 26 64. UK Department of Health. UK influenza pandemic preparedness strategy 2011 2011. Available from:
 27 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/215666/dh_125333.pdf.
- 28 65. Robert Koch Institut. Nationaler Pandemieplan Teil II 2016. Available from:
 29 [https://www.rki.de/DE/Content/InfAZ/I/Influenza/Pandemieplanung/Downloads/Pandemieplan_Teil_II_gesamt.pdf?__blob=
 30 publicationFile](https://www.rki.de/DE/Content/InfAZ/I/Influenza/Pandemieplanung/Downloads/Pandemieplan_Teil_II_gesamt.pdf?__blob=publicationFile).
- 31 66. Ministry of Health Singapore. MOH pandemic readiness and response plan for influenza and other acute respiratory
 32 diseases. 2014. Available from:
 33 https://www.moh.gov.sg/content/dam/moh_web/Diseases%20and%20Conditions/DORSCON%202013/Interim%20Pandemic%20Plan%20Public%20Ver%20April%202014.pdf.
- 34 67. Government of New Zealand. New Zealand influenza pandemic plan: a framework for action. 2017. Available from:
 35 <https://www.health.govt.nz/publication/new-zealand-influenza-pandemic-plan-framework-action>.
- 36 68. Australian government Department of Health. Australian Health Management Plan for Pandemic Influenza. 2014.
- 37 69. Royal Australian College of General Practitioners. Infection prevention and control standards for general practices
 38 and other office-based and community-based practices (5th edition) 2014. Available from:
 39 <https://www.dermcoll.edu.au/wp-content/uploads/RACGP-Infection-Prevention-and-Control-Standards.pdf>.
- 40 70. Lee VJ, Lye DC, Wilder-Smith A. Combination strategies for pandemic influenza response - a systematic review of
 41 mathematical modeling studies. *BMC Med*. 2009 Dec 10;7:76.
- 42 71. Teasdale E, Santer M, Geraghty AW, Little P, Yardley L. Public perceptions of non-pharmaceutical interventions for
 43 reducing transmission of respiratory infection: systematic review and synthesis of qualitative studies. *BMC Public Health*.
 44 2014 Jun 11;14:589.
- 45 72. Mao L. Evaluating the combined effectiveness of influenza control strategies and human preventive behavior. *PLoS*
 46 *One*. 2011;6(10):e24706.
- 47 73. Toohar R, Collins JE, Street JM, Braunack-Mayer A, Marshall H. Community knowledge, behaviours and attitudes
 48 about the 2009 H1N1 Influenza pandemic: a systematic review. *Influenza Other Respir Viruses*. 2013 Nov;7(6):1316-27.
- 49 74. Sim SW, Moey KS, Tan NC. The use of facemasks to prevent respiratory infection: a literature review in the context
 50 of the Health Belief Model. *Singapore Med J*. 2014 Mar;55(3):160-7.
- 51 75. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic
 52 reviews that include randomised or non-randomised studies of healthcare interventions, or both. *Bmj*. 2017 Sep
 53 21;358:j4008.
- 54 76. Saunders-Hastings P, Crispo JAG, Sikora L, Krewski D. Effectiveness of personal protective measures in reducing
 55 pandemic influenza transmission: A systematic review and meta-analysis. *Epidemics*. 2017 Sep;20:1-20.
- 56 77. Qualls N, Levitt A, Kanade N, Wright-Jegede N, Dopson S, Biggerstaff M, et al. Community Mitigation Guidelines to
 57 Prevent Pandemic Influenza - United States, 2017. *MMWR Recomm Rep*. 2017 Apr 21;66(1):1-34.
- 58 78. Offeddu V, Yung CF, Low MSF, Tam CC. Effectiveness of Masks and Respirators Against Respiratory Infections in
 59 Healthcare Workers: A Systematic Review and Meta-Analysis. *Clin Infect Dis*. 2017 Nov 13;65(11):1934-42.
- 60 79. Moghadas SM, Haworth-Brockman M, Isfeld-Kiely H, Kettner J. Improving public health policy through infection
 61 transmission modelling: Guidelines for creating a Community of Practice. *Can J Infect Dis Med Microbiol*. 2015 Jul-
 62 Aug;26(4):191-5.

- 1 80. Mateus AL, Otete HE, Beck CR, Dolan GP, Nguyen-Van-Tam JS. Effectiveness of travel restrictions in the rapid
2 containment of human influenza: a systematic review. *Bull World Health Organ.* 2014 Dec 1;92(12):868-80d.
- 3 81. Kilinc FS. A Review of Isolation Gowns in Healthcare: Fabric and Gown Properties. *J Eng Fiber Fabr.* 2015
4 Sep;10(3):180-90.
- 5 82. Godoy P, Castilla J, Delgado-Rodriguez M, Martin V, Soldevila N, Alonso J, et al. Effectiveness of hand hygiene and
6 provision of information in preventing influenza cases requiring hospitalization. *Prev Med.* 2012 Jun;54(6):434-9.
- 7 83. Gautret P, Steffen R. Communicable diseases as health risks at mass gatherings other than Hajj: what is the
8 evidence? *Int J Infect Dis.* 2016 Jun;47:46-52.
- 9 84. Fumanelli L, Ajelli M, Merler S, Ferguson NM, Cauchemez S. Model-Based Comprehensive Analysis of School Closure
10 Policies for Mitigating Influenza Epidemics and Pandemics. *PLoS Comput Biol.* 2016 Jan;12(1):e1004681.
- 11 85. Zayas G, Chiang MC, Wong E, MacDonald F, Lange CF, Senthilselvan A, et al. Effectiveness of cough etiquette
12 maneuvers in disrupting the chain of transmission of infectious respiratory diseases. *BMC Public Health.* 2013 Sep 8;13:811.
- 13 86. Wong VW, Cowling BJ, Aiello AE. Hand hygiene and risk of influenza virus infections in the community: a systematic
14 review and meta-analysis. *Epidemiol Infect.* 2014 May;142(5):922-32.
- 15 87. Talaat M, Afifi S, Dueger E, El-Ashry N, Marfin A, Kandeel A, et al. Effects of hand hygiene campaigns on incidence of
16 laboratory-confirmed influenza and absenteeism in schoolchildren, Cairo, Egypt. *Emerg Infect Dis.* 2011 Apr;17(4):619-25.
- 17 88. Suess T, Remschmidt C, Schink SB, Schweiger B, Nitsche A, Schroeder K, et al. The role of facemasks and hand
18 hygiene in the prevention of influenza transmission in households: results from a cluster randomised trial; Berlin, Germany,
19 2009-2011. *BMC Infect Dis.* 2012 Jan 26;12:26.
- 20 89. Smith SM, Sonogo S, Wallen GR, Waterer G, Cheng AC, Thompson P. Use of non-pharmaceutical interventions to
21 reduce the transmission of influenza in adults: A systematic review. *Respirology.* 2015 Aug;20(6):896-903.
- 22 90. Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 respirators versus
23 surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis.
24 *Cmaj.* 2016 May 17;188(8):567-74.
- 25 91. World Health Organization (WHO). Pandemic influenza risk management: WHO interim guidance 2013. Available
26 from:
27 [http://www.who.int/influenza/preparedness/pandemic/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.p](http://www.who.int/influenza/preparedness/pandemic/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf?ua=1)
28 [df?ua=1](http://www.who.int/influenza/preparedness/pandemic/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf?ua=1).
- 29 92. World Health Organization (WHO). Pandemic influenza risk management 2017. Available from:
30 <http://apps.who.int/iris/bitstream/10665/259893/1/WHO-WHE-IHM-GIP-2017.1-eng.pdf?ua=1>.
- 31 93. World Health Organization (WHO). WHO Guidelines on Hand Hygiene in Health Care 2009. Available from:
32 http://apps.who.int/iris/bitstream/10665/44102/1/9789241597906_eng.pdf.
- 33 94. Centers for Disease Control and Prevention (CDC). Interim Pre-pandemic Planning Guidance: Community Strategy for
34 Pandemic Influenza Mitigation in the United States 2007. Available from: [https://www.cdc.gov/flu/pandemic-](https://www.cdc.gov/flu/pandemic-resources/pdf/community_mitigation-sm.pdf)
35 [resources/pdf/community_mitigation-sm.pdf](https://www.cdc.gov/flu/pandemic-resources/pdf/community_mitigation-sm.pdf).
- 36 95. European Centre for Disease Prevention and Control (ECDC). ECDC Expert meeting on non-pharmaceutical
37 countermeasures for Pandemic flu 2018 [cited 2019]. Available from: [https://www.ecdc.europa.eu/en/news-events/ecdc-](https://www.ecdc.europa.eu/en/news-events/ecdc-expert-meeting-non-pharmaceutical-countermeasures-pandemic-flu)
38 [expert-meeting-non-pharmaceutical-countermeasures-pandemic-flu](https://www.ecdc.europa.eu/en/news-events/ecdc-expert-meeting-non-pharmaceutical-countermeasures-pandemic-flu).
- 39 96. World Health Organization (WHO). Non-pharmaceutical public health measures for mitigating the risk and impact of
40 epidemic and pandemic influenza. 2019.
- 41 97. Cox NJ, Tambyn SE, Tam T. Influenza pandemic planning. *Vaccine.* 2003 May 1;21(16):1801-3.
- 42 98. Kilbourne ED. Influenza pandemics of the 20th century. *Emerg Infect Dis.* 2006 Jan;12(1):9-14.
- 43 99. Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, Stern AM, et al. Nonpharmaceutical interventions
44 implemented by US cities during the 1918-1919 influenza pandemic. *Jama.* 2007 Aug 8;298(6):644-54.
- 45 100. Rashid H, Ridda I, King C, Begun M, Tekin H, Wood JG, et al. Evidence compendium and advice on social distancing
46 and other related measures for response to an influenza pandemic. *Paediatr Respir Rev.* 2015 Mar;16(2):119-26.
- 47 101. Aiello AE, Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Cowling BJ, et al. Research findings from
48 nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. *Am J Infect Control.* 2010
49 May;38(4):251-8.
- 50 102. van der Weerd W, Timmermans DR, Beaujean DJ, Oudhoff J, van Steenbergen JE. Monitoring the level of
51 government trust, risk perception and intention of the general public to adopt protective measures during the influenza A
52 (H1N1) pandemic in The Netherlands. *BMC Public Health.* 2011 Jul 19;11:575.
- 53 103. Barrios LC, Koonin LM, Kohl KS, Cetron M. Selecting nonpharmaceutical strategies to minimize influenza spread: the
54 2009 influenza A (H1N1) pandemic and beyond. *Public Health Rep.* 2012 Nov-Dec;127(6):565-71.
- 55 104. Aiello AE, Murray GF, Perez V, Coulborn RM, Davis BM, Uddin M, et al. Mask use, hand hygiene, and seasonal
56 influenza-like illness among young adults: a randomized intervention trial. *J Infect Dis.* 2010 Feb 15;201(4):491-8.
- 57 105. Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, et al. Non-pharmaceutical interventions for pandemic
58 influenza, national and community measures. *Emerg Infect Dis.* 2006 Jan;12(1):88-94.
- 59 106. Canini L, Andreoletti L, Ferrari P, D'Angelo R, Blanchon T, Lemaitre M, et al. Surgical mask to prevent influenza
60 transmission in households: a cluster randomized trial. *PLoS One.* 2010 Nov 17;5(11):e13998.
- 61 107. MacIntyre CR, Cauchemez S, Dwyer DE, Seale H, Cheung P, Browne G, et al. Face mask use and control of
62 respiratory virus transmission in households. *Emerg Infect Dis.* 2009 Feb;15(2):233-41.
- 63 108. Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, Wai W, et al. Facemasks and hand hygiene to prevent influenza
64 transmission in households: a cluster randomized trial. *Ann Intern Med.* 2009 Oct 6;151(7):437-46.

- 1 109. Roberts L, Smith W, Jom L, Patel M, Douglas RM, McGilchrist C. Effect of infection control measures on the
2 frequency of upper respiratory infection in child care: a randomized, controlled trial. *Pediatrics*. 2000 Apr;105(4 Pt 1):738-
3 42.
- 4 110. Ryan MA, Christian RS, Wohlrabe J. Handwashing and respiratory illness among young adults in military training. *Am*
5 *J Prev Med*. 2001 Aug;21(2):79-83.
- 6 111. Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, et al. Non-pharmaceutical interventions for pandemic
7 influenza, international measures. *Emerg Infect Dis*. 2006 Jan;12(1):81-7.
- 8 112. Institute of Medicine Forum on Microbial T. The National Academies Collection: Reports funded by National Institutes
9 of Health. The Domestic and International Impacts of the 2009-H1N1 Influenza A Pandemic: Global Challenges, Global
10 Solutions: Workshop Summary. Washington (DC): National Academies Press (US)
11 National Academy of Sciences.; 2010.
- 12 113. Nicoll A. Personal (non-pharmaceutical) protective measures for reducing transmission of influenza--ECDC interim
13 recommendations. *Euro Surveill*. 2006 Oct 12;11(10):E061012.1.
- 14 114. Rabie T, Curtis V. Handwashing and risk of respiratory infections: a quantitative systematic review. *Trop Med Int*
15 *Health*. 2006 Mar;11(3):258-67.
- 16 115. Azor-Martinez E, Gonzalez-Jimenez Y, Seijas-Vazquez ML, Cobos-Carrascosa E, Santisteban-Martinez J, Martinez-
17 Lopez JM, et al. The impact of common infections on school absenteeism during an academic year. *Am J Infect Control*.
18 2014 Jun;42(6):632-7.
- 19 116. Tomer N, Soldevila N, Garcia JJ, Launes C, Godoy P, Castilla J, et al. Effectiveness of non-pharmaceutical measures
20 in preventing pediatric influenza: a case-control study. *BMC Public Health*. 2015 Jun 9;15:543.
- 21 117. Cheng VC, Tai JW, Wong LM, Chan JF, Li IW, To KK, et al. Prevention of nosocomial transmission of swine-origin
22 pandemic influenza virus A/H1N1 by infection control bundle. *J Hosp Infect*. 2010 Mar;74(3):271-7.
- 23 118. Kuster SP, Coleman BL, Raboud J, McNeil S, De Serres G, Gubbay J, et al. Risk factors for influenza among health
24 care workers during 2009 pandemic, Toronto, Ontario, Canada. *Emerg Infect Dis*. 2013 Apr;19(4):606-15.
- 25 119. Deng Y, Zhang Y, Wang XL, Liu WT, Duan W, Yang P, et al. [Pandemic influenza A (H1N1) virus infection factors
26 among healthcare workers - a case-control study]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2010 Dec;44(12):1075-8.
- 27 120. Zhang Y, Seale H, Yang P, MacIntyre CR, Blackwell B, Tang S, et al. Factors associated with the transmission of
28 pandemic (H1N1) 2009 among hospital healthcare workers in Beijing, China. *Influenza Other Respir Viruses*. 2013
29 May;7(3):466-71.
- 30 121. Levy JW, Suntarattiwong P, Simmerman JM, Jarman RG, Johnson K, Olsen SJ, et al. Increased hand washing reduces
31 influenza virus surface contamination in Bangkok households, 2009-2010. *Influenza Other Respir Viruses*. 2014 Jan;8(1):13-
32 6.
- 33 122. Grayson ML, Melvani S, Druce J, Barr IG, Ballard SA, Johnson PD, et al. Efficacy of soap and water and alcohol-based
34 hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. *Clin Infect Dis*. 2009 Feb
35 1;48(3):285-91.
- 36 123. Carlson AL, Budd AP, Perl TM. Control of influenza in healthcare settings: early lessons from the 2009 pandemic.
37 *Curr Opin Infect Dis*. 2010 Aug;23(4):293-9.
- 38 124. Willmott M, Nicholson A, Busse H, MacArthur GJ, Brookes S, Campbell R. Effectiveness of hand hygiene interventions
39 in reducing illness absence among children in educational settings: a systematic review and meta-analysis. *Arch Dis Child*.
40 2016 Jan;101(1):42-50.
- 41 125. Hansen S, Zimmerman PA, van de Mortel TF. Infectious illness prevention and control methods and their
42 effectiveness in non-health workplaces: an integrated literature review. *J Infect Prev*. 2018 Sep;19(5):212-8.
- 43 126. Lee BY, Shah M. Prevention of influenza in healthy children. *Expert Rev Anti Infect Ther*. 2012 Oct;10(10):1139-52.
- 44 127. Warren-Gash C, Fragaszy E, Hayward AC. Hand hygiene to reduce community transmission of influenza and acute
45 respiratory tract infection: a systematic review. *Influenza Other Respir Viruses*. 2013 Sep;7(5):738-49.
- 46 128. Hocine MN, Temime L. Impact of hand hygiene on the infectious risk in nursing home residents: A systematic review.
47 *Am J Infect Control*. 2015 Sep 1;43(9):e47-52.
- 48 129. Zivich PN, Gancz AS, Aiello AE. Effect of hand hygiene on infectious diseases in the office workplace: A systematic
49 review. *Am J Infect Control*. 2018 Apr;46(4):448-55.
- 50 130. Mbakaya BC, Lee PH, Lee RL. Hand Hygiene Intervention Strategies to Reduce Diarrhoea and Respiratory Infections
51 among Schoolchildren in Developing Countries: A Systematic Review. *Int J Environ Res Public Health*. 2017 Apr 1;14(4).
- 52 131. McCloskey B, Dar O, Zumla A, Heymann DL. Emerging infectious diseases and pandemic potential: status quo and
53 reducing risk of global spread. *Lancet Infect Dis*. 2014 Oct;14(10):1001-10.
- 54 132. Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or
55 reduce the spread of respiratory viruses. *Cochrane Database Syst Rev*. 2010 Jan 20(1):Cd006207.
- 56 133. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or
57 reduce the spread of respiratory viruses. *Cochrane Database Syst Rev*. 2011 Jul 6(7):Cd006207.
- 58 134. Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or
59 reduce the spread of respiratory viruses: systematic review. *Bmj*. 2009 Sep 21;339:b3675.
- 60 135. McGuinness SL, Barker SF, O'Toole J, Cheng AC, Forbes AB, Sinclair M, et al. Effect of hygiene interventions on acute
61 respiratory infections in childcare, school and domestic settings in low- and middle-income countries: a systematic review.
62 *Trop Med Int Health*. 2018 Aug;23(8):816-33.
- 63 136. World Health Organization (WHO). Non-pharmaceutical public health measures for mitigating the risk and impact of
64 epidemic and pandemic influenza. Licence: CC BY-NC-SA 3.0 IGO. 2019. Available from:
65 <https://apps.who.int/iris/bitstream/handle/10665/329438/9789241516839-eng.pdf?ua=1>.

- 1 137. World Health Organization (WHO), Unicef. Behavioural interventions for reducing the transmission and impact of
2 influenza A(H1N1) virus: a framework for communication strategies. 2009. Available from:
3 <http://www.who.int/csr/resources/publications/swineflu/framework/en/>.
- 4 138. Ajelli M, Poletti P, Melegaro A, Merler S. The role of different social contexts in shaping influenza transmission during
5 the 2009 pandemic. *Sci Rep*. 2014 Nov 27;4:7218.
- 6 139. Widmer AF. Surgical hand hygiene: scrub or rub? *J Hosp Infect*. 2013 Feb;83 Suppl 1:S35-9.
- 7 140. Price L, Melone L, McLarmon N, Bunyan D, Kilpatrick C, Flowers P, et al. A systematic review to evaluate the evidence
8 base for the World Health Organization's adopted hand hygiene technique for reducing the microbial load on the hands of
9 healthcare workers. *Am J Infect Control*. 2018 Jul;46(7):814-23.
- 10 141. Kingston L, O'Connell NH, Dunne CP. Hand hygiene-related clinical trials reported since 2010: a systematic review. *J*
11 *Hosp Infect*. 2016 Apr;92(4):309-20.
- 12 142. Huis A, van Achterberg T, de Bruin M, Grol R, Schoonhoven L, Hulscher M. A systematic review of hand hygiene
13 improvement strategies: a behavioural approach. *Implement Sci*. 2012 Sep 14;7:92.
- 14 143. Kumar V. Influenza in Children. *Indian J Pediatr*. 2017 Feb;84(2):139-43.
- 15 144. Lidal IB, Berg RC, Austvoll-Dahlgren A, Hval Straumann G, Vist GE. NIPH Systematic Reviews: Executive Summaries.
16 Infection Control in Day-Care Facilities: Effect of Handhygiene, Training and Physical Interventions. Oslo, Norway:
17 Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH)
18 Copyright (c)2015 by The Norwegian Institute of Public Health (NIPH). 2015.
- 19 145. Benkouiten S, Brouqui P, Gautret P. Non-pharmaceutical interventions for the prevention of respiratory tract
20 infections during Hajj pilgrimage. *Travel Med Infect Dis*. 2014 Sep-Oct;12(5):429-42.
- 21 146. Haworth E, Barasheed O, Memish ZA, Rashid H, Booy R. Prevention of influenza at Hajj: applications for mass
22 gatherings. *J R Soc Med*. 2013 Jun;106(6):215-23.
- 23 147. Stanley WM. The size of influenza virus. *J Exp Med*. 1944 Mar 1;79(3):267-83.
- 24 148. Brouqui P, Puro V, Fusco FM, Bannister B, Schilling S, Follin P, et al. Infection control in the management of highly
25 pathogenic infectious diseases: consensus of the European Network of Infectious Disease. *Lancet Infect Dis*. 2009
26 May;9(5):301-11.
- 27 149. Collignon PJ, Camie JA. Infection control and pandemic influenza. *Med J Aust*. 2006 Nov 20;185(10 Suppl):S54-7.
- 28 150. Sebastian MR, Lodha R, Kabra SK. Swine origin influenza (swine flu). *Indian J Pediatr*. 2009 Aug;76(8):833-41.
- 29 151. Rathore MH, Jackson MA. Infection Prevention and Control in Pediatric Ambulatory Settings. *Pediatrics*. 2017
30 Nov;140(5).
- 31 152. Bartlett JG, Borio L. Healthcare epidemiology: the current status of planning for pandemic influenza and implications
32 for health care planning in the United States. *Clin Infect Dis*. 2008 Mar 15;46(6):919-25.
- 33 153. Narain JP, Kumar R, Bhatia R. Pandemic (H1N1) 2009: epidemiological, clinical and prevention aspects. *Natl Med J*
34 *India*. 2009 Sep-Oct;22(5):242-7.
- 35 154. MacIntyre CR, Chughtai AA. Facemasks for the prevention of infection in healthcare and community settings. *Bmj*.
36 2015 Apr 9;350:h694.
- 37 155. Coia JE, Ritchie L, Adisesh A, Makison Booth C, Bradley C, Bunyan D, et al. Guidance on the use of respiratory and
38 facial protection equipment. *J Hosp Infect*. 2013 Nov;85(3):170-82.
- 39 156. European Committee for Standardization. Respiratory protective devices - Filtering half masks to protect against
40 particles - Requirements, testing, marking 2009. Available from:
41 https://standards.cen.eu/dyn/www/f?p=204:110:0:::FSP_PROJECT:32928&cs=1B0AB06FEB70E43960D46D1198C37CC09.
- 42 157. Johnson DF, Druce JD, Birch C, Grayson ML. A quantitative assessment of the efficacy of surgical and N95 masks to
43 filter influenza virus in patients with acute influenza infection. *Clin Infect Dis*. 2009 Jul 15;49(2):275-7.
- 44 158. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al. Epidemiological determinants of spread of
45 causal agent of severe acute respiratory syndrome in Hong Kong. *Lancet*. 2003 May 24;361(9371):1761-6.
- 46 159. Barasheed O, Alfelali M, Mushta S, Bokhary H, Alshehri J, Attar AA, et al. Uptake and effectiveness of facemask
47 against respiratory infections at mass gatherings: a systematic review. *Int J Infect Dis*. 2016 Jun;47:105-11.
- 48 160. Cowling BJ, Zhou Y, Ip DK, Leung GM, Aiello AE. Face masks to prevent transmission of influenza virus: a systematic
49 review. *Epidemiol Infect*. 2010 Apr;138(4):449-56.
- 50 161. Bunyan D, Ritchie L, Jenkins D, Coia JE. Respiratory and facial protection: a critical review of recent literature. *J Hosp*
51 *Infect*. 2013 Nov;85(3):165-9.
- 52 162. Maltezos HC. Novel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control.
53 *Scand J Infect Dis*. 2010 Jul;42(6-7):412-20.
- 54 163. Gralton J, McLaws ML. Protecting healthcare workers from pandemic influenza: N95 or surgical masks? *Crit Care*
55 *Med*. 2010 Feb;38(2):657-67.
- 56 164. Seale H, Dwyer DE, Cowling BJ, Wang Q, Yang P, Macintyre CR. A review of medical masks and respirators for use
57 during an influenza pandemic. *Influenza Other Respir Viruses*. 2009 Sep;3(5):205-6.
- 58 165. Schuchat A, Bell BP, Redd SC. The science behind preparing and responding to pandemic influenza: the lessons and
59 limits of science. *Clin Infect Dis*. 2011 Jan 1;52 Suppl 1:S8-12.
- 60 166. Toyokawa T, Sunagawa T, Yahata Y, Ohyama T, Kodama T, Satoh H, et al. Seroprevalence of antibodies to
61 pandemic (H1N1) 2009 influenza virus among health care workers in two general hospitals after first outbreak in Kobe,
62 Japan. *J Infect*. 2011 Oct;63(4):281-7.
- 63 167. Wei J, Li Y. Airborne spread of infectious agents in the indoor environment. *Am J Infect Control*. 2016 Sep 2;44(9
64 Suppl):S102-8.

- 1 168. Bin-Reza F, Lopez Chavarrias V, Nicoll A, Chamberland ME. The use of masks and respirators to prevent transmission
2 of influenza: a systematic review of the scientific evidence. *Influenza Other Respir Viruses*. 2012 Jul;6(4):257-67.
- 3 169. Cummings KJ, Cox-Ganser J, Riggs MA, Edwards N, Kreiss K. Respirator donning in post-hurricane New Orleans.
4 *Emerg Infect Dis*. 2007 May;13(5):700-7.
- 5 170. World Health Organization (WHO). Advice on the use of masks in the community setting in Influenza A (H1N1)
6 outbreaks 2009. Available from: <http://www.who.int/csr/resources/publications/Adviceusemaskscommunityrevised.pdf>.
- 7 171. Chao YS, Spry C. CADTH Rapid Response Reports. The Use of N95 Respirators for Protection against Droplet Borne
8 Illness: A Review of the Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in
9 Health
- 10 Copyright (c) 2017 Canadian Agency for Drugs and Technologies in Health.; 2017.
- 11 172. Seto WH. Airborne transmission and precautions: facts and myths. *J Hosp Infect*. 2015 Apr;89(4):225-8.
- 12 173. CADTH Rapid Response Reports. Respiratory Precautions for Protection from Bioaerosols or Infectious Agents: A
13 Review of the Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health
14 Copyright (c) 2014 Canadian Agency for Drugs and Technologies in Health.; 2014.
- 15 174. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of
16 acute respiratory infections to healthcare workers: a systematic review. *PLoS One*. 2012;7(4):e35797.
- 17 175. Mukerji S, MacIntyre CR, Newall AT. Review of economic evaluations of mask and respirator use for protection
18 against respiratory infection transmission. *BMC Infect Dis*. 2015 Oct 13;15:413.
- 19 176. Health Protection Agency (HPA). The use of facemasks during an influenza pandemic 2007. Available from:
20 http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_077781.pdf.
- 21 177. Roberge R. Facemask use by children during infectious disease outbreaks. *Biosecur Bioterror*. 2011 Sep;9(3):225-31.
- 22 178. Al-Tawfiq JA, Zumla A, Memish ZA. Respiratory tract infections during the annual Hajj: potential risks and mitigation
23 strategies. *Curr Opin Pulm Med*. 2013 May;19(3):192-7.
- 24 179. Cowling BJ, Fung RO, Cheng CK, Fang VJ, Chan KH, Seto WH, et al. Preliminary findings of a randomized trial of
25 non-pharmaceutical interventions to prevent influenza transmission in households. *PLoS One*. 2008 May 7;3(5):e2101.
- 26 180. Rainwater-Lovett K, Chun K, Lessler J. Influenza outbreak control practices and the effectiveness of interventions in
27 long-term care facilities: a systematic review. *Influenza Other Respir Viruses*. 2014 Jan;8(1):74-82.
- 28 181. Thompson KA, Pappachan JV, Bennett AM, Mittal H, Macken S, Dove BK, et al. Influenza aerosols in UK hospitals
29 during the H1N1 (2009) pandemic--the risk of aerosol generation during medical procedures. *PLoS One*. 2013;8(2):e56278.
- 30 182. Weber DJ, Rutala WA, Schaffner W. Lessons learned: protection of healthcare workers from infectious disease risks.
31 *Crit Care Med*. 2010 Aug;38(8 Suppl):S306-14.
- 32 183. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS
33 coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect*. 2016
34 Mar;92(3):235-50.
- 35 184. World Health Organization (WHO). Natural Ventilation for Infection Control in Health-Care Settings 2009. Available
36 from: http://www.who.int/water_sanitation_health/publications/natural_ventilation.pdf.
- 37 185. Weber TP, Stillanakis NI. Inactivation of influenza A viruses in the environment and modes of transmission: a critical
38 review. *J Infect*. 2008 Nov;57(5):361-73.
- 39 186. Oxford J, Berezin EN, Courvalin P, Dwyer DE, Exner M, Jana LA, et al. The survival of influenza A(H1N1)pdm09 virus
40 on 4 household surfaces. *Am J Infect Control*. 2014 Apr;42(4):423-5.
- 41 187. Boone SA, Gerba CP. The occurrence of influenza A virus on household and day care center fomites. *J Infect*. 2005
42 Aug;51(2):103-9.
- 43 188. Scott E. Community-based infections and the potential role of common touch surfaces as vectors for the transmission
44 of infectious agents in home and community settings. *Am J Infect Control*. 2013 Nov;41(11):1087-92.
- 45 189. Thompson KA, Bennett AM. Persistence of influenza on surfaces. *J Hosp Infect*. 2017 Feb;95(2):194-9.
- 46 190. Patnayak DP, Prasad AM, Malik YS, Ramakrishnan MA, Goyal SM. Efficacy of disinfectants and hand sanitizers against
47 avian respiratory viruses. *Avian Dis*. 2008 Jun;52(2):199-202.
- 48 191. Serra ME. Prevention of respiratory infections at day care centers: recommendations and systematic review of the
49 evidence. *Arch Argent Pediatr*. 2014 Aug;112(4):323-31.
- 50 192. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. *Curr*
51 *Opin Infect Dis*. 2013 Aug;26(4):338-44.
- 52 193. Rutala WA, Weber DJ. Disinfectants used for environmental disinfection and new room decontamination technology.
53 *Am J Infect Control*. 2013 May;41(5 Suppl):S36-41.
- 54 194. Jeong EK, Bae JE, Kim IS. Inactivation of influenza A virus H1N1 by disinfection process. *Am J Infect Control*. 2010
55 Jun;38(5):354-60.
- 56 195. Goyal SM, Chander Y, Yezli S, Otter JA. Evaluating the virucidal efficacy of hydrogen peroxide vapour. *J Hosp Infect*.
57 2014 Apr;86(4):255-9.
- 58 196. Thomas RE. Do we have enough evidence how seasonal influenza is transmitted and can be prevented in hospitals
59 to implement a comprehensive policy? *Vaccine*. 2016 Jun 8;34(27):3014-21.
- 60 197. Rudnick SN, McDevitt JJ, First MW, Spengler JD. Inactivating influenza viruses on surfaces using hydrogen peroxide
61 or triethylene glycol at low vapor concentrations. *Am J Infect Control*. 2009 Dec;37(10):813-9.
- 62 198. Klaus J, Gnirs P, Holterhoff S, Wirtz A, Jeglitza M, Gaber W, et al. Disinfection of aircraft : Appropriate disinfectants
63 and standard operating procedures for highly infectious diseases. *Bundesgesundheitsblatt Gesundheitsforschung*
64 *Gesundheitsschutz*. 2016 Dec;59(12):1544-8.

- 1 199. Zeitler B, Rapp I. Surface-Dried Viruses Can Resist Glucoprotamin-Based Disinfection. *Appl Environ Microbiol*. 2014
2 Dec;80(23):7169-75.
- 3 200. Weber DJ, Rutala WA. Self-disinfecting surfaces: review of current methodologies and future prospects. *Am J Infect*
4 *Control*. 2013 May;41(5 Suppl):S31-5.
- 5 201. O'Gorman J, Humphreys H. Application of copper to prevent and control infection. Where are we now? *J Hosp Infect*.
6 2012 Aug;81(4):217-23.
- 7 202. Vincent M, Hartemann P, Engels-Deutsch M. Antimicrobial applications of copper. *Int J Hyg Environ Health*. 2016
8 Oct;219(7 Pt A):585-91.
- 9 203. Cook N, Knight A, Richards GP. Persistence and Elimination of Human Norovirus in Food and on Food Contact
10 Surfaces: A Critical Review. *J Food Prot*. 2016 Jul;79(7):1273-94.
- 11 204. Muller MP, MacDougall C, Lim M. Antimicrobial surfaces to prevent healthcare-associated infections: a systematic
12 review. *J Hosp Infect*. 2016 Jan;92(1):7-13.
- 13 205. Grass G, Rensing C, Solioz M. Metallic copper as an antimicrobial surface. *Appl Environ Microbiol*. 2011
14 Mar;77(5):1541-7.
- 15 206. Villapun VM, Dover LG, Cross A, Gonzalez S. Antibacterial Metallic Touch Surfaces. *Materials (Basel)*. 2016 Aug
16 29;9(9).
- 17 207. Qian H, Zheng X. Ventilation control for airborne transmission of human exhaled bio-aerosols in buildings. *J Thorac*
18 *Dis*. 2018 Jul;10(Suppl 19):S2295-s304.
- 19 208. Rajakaruna SJ, Liu WB, Ding YB, Cao GW. Strategy and technology to prevent hospital-acquired infections: Lessons
20 from SARS, Ebola, and MERS in Asia and West Africa. *Mil Med Res*. 2017 Oct 27;4(1):32.
- 21 209. Institute RK. Tipps und Informationen zur Neuen Grippe A/H1N1, Robert Koch Institute, 2009, GrippeWeb 2009.
22 Available from: <https://grippeweb.rki.de/>.
- 23 210. Hobday RA, Dancer SJ. Roles of sunlight and natural ventilation for controlling infection: historical and current
24 perspectives. *J Hosp Infect*. 2013 Aug;84(4):271-82.
- 25 211. Hobday RA, Cason JW. The open-air treatment of pandemic influenza. *Am J Public Health*. 2009 Oct;99 Suppl
26 2:S236-42.
- 27 212. Welch D, Buonanno M, Grijl V, Shuryak I, Crickmore C, Bigelow AW, et al. Far-UVC light: A new tool to control the
28 spread of airborne-mediated microbial diseases. *Sci Rep*. 2018 Feb 9;8(1):2752.
- 29 213. Maclean M, McKenzie K, Anderson JG, Gettinby G, MacGregor SJ. 405 nm light technology for the inactivation of
30 pathogens and its potential role for environmental disinfection and infection control. *J Hosp Infect*. 2014 Sep;88(1):1-11.
- 31 214. Boyce JM. Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals.
32 *Antimicrob Resist Infect Control*. 2016;5:10.
- 33 215. Reiman JM, Das B. Humidity as a non-pharmaceutical intervention for influenza A. 2018;13(9):e0204337.
- 34 216. Han JH, Sullivan N, Leas BF, Pegues DA, Kaczmarek JL, Umscheid CA. Cleaning Hospital Room Surfaces to Prevent
35 Health Care-Associated Infections: A Technical Brief. *Ann Intern Med*. 2015 Oct 20;163(8):598-607.
- 36 217. Perez Velasco R, Praditsithikorn N, Wichmann K, Mohara A, Kotirum S, Tantivess S, et al. Systematic review of
37 economic evaluations of preparedness strategies and interventions against influenza pandemics. *PLoS One*.
38 2012;7(2):e30333.
- 39 218. Borse RH, Behraves CB, Dumanovsky T, Zucker JR, Swerdlow D, Edelson P, et al. Closing schools in response to the
40 2009 pandemic influenza A H1N1 virus in New York City: economic impact on households. *Clin Infect Dis*. 2011 Jan 1;52
41 Suppl 1:S168-72.
- 42 219. Jackson C, Vynnycky E, Hawker J, Olowokure B, Mangtani P. School closures and influenza: systematic review of
43 epidemiological studies. *BMJ Open*. 2013;3(2).
- 44 220. Jackson C, Mangtani P, Hawker J, Olowokure B, Vynnycky E. The effects of school closures on influenza outbreaks
45 and pandemics: systematic review of simulation studies. *PLoS One*. 2014;9(5):e97297.
- 46 221. Cauchemez S, Van Kerkhove MD, Archer BN, Cetron M, Cowling BJ, Grove P, et al. School closures during the 2009
47 influenza pandemic: national and local experiences. *BMC Infect Dis*. 2014 Apr 16;14:207.
- 48 222. Kelso JK, Milne GJ, Kelly H. Simulation suggests that rapid activation of social distancing can arrest epidemic
49 development due to a novel strain of influenza. *BMC Public Health*. 2009 Apr 29;9:117.
- 50 223. Lau LL, ^{5.1.2a}, Kelly H, Ip DK, Leung GM, Cowling BJ. Household transmission of 2009 pandemic influenza A
51 (H1N1): a systematic review and meta-analysis. *Epidemiology*. 2012 Jul;23(4):531-42.
- 52 224. Uscher-Pines L, Schwartz HL, Ahmed F, Zheteyeva Y, Meza E, Baker G, et al. School practices to promote social
53 distancing in K-12 schools: review of influenza pandemic policies and practices. *BMC Public Health*. 2018 Mar 27;18(1):406.
- 54 225. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral
55 infections: a systematic review. *Lancet Infect Dis*. 2009 May;9(5):291-300.
- 56 226. Killingley B, Greatorex J, Digard P, Wise H, Garcia F, Varsani H, et al. The environmental deposition of influenza virus
57 from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control. *J Infect Public*
58 *Health*. 2016 May-Jun;9(3):278-88.
- 59 227. Germann TC, Kadau K, ^{5.1.2e} IM, Jr., Macken CA. Mitigation strategies for pandemic influenza in the United States.
60 *Proc Natl Acad Sci U S A*. 2006 Apr 11;103(15):5935-40.
- 61 228. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza
62 pandemic. *Nature*. 2006 Jul 27;442(7101):448-52.
- 63 229. World Health Organization (WHO). Reducing transmission of pandemic (H1N1) 2009 in school settings 2009.
64 Available from: http://www.who.int/csr/resources/publications/reducing_transmission_h1n1_2009.pdf.

- 1 230. Leung GM, Nicoll A. Reflections on pandemic (H1N1) 2009 and the international response. *PLoS Med.* 2010 Oct
2 5;7(10).
- 3 231. Pada S, Tambyah PA. Overview/reflections on the 2009 H1N1 pandemic. *Microbes Infect.* 2011 May;13(5):470-8.
- 4 232. van Gernert C, Hellard M, McBryde ES, Fielding J, Spelman T, Higgins N, et al. Intrahousehold transmission of
5 pandemic (H1N1) 2009 virus, Victoria, Australia. *Emerg Infect Dis.* 2011 Sep;17(9):1599-607.
- 6 233. Rothstein MA, Talbott MK. Encouraging compliance with quarantine: a proposal to provide job security and income
7 replacement. *Am J Public Health.* 2007 Apr;97 Suppl 1:S49-56.
- 8 234. DiGiovanni C, Conley J, Chiu D, Zaborski J. Factors influencing compliance with quarantine in Toronto during the
9 2003 SARS outbreak. *Biosecur Bioterror.* 2004;2(4):265-72.
- 10 235. World Health Organization (WHO). WHO Consultation on suspension of classes and restriction of mass gatherings to
11 mitigate the impact of epidemics caused by the new influenza A (H1N1); Summary of the third scientific teleconference on
12 influenza A (H1N1) 2009. Available from:
13 http://www.who.int/csr/resources/publications/swineflu/who_consultation_20090624_en.pdf.
- 14 236. Cauchemez S, Valleron AJ, Boelle PY, Flahault A, Ferguson NM. Estimating the impact of school closure on influenza
15 transmission from Sentinel data. *Nature.* 2008 Apr 10;452(7188):750-4.
- 16 237. Copeland DL, Basurto-Davila R, Chung W, Kurian A, Fishbein DB, Szymanowski P, et al. Effectiveness of a school
17 district closure for pandemic influenza A (H1N1) on acute respiratory illnesses in the community: a natural experiment. *Clin
18 Infect Dis.* 2013 Feb;56(4):509-16.
- 19 238. Jackson C, Vynnycky E, Mangtani P. The Relationship Between School Holidays and Transmission of Influenza in
20 England and Wales. *Am J Epidemiol.* 2016 Nov 1;184(9):644-51.
- 21 239. Cowling BJ, Ip DK, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al. Modes of transmission of influenza B virus in
22 households. *PLoS One.* 2014;9(9):e108850.
- 23 240. Inglesby TV, Nuzzo JB, O'Toole T, Henderson DA. Disease mitigation measures in the control of pandemic influenza.
24 *Biosecur Bioterror.* 2006;4(4):366-75.
- 25 241. Guclu H, Read J, Vukotich CJ, Jr., Galloway DD, Gao H, Rainey JJ, et al. Social Contact Networks and Mixing among
26 Students in K-12 Schools in Pittsburgh, PA. *PLoS One.* 2016;11(3):e0151139.
- 27 242. Hens N, Ayele GM, Goeyvaerts N, Aerts M, Mossong J, Edmunds JW, et al. Estimating the impact of school closure on
28 social mixing behaviour and the transmission of close contact infections in eight European countries. *BMC Infect Dis.* 2009
29 Nov 27;9:187.
- 30 243. Wu JT, Cowling BJ, Lau EH, Ip DK, Ho LM, Tsang T, et al. School closure and mitigation of pandemic (H1N1) 2009,
31 Hong Kong. *Emerg Infect Dis.* 2010 Mar;16(3):538-41.
- 32 244. Bin Nafisah S, Alamery AH, Al Nafesa A, Aleid B, Brazanji NA. School closure during novel influenza: A systematic
33 review. *J Infect Public Health.* 2018 Jan 30.
- 34 245. Centers for Disease Control and Prevention (CDC). CDC guidance for state and local public health officials and school
35 administrators for school (K-12) responses to influenza during the 2009-2010 school year 2010. Available from:
36 <https://www.cdc.gov/h1n1flu/schools/schoolguidance.htm>.
- 37 246. Berkman BE. Mitigating pandemic influenza: the ethics of implementing a school closure policy. *J Public Health
38 Manag Pract.* 2008 Jul-Aug;14(4):372-8.
- 39 247. Centers for Disease Control and Prevention (CDC). Parental attitudes and experiences during school dismissals
40 related to 2009 influenza A (H1N1) --- United States, 2009. *MMWR Morb Mortal Wkly Rep.* 2010 Sep 10;59(35):1131-4.
- 41 248. Mizumoto K, Yamamoto T, s 1.2e. Contact behaviour of children and parental employment behaviour during
42 school closures against the pandemic influenza A (H1N1-2009) in Japan. *J Int Med Res.* 2013 Jun;41(3):716-24.
- 43 249. Pasquini-Descomps H, Brender N, Maradan D. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-
44 Effectiveness of Pandemic Interventions. *Value Health.* 2017 Jun;20(6):819-27.
- 45 250. Kann L, Kinchen S, Modzelski B, Sullivan M, Carr D, Zaza S, et al. ILI-related school dismissal monitoring system: an
46 overview and assessment. *Disaster Med Public Health Prep.* 2012 Jun;6(2):104-12.
- 47 251. Potter MA, Brown ST, Cooley PC, Sweeney PM, Hershey TB, Gleason SM, et al. School closure as an influenza
48 mitigation strategy: how variations in legal authority and plan criteria can alter the impact. *BMC Public Health.* 2012 Nov
49 14;12:977.
- 50 252. Dooyema CA, Copeland D, Sinclair JR, Shi J, Wilkins M, Wells E, et al. Factors influencing school closure and
51 dismissal decisions: influenza A (H1N1), Michigan 2009. *J Sch Health.* 2014 Jan;84(1):56-62.
- 52 253. Ahmed F, Zviedrite N, Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza
53 transmission: a systematic review. *BMC Public Health.* 2018 Apr 18;18(1):518.
- 54 254. Carrat F, Luong J, Lao H, Salle AV, Lajaunie C, Wackernagel H. A 'small-world-like' model for comparing interventions
55 aimed at preventing and controlling influenza pandemics. *BMC Med.* 2006 Oct 23;4:26.
- 56 255. Xia H, Nagaraj K, Chen J, Marathe MV. Synthesis of a high resolution social contact network for Delhi with application
57 to pandemic planning. *Artif Intell Med.* 2015 Oct;65(2):113-30.
- 58 256. Kumar S, Grefenstette JJ, Galloway D, Albert SM, Burke DS. Policies to reduce influenza in the workplace: impact
59 assessments using an agent-based model. *Am J Public Health.* 2013 Aug;103(8):1406-11.
- 60 257. World Health Organization (WHO). Public health for mass gatherings-key considerations 2015. Available from:
61 http://apps.who.int/iris/bitstream/handle/10665/162109/WHO_HSE_GCR_2015.5_eng.pdf?sequence=1.
- 62 258. Abubakar I, Gautret P, Brunette GW, Blumberg L, Johnson D, Pomeroy G, et al. Global perspectives for prevention
63 of infectious diseases associated with mass gatherings. *Lancet Infect Dis.* 2012 Jan;12(1):66-74.
- 64 259. Gutierrez I, Litzroth A, Hammadi S, Van Oyen H, Gerard C, Robesyn E, et al. Community transmission of influenza A
65 (H1N1)v virus at a rock festival in Belgium, 2-5 July 2009. *Euro Surveill.* 2009 Aug 6;14(31).

- 1 260. Rashid H, Haworth E, Shafi S, Memish ZA, Booy R. Pandemic influenza: mass gatherings and mass infection. *Lancet Infect Dis*. 2008 Sep;8(9):526-7.
- 2
- 3 261. Rainey JJ, Phelps T, Shi J. Mass Gatherings and Respiratory Disease Outbreaks in the United States - Should We Be
- 4 Worried? Results from a Systematic Literature Review and Analysis of the National Outbreak Reporting System. *PLoS One*.
- 5 2016;11(8):e0160378.
- 6 262. World Health Organization (WHO). WHO Consultation on suspension of classes and restriction of mass gatherings to
- 7 mitigate the impact of epidemics caused by the new influenza A (H1N1) 2009. Available from:
- 8 [https://ecdc.europa.eu/EnterpriseVault/Search/htmlview.aspx?VaultId=1A6178B738C995E42A4F12A94C54AE](https://ecdc.europa.eu/EnterpriseVault/Search/htmlview.aspx?VaultId=1A6178B738C995E42A4F12A94C54AE3771110000ecdcvault&SaveSetId=201808224954183~201805181539090000~Z~A102A351B046590940A79BF0F2C3DF11&AttachmentId=1)
- 9 [3771110000ecdcvault&SaveSetId=201808224954183~201805181539090000~Z~A102A351B046590940A79BF0F2C3DF11](https://ecdc.europa.eu/EnterpriseVault/Search/htmlview.aspx?VaultId=1A6178B738C995E42A4F12A94C54AE3771110000ecdcvault&SaveSetId=201808224954183~201805181539090000~Z~A102A351B046590940A79BF0F2C3DF11&AttachmentId=1)
- 10 [&AttachmentId=1](https://ecdc.europa.eu/EnterpriseVault/Search/htmlview.aspx?VaultId=1A6178B738C995E42A4F12A94C54AE3771110000ecdcvault&SaveSetId=201808224954183~201805181539090000~Z~A102A351B046590940A79BF0F2C3DF11&AttachmentId=1).
- 11 263. World Health Organization (WHO). Interim planning considerations for mass gatherings in the context of pandemic
- 12 (H1N1) 2009 influenza 2009. Available from: [http://www.who.int/csr/resources/publications/swineflu/cp002_2009-](http://www.who.int/csr/resources/publications/swineflu/cp002_2009-0511_planning_considerations_for_mass_gatherings.pdf)
- 13 [0511_planning_considerations_for_mass_gatherings.pdf](http://www.who.int/csr/resources/publications/swineflu/cp002_2009-0511_planning_considerations_for_mass_gatherings.pdf).
- 14 264. Hoang VT, Gautret P. *Infectious Diseases and Mass Gatherings*. *Curr Infect Dis Rep*. 2018 Aug 28;20(11):44.
- 15 265. Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardiere A. Hajj-associated infections. *Med Mal Infect*. 2016
- 16 Oct;46(7):346-54.
- 17 266. Botelho-Nevers E, Gautret P. Outbreaks associated to large open air festivals, including music festivals, 1980 to
- 18 2012. *Euro Surveill*. 2013 Mar 14;18(11):20426.
- 19 267. Al-Tawfiq JA, Benkouiten S, Memish ZA. A systematic review of emerging respiratory viruses at the Hajj and possible
- 20 coinfection with *Streptococcus pneumoniae*. *Travel Med Infect Dis*. 2018 May - Jun;23:6-13.
- 21 268. Ishola DA, Phin N. Could influenza transmission be reduced by restricting mass gatherings? Towards an evidence-
- 22 based policy framework. *J Epidemiol Glob Health*. 2011 Dec;1(1):33-60.
- 23 269. Shi P, Keskinocak P, Swann JL, Lee BY. The impact of mass gatherings and holiday traveling on the course of an
- 24 influenza pandemic: a computational model. *BMC Public Health*. 2010 Dec 21;10:778.
- 25 270. SteelFisher GK, Blendon RJ, Ward JR, Rapoport R, Kahn EB, Kohl KS. Public response to the 2009 influenza A H1N1
- 26 pandemic: a polling study in five countries. *Lancet Infect Dis*. 2012 Nov;12(11):845-50.
- 27 271. Cooper BS, Pitman RJ, Edmunds WJ, Gay NJ. Delaying the international spread of pandemic influenza. *PLoS Med*.
- 28 2006 Jun;3(6):e212.
- 29 272. Selvey LA, Antao C, Hall R. Entry screening for infectious diseases in humans. *Emerg Infect Dis*. 2015 Feb;21(2):197-
- 30 201.
- 31 273. Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD. Travellers and influenza: risks
- 32 and prevention. *J Travel Med*. 2017 Jan;24(1).
- 33 274. European Centre for Disease Prevention and Control(ECDC). Infection prevention and control measures for Ebola
- 34 virus disease: Entry and exit screening measures 2014. Available from:
- 35 [https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Ebola-outbreak-technicalreport-exit-entry-](https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Ebola-outbreak-technicalreport-exit-entry-screening-13Oct2014.pdf)
- 36 [screening-13Oct2014.pdf](https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Ebola-outbreak-technicalreport-exit-entry-screening-13Oct2014.pdf).
- 37 275. Bell DM. Public health interventions and SARS spread, 2003. *Emerg Infect Dis*. 2004 Nov;10(11):1900-6.
- 38 276. Bitar D, Goubar A, Desenclos JC. International travels and fever screening during epidemics: a literature review on
- 39 the effectiveness and potential use of non-contact infrared thermometers. *Euro Surveill*. 2009 Feb 12;14(6).
- 40 277. Chen J, Yang K, Zhang M, Shen C, Chen J, Wang G, et al. Rapid identification of imported influenza viruses at
- 41 Xiamen International Airport via an active surveillance program. *Clin Microbiol Infect*. 2018 Mar;24(3):289-94.
- 42 278. Priest PC, Jennings LC, Duncan AR, Brunton CR, Baker MG. Effectiveness of border screening for detecting influenza
- 43 in arriving airline travelers. *Am J Public Health*. 2015 Oct;105 Suppl 4:S607-13, s0-6.
- 44 279. Jennings LC, Priest PC, Psutka RA, Duncan AR, Anderson T, Mahagamasekera P, et al. Respiratory viruses in airline
- 45 travellers with influenza symptoms: Results of an airport screening study. *J Clin Virol*. 2015 Jun;67:8-13.
- 46 280. Cowling BJ, Lau LL, Wu P, Wong HW, Fang VJ, Riley S, et al. Entry screening to delay local transmission of 2009
- 47 pandemic influenza A (H1N1). *BMC Infect Dis*. 2010 Mar 30;10:82.
- 48 281. Health Canada. Learning from SARS. Renewal of public health in Canada. A report of the National Advisory
- 49 Committee on SARS and Public Health, October 2003 2003. Available from: [http://www.phac-aspc.gc.ca/publicat/sars-](http://www.phac-aspc.gc.ca/publicat/sars-sras/pdf/sars-e.pdf)
- 50 [sras/pdf/sars-e.pdf](http://www.phac-aspc.gc.ca/publicat/sars-sras/pdf/sars-e.pdf).
- 51 282. World Health Organization (WHO). No rationale for travel restrictions 2009. Available from:
- 52 http://www.who.int/csr/disease/swineflu/guidance/public_health/travel_advice/en/.
- 53 283. World Health Organisation(WHO). Communicating risk in public health emergencies. A WHO guideline for emergency
- 54 risk
- 55 communication (ERC) policy and practice. 2017.
- 56 284. Centre for Disease Control and Prevention(CDC). NIOSH-Approved Particulate Filtering Facepiece Respirators.
- 57 Available from: https://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/default.html.
- 58 285. Centre for Disease Control and Prevention(CDC). Crisis & Emergency Risk Communication (CERC) [cited 2018].
- 59 Available from: <https://emergency.cdc.gov/cerc/index.asp>.
- 60 286. European Centre for Disease Prevention and Control(ECDC). ECDC Virtual Academy [cited 2018]. Available from:
- 61 <https://eva.ecdc.europa.eu/>.
- 62 287. World Health Organisation(WHO). Infection prevention and control:Tools for training and education [cited 2018].
- 63 Available from: <https://www.who.int/infection-prevention/tools/hand-hygiene/slides/en/>.
- 64 288. World Health Organization(WHO). Report prepared for the WHO annual consultation on the composition of influenza
- 65 vaccine for the Northern Hemisphere 2019-2020. 2019.

- 1 289. World Health Organization (WHO). WHO public health research agenda for influenza: limiting the spread of
 2 pandemic, zoonotic and seasonal epidemic influenza, 2017 update 2017. Available from:
 3 <http://apps.who.int/iris/handle/10665/259892>.
 4 290. World Health Organization (WHO). WHO public health research agenda for influenza 2017. Available from:
 5 <http://www.who.int/influenza/resources/research/en/>.
 6 291. Postma MJ, Milne G, Nelson EA, Pyenson B, Basili M, Coker R, et al. Pharmaceutical interventions for mitigating an
 7 influenza pandemic: modeling the risks and health-economic impacts. *Expert Rev Anti Infect Ther*. 2010 Dec;8(12):1431-9.
 8 292. Killingley B, Enstone J, Booy R, Hayward A, Oxford J, Ferguson N, et al. Potential role of human challenge studies for
 9 investigation of influenza transmission. *Lancet Infect Dis*. 2011 Nov;11(11):879-86.
 10 293. Vukotich CJ, Jr., Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Aiello AE, et al. Findings, gaps, and future direction
 11 for research in nonpharmaceutical interventions for pandemic influenza. *Emerg Infect Dis*. 2010 Apr;16(4):e2.

13 Annex. I

14 PubMed search strategy

15 PubMed searches were performed until 18 December 2018. The key terms: 'influenza', 'pandemic', 'respiratory infection',
 16 'respiratory tract infection', 'respiratory virus', 'non-pharmaceutical measures', 'public health measures', 'non-pharmaceutical
 17 interventions', 'personal protective measures', 'personal protective equipment', 'environmental', 'cleaning', 'surface',
 18 'humidification', 'ventilation', 'disinfectants', 'disinfection', 'copper', 'alloy', 'sunlight', 'hand hygiene', 'mask', 'respirator', 'hand
 19 disinfection', 'social distancing', 'voluntary isolation', 'workplace', 'quarantine', 'mass gatherings', 'Hajj', 'school closure',
 20 'entry screening', 'exit screening', 'border closure', 'travel advice', 'travel measures', were used in the following
 21 combinations:
 22

Measure	Search terms
Non-pharmaceutical countermeasures	(non[All Fields] AND ("pharmaceutical"[All Fields]) AND interventions[All Fields] AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp] (non[All Fields] AND "pharmaceutical"[All Fields][All Fields]) AND ("measures"[All Fields] AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp] (non[All Fields] AND ("pharmaceutical"[All Fields] AND "measures"[All Fields]) OR "weights and measures"[All Fields] OR "measures"[All Fields]) AND effectiveness[All Fields] AND Review[ptyp] (non[All Fields] AND ("pharmaceutical"[All Fields]) AND interventions[All Fields] AND effectiveness[All Fields]) AND Review[ptyp]
Hand hygiene	((("hand hygiene"[MeSH Terms] OR ("hand"[All Fields] AND "hygiene"[All Fields]) OR "hand hygiene"[All Fields]) AND ("influenza, human"[MeSH Terms] OR "influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp] ((("hand disinfection"[MeSH Terms] OR ("hand"[All Fields] AND "disinfection"[All Fields]) OR "hand disinfection"[All Fields] OR ("hand"[All Fields] AND "washing"[All Fields]) OR "hand washing"[All Fields]) AND ("influenza, human"[MeSH Terms] OR "influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp] ((("hand disinfection"[MeSH Terms] OR ("hand"[All Fields] AND "disinfection"[All Fields]) OR "hand disinfection"[All Fields] OR ("hand"[All Fields] AND "washing"[All Fields]) OR "hand washing"[All Fields]) AND effectiveness[All Fields]) AND Review[ptyp] ((("hand hygiene"[MeSH Terms] OR ("hand"[All Fields] AND "hygiene"[All Fields]) OR "hand hygiene"[All Fields]) AND effectiveness[All Fields]) AND Review[ptyp]
Respiratory etiquette	(respiratory[All Fields] AND etiquette[All Fields]) AND Review[ptyp]

	(("cough"[MeSH Terms] OR "cough"[All Fields]) AND etiquette[All Fields]) AND Review[ptyp]
	(respiratory[All Fields] AND ("hygiene"[MeSH Terms] OR "hygiene"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(respiratory[All Fields] AND ("hygiene"[MeSH Terms] OR "hygiene"[All Fields]) AND ("respiratory tract infections"[MeSH Terms] OR ("respiratory"[All Fields] AND "tract"[All Fields] AND "infections"[All Fields]) OR "respiratory tract infections"[All Fields] OR ("respiratory"[All Fields] AND "infections"[All Fields]) OR "respiratory infections"[All Fields])) AND Review[ptyp]
Facemasks	(facemask[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(("face"[MeSH Terms] OR "face"[All Fields]) AND ("masks"[MeSH Terms] OR "masks"[All Fields] OR "mask"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(("masks"[MeSH Terms] OR "masks"[All Fields] OR "mask"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(("masks"[MeSH Terms] OR "masks"[All Fields] OR "mask"[All Fields]) AND ("respiratory tract infections"[MeSH Terms] OR ("respiratory"[All Fields] AND "tract"[All Fields] AND "infections"[All Fields]) OR "respiratory tract infections"[All Fields] OR ("respiratory"[All Fields] AND "infection"[All Fields]) OR "respiratory infection"[All Fields])) AND Review[ptyp]
Other personal protective equipment	(("personal protective equipment"[MeSH Terms] OR ("personal"[All Fields] AND "protective"[All Fields] AND "equipment"[All Fields]) OR "personal protective equipment"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(personal[All Fields] AND protective[All Fields] AND ("weights and measures"[MeSH Terms] OR ("weights"[All Fields] AND "measures"[All Fields]) OR "measures"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(personal[All Fields] AND protective[All Fields] AND interventions[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(personal[All Fields] AND protective[All Fields] AND interventions[All Fields] AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]
Environmental measures	(("environment"[MeSH Terms] OR "environment"[All Fields] OR "environmental"[All Fields]) OR ("weights"[All Fields] AND "measures"[All Fields]) OR "measure"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	(surface[All Fields] AND cleaning[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]

	(humidification[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	((("ventilation"[MeSH Terms] OR "ventilation"[All Fields] OR "respiration"[MeSH Terms] OR "respiration"[All Fields]) AND ("respiratory tract infections"[MeSH Terms] OR ("respiratory"[All Fields] AND "tract"[All Fields] AND "infections"[All Fields]) OR "respiratory tract infections"[All Fields] OR ("respiratory"[All Fields] AND "infection"[All Fields]) OR "respiratory infection"[All Fields]) AND effectiveness[All Fields]) AND Review[ptyp]
	(cleaning[All Fields] AND ("respiratory tract infections"[MeSH Terms] OR ("respiratory"[All Fields] AND "tract"[All Fields] AND "infections"[All Fields]) OR "respiratory tract infections"[All Fields] OR ("respiratory"[All Fields] AND "infection"[All Fields]) OR "respiratory infection"[All Fields]) AND effectiveness[All Fields]) AND Review[ptyp]
	((("disinfectants"[Pharmacological Action] OR "disinfectants"[MeSH Terms] OR "disinfectants"[All Fields] OR "disinfectant"[All Fields]) AND ("respiratory tract infections"[MeSH Terms] OR ("respiratory"[All Fields] AND "tract"[All Fields] AND "infections"[All Fields]) OR "respiratory tract infections"[All Fields] OR ("respiratory"[All Fields] AND "infection"[All Fields]) OR "respiratory infection"[All Fields]) AND effectiveness[All Fields]) AND Review[ptyp]
	((("disinfection"[MeSH Terms] OR "disinfection"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND effectiveness[All Fields]) AND Review[ptyp]
	((("disinfection"[MeSH Terms] OR "disinfection"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	((("disinfectants"[Pharmacological Action] OR "disinfectants"[MeSH Terms] OR "disinfectants"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
	((("infection"[MeSH Terms] OR "infection"[All Fields]) AND ("sunlight"[MeSH Terms] OR "sunlight"[All Fields]) AND ("ventilation"[MeSH Terms] OR "ventilation"[All Fields] OR "respiration"[MeSH Terms] OR "respiration"[All Fields])) AND Review[ptyp]
	((("copper"[MeSH Terms] OR "copper"[All Fields]) AND ("disinfection"[MeSH Terms] OR "disinfection"[All Fields])) AND Review[ptyp]
Social distancing measures	(social[All Fields] AND distancing[All Fields]) AND Review[ptyp]
	(social[All Fields] AND distancing[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]
Isolation of infected individuals	((("quarantine"[MeSH Terms] OR "quarantine"[All Fields]) AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]
Voluntary quarantine of exposed individuals	voluntary[All Fields] AND ("isolation and purification"[Subheading] OR "isolation"[All Fields] OR "isolation"[All Fields]) AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields]) AND Review[ptyp]
School closure	((("schools"[MeSH Terms] OR "school"[All Fields]) AND closure[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]

Scientific advice - Expert opinion	ECDC	Draft for public consultation 27 August 2019
Workplace closure	<p>("workplace"[MeSH Terms] OR "workplace"[All Fields]) AND closure[All Fields]</p> <p>("workplace"[MeSH Terms] OR "workplace"[All Fields]) AND closure[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])</p>	
Workplace measures	<p>"workplace"[MeSH Terms] OR "workplace"[All Fields]) AND "measures"[All Fields] OR "measure"[All Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])</p>	
Mass gatherings	<p>((("mass"[All Fields]) AND gathering[All Fields] AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]</p> <p>((("mass"[All Fields]) AND gathering[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]</p> <p>(Hajj[All Fields] AND effectiveness[All Fields]) AND Review[ptyp]</p> <p>(Hajj[All Fields] AND ("public health"[MeSH Terms] OR ("public"[All Fields] AND "health"[All Fields]) OR "public health"[All Fields]) AND "measures"[All Fields]) OR "measures"[All Fields])) AND Review[ptyp]</p>	
Travel advice	<p>((("travel"[MeSH Terms] OR "travel"[All Fields]) AND advice[All Fields] AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]</p>	
Entry and exit screening	<p>(entry[All Fields] AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "screening"[All Fields] OR "mass screening"[MeSH Terms] OR ("mass"[All Fields] AND "screening"[All Fields]) OR "mass screening"[All Fields] OR "screening"[All Fields] [MOR ("early"[All Fields] AND "detection"[All Fields]) AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]</p> <p>(entry[All Fields] AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "screening"[All Fields] OR "mass screening"[MeSH Terms] OR ("mass"[All Fields] AND "screening"[All Fields]) OR "mass screening"[All Fields] OR "screening"[All Fields] OR ("early"[All Fields] AND "detection"[All Fields] AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields])) AND Review[ptyp]</p> <p>(entry[All Fields] AND ("diagnosis"[Subheading] OR "diagnosis"[All Fields] OR "screening"[All Fields] OR "mass screening"[MeSH Terms] OR ("mass"[All Fields] AND "screening"[All Fields]) OR "mass screening"[All Fields] OR "screening"[All Fields] OR ("early"[All Fields] AND "detection"[All Fields] AND respiratory[All Fields]) AND Review[ptyp]</p>	
Internal travel restriction	<p>((("travel"[MeSH Terms] OR "travel"[All Fields]) AND ("measures"[All Fields]) OR "measures"[All Fields]) AND ("pandemics"[MeSH Terms] OR "pandemics"[All Fields] OR "pandemic"[All Fields])) AND Review[ptyp]</p>	
Border closure	<p>((("travel"[MeSH Terms] OR "travel"[All Fields]) AND restriction[All Fields] AND effectiveness[All Fields]) AND Review[ptyp]</p> <p>((("border"[All Fields]) AND closure[All Fields] AND effectiveness[All Fields]) AND Review[ptyp]</p>	

1
2
3
4

